Oxygen and platelets. Translational studies on therapeutic targets for immunomodulation by Kiers, H.D.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/200678
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Dorien Kiers
Oxygen & platelets
Translational studies on therapeutic targets 
for immunomodulation
Oxygen and platelets
Translational studies on therapeutic targets 
for immunomodulation
HD Kiers
Oxygen and platelets. Translational studies on therapeutic targets for immunomodulation
ISBN: 978-94-92332-23-3
The work described in this thesis was performed at the Department of Intensive Care 
Medicine and Anesthesiology, Radboud University Medical Centre, Nijmegen, Netherlands. 
The work was supported by a grant from Radboudumc Center for Infectious Diseases and 
the Dutch Society for Anesthesiology. Chapter 8 was supported by AstraZeneca. 
Cover design and layout: Esther Scheide, www.proefschriftomslag.nl 
Printed by: Ridderprint
© 2019, Dorien Kiers, Nijmegen
All rights reserved. No part of this thesis may be reproduced or transmitted in any for mor 
by any means, electronic or mechanical, including photocopy, recording of otherwise 
without permission of the author.
Oxygen and platelets
Translational studies on therapeutic targets for immunomodulation
Proefschrift ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op
4 februari 2019
om 14.30 uur precies
door
Harmke Dorien Kiers
geboren op 30 maart 1986
te Hengelo
Promotoren
Prof. dr. P. Pickkers 
Prof. dr. G.J. Scheffer 
Co-promotor
Dr. M. Kox 
Manuscriptcommissie
Prof. dr. R. van Crevel (voorzitter)
Prof. dr. R.J.M. van Geuns ErasmusMC
Prof. dr. N.P. Juffermans Amsterdam UMC
Contents
Chapter 1 General introduction, aim and outline
Part I  Oxygen: Immunomodulation through oxygenation  
and oxygen-dependent pathways 
Chapter 2  Immunological Consequences of Hypoxia during Critical Illness 
Anesthesiology 2016:125:237-49
Chapter 3  Short-term hypoxia dampens inflammation in vivo via enhanced 
adenosine release and adenosine 2B receptor stimulation 
EBioMedicine 2018:33:144-156
Chapter 4   Hypoxia attenuates inflammation-induced hepcidin production  
in humans in vivo 
Submitted for publication
Chapter 5   Effects of hypoxia on platelet function and coagulation during 
systemic inflammation in humans in vivo 
In press: Platelets
Chapter 6  LPS-Induced ex vivo Cytokine Production is Not Augmented  
in Patients with Von Hippel-Lindau Disease 
Scandinavian Journal of Immunology 2017:86:179-180
Chapter 7  Short-term hyperoxia does not exert immunologic effects during 
experimental murine and human endotoxemia 
Scientific reports 2015 5:17441
Part II  Platelets: Immunomodulation through anti-platelet therapy 
Chapter 8  A randomized trial on the effect of anti-platelet therapy on  
the systemic inflammatory response in human endotoxemia 
Thrombosis and Haemostasis 2017:117:1798-1807
Chapter 9  Aspirin may improve outcome in sepsis by augmentation of  
the inflammatory response 
Intensive Care Medicine 2016:42:1096
Chapter 10  Acetylsalicylic acid partially reverses endotoxin tolerance in vivo  
in humans 
In press: Critical Care Medicine
9
25
47
77
87
97
103
125
159
165
Part III  Experimental endotoxemia as a model of systemic 
inflammation
Chapter 11  Characterization of a model of systemic inflammation in humans 
in vivo elicited by continuous infusion of endotoxin 
Scientific Reports 2017:7:20149
Chapter 12  Evaluation of the response to intravenous endotoxin 
administration over time and between different batches 
In press: Innate Immunity
Chapter 13 Summary
Chapter 14  Discussion and future perspectives
Chapter 15 Nederlandse samenvatting, discussie en toekomstperspectieven
 Dankwoord
 Curriculum Vitae
 Publicaties
193
213
233
241
263
277
280
281


CHAPTER 1
General introduction, aim and outline
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The body has several lines of defense to protect itself against invading pathogens, such 
as bacteria, viruses and fungi. The first line of defense is the physical barrier of the skin 
and mucosal tissues, which is impermeable to most infectious agents. When pathogens 
penetrate this first line of defense, an innate immune response is mounted to eliminate 
these invading pathogens. Two important hallmarks of the innate immune response are 
the production of inflammatory mediators and the recruitment of immune cells to the site 
of infection. 
Sepsis is characterized by a dysregulated immune response against an infection, which 
can lead to tissue injury, organ damage and ultimately may result in death in up to 30% 
of patients admitted to the ICU1. Although sepsis is the archetypical illness that is charac-
terized by immune dysregulation, many other critically ill patients in the ICU suffer from 
a dysregulated immune response, including those with trauma, burns and after major 
surgery2,3. So, although much research has focused on immune dysregulation in sepsis, 
these concepts are likely to be applicable to other critically ill patients as well. 
The only treatments currently available in sepsis are aimed at pathogen elimination with 
antibiotics and supportive care, e.g. mechanical ventilation, renal replacement therapy or 
treatment of shock. There is no treatment strategy to restore the dysregulated immune 
response4. In order to develop effective immunomodulatory therapies for patients with 
sepsis and critical illness-induced immune dysregulation, a better understanding of this 
phenomenon is paramount. These insights can be acquired through various complementary 
approaches, such as in vitro and animal studies, epidemiologic observations, as well as 
translational and clinical patient studies. In the case of sepsis, epidemiologic studies have 
identified several factors that influence outcome in critically ill patients, independent 
of disease severity. Two of these factors are blood oxygen level (oxygenation) at ICU 
admittance5,6 and the use of anti-platelet therapy7. In addition, oxygenation8 and anti-
platelet drugs9,10 have both been shown to influence the immune response in laboratory 
settings. Therefore, it appears plausible that these factors may modulate the immune 
response in vivo as well, and thereby contribute to the outcome of critically ill patients with 
a dysregulated immune response. 
If we gain insight if and how these factors modify the immune response in vivo, these 
insights may provide a foundation for developing treatment strategies that target immune 
dysregulation in critically ill patients. In addition, modulating the inflammatory response 
with interventions that have been used in medicine for over a century11,12 has the benefits 
of a well-known risk profile, low cost and excellent availability.
The innate immune response
When pathogens cross the anatomical barriers, they are recognized by the cells of the 
innate immune system, which are monocytes, macrophages, dendritic cells, granulocytes 
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and mast cells. These cells can recognize certain components of pathogens, named 
pathogen associated molecular patterns (PAMPS) with their pattern recognition receptors 
(PRRs)13. The most extensively studied PRR is the family of the Toll Like Receptors. Each 
of its members recognizes different PAMPs, for instance, TLR2 recognizes peptidoglycan 
from Gram positive bacteria, TLR3 viral double stranded RNA and TLR4 lipopolysaccharide 
from Gram negative bacteria13. Ligation of a PAMP to a PRR results in a non-specific innate 
response, a major hallmark of which is the release of pro-inflammatory mediators to recruit 
more immune cells to the site of infection and to activate the specific adaptive immune 
system. These pro-inflammatory mediators include cytokines such as Tumor Necrosis 
Factor (TNF)-α, Interleukin (IL)-1β, IL-6 and chemokines like IL-8, macrophage inflammatory 
proteins (MIP) and monocyte chemoattractant protein (MCP)-1. These molecules mediate 
the recruitment and activation of monocytes and neutrophils, specialized in pathogen 
killing, and lymphocytes, which bridge activation of the innate immune response to the 
specific adaptive immune response14. Furthermore, the initiation of the inflammatory 
response also triggers non-immunologic processes. For instance, vasodilatation and de-
creased vascular integrity facilitate leukocyte migration to the site of infection, coagulation 
is activated, body temperature rises, glucose consumption increases and insulin sensitivity 
decreases14. Next to PAMPs, endogenous molecules that are released upon tissue injury 
further activates the innate immune system through ligation of PPRs. These molecules 
are named ‘danger associated molecular patterns’ (DAMPs)15, and examples are hyaluronic 
acid and mitochondrial DNA. This mechanism explains why tissue injury, for example from 
surgery or trauma, causes an inflammatory response without invasion of pathogens15. 
In a well-functioning immune system, inflammation is curtailed by self-regulatory anti-
inflammatory response, which, among others consists of production of the potent anti-
inflammatory cytokines, for example IL-1016. 
Sepsis 
Patients with severe sepsis and septic shock constitute a large proportion of critically ill 
patients (11% in the Netherlands17, 10-14% in other developed countries18–20), with high 
mortality rates, ranging from 25 to 50%4. In these patients, immune dysregulation can 
consist of either excessive pro-inflammation or a hyporesponsive, suppressed state of the 
immune system, also known as immunoparalysis. An excessive pro-inflammatory response 
may lead to multiple organ dysfunction and subsequent death, whereas immunoparalysis 
compromises host defense and enhances susceptibility to secondary infections, associated 
with late mortality in sepsis patients. Currently, there are no interventions available that 
successfully intervene in this dysregulated inflammatory response in sepsis. The only 
evidence-based treatments are antibiotic therapy and supportive care4.
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The course of the inflammatory response in sepsis is dependent on many things, including 
the type of invading pathogen, but also patient characteristics such as age, race, genetic 
determinants and comorbidities. Furthermore, the nature of the inflammatory response 
may also change over time. 
Conceptually, the inflammatory course can be described by a predominant pro- inflamma tory 
state or a predominant anti-inflammatory state. If the pro- and anti-inflammatory response 
are adequate and well-balanced, the invading pathogens will be eradicated without harm to 
the bodily tissues of the host. However, depending on many factors alluded to before, the 
magnitude of the pro- and anti-inflammatory response vary. It is commonly believed that in 
the early phase of sepsis, a hyperdynamic, pro-inflammatory response prevails, characterized 
by high levels of pro-inflammatory cytokines, vasodilation and decreased vascular integrity 
and coagulopathy21. In this phase, patients are hemo dynamically unstable and may suffer 
from coagulopathy and other organ dysfunctions, which can ultimately lead to septic shock 
and death. A concurrent counterbalancing anti-inflammatory response is aimed at restoring 
homeostasis and preventing organ injury. However, when too pronounced or persistent, this 
anti-inflammatory response may induce a hyporeactive, immunoparalysed state, which results 
in an inadequacy to combat the ongoing infection and increases susceptibility to secondary 
and opportunistic infections. These patients are prone to deferred death from sepsis21.
As it used to be assumed that the overriding cause of death is a pro-inflammatory cytokine 
storm, it is understandable that the development of adjunctive treatments in sepsis has 
previously focused on anti-inflammatory agents such as anti-TNFα22,23, IL-1RA24,25 lipo-
polysaccharide antibodies26, TLR4 antagonists27 and activated protein C28. Bearing the 
concept of immunoparalysis in mind, it is not surprising that all of these approaches 
were unsuccessful. However, it is conceivable that anti-inflammatory therapy may be 
effective when only used in a subgroup of hyperinflamed patients with an overriding pro-
inflammatory immune response, instead of all patients with sepsis. 
Because the detrimental role of immunoparalysis is increasingly recognized, research into 
sepsis therapies has shifted towards interventions that may restore immunocompentence21. 
Several compounds, such as anti-PD-(L)1, IFNy, GM-CSF and IL-7 have shown encouraging 
results in preclinical work, and some even in small patient studies. However, we should 
not make the same mistake again by using these compounds in unselected patients with 
sepsis, but we should focus on the patients that are most likely to benefit from it, which are 
those with immunoparalysis. 
Taken together, it is pivotal that we find markers of the immune status and identify the 
type of immunologic dysfunction before attempting to attenuate hyperinflammation or 
to restore immunocompetence21. However, establishing the immunologic state of patients 
with sepsis is difficult, as there are no clinical criteria and the immunologic mechanisms 
that contribute to the clinical symptoms sepsis are still not fully unraveled29. 
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Putative amenable factors involved in immunomodulation and outcome in sepsis
Several epidemiologic studies have identified amenable factors that are associated with 
impaired or improved survival in critically ill patients in general or sepsis patients in particular. 
For instance, a low level of arterial oxygen content at ICU admittance was independently 
associated with an increased mortality5,6. Furthermore, the use of acetylsalicylic acid and 
other anti-platelet therapy before hospital admittance has been associated with improved 
outcomes in patients with sepsis and pneumonia7. However, due to the observational 
nature of these studies, a causal relationship between oxygenation or anti-platelet therapy 
with clinical outcome cannot be established. 
Nevertheless, in vitro studies have shown that the oxygen concentration8, use of acetyl sali cylic 
acid9 and other anti-platelet drugs10 affect the function of innate immune cells. Therefore, it is 
tenable that the innate immune response may be modulated by either altering oxygen levels, 
or by treatment with acetylsalicylic acid or anti-platelet drugs. These immunomodulatory 
effects may have contributed to the association of these factors with outcome. The under-
standing of these putative immunomodulatory mechanisms could contribute to a meaning ful 
understanding of the pathogenesis of a dysregulated immune response and may eventually 
result in the application of interventions targeting these immunomodulatory mechanisms to 
improve the outcome of patients with sepsis, as well as those suffering from other conditions 
where a dysregulated immune response plays a detrimental role. 
The interplay between oxygenation and the immune response
Oxygenation and inflammation are closely intertwined. Inflammation can lead to tissue 
hypoxia, due to enhanced and unmet metabolic needs and a decreased availability due 
to inadequate circulation, microthrombi and edema formation30. Conversely, hypoxia may 
lead to activation of the inflammatory response31. This close interaction is reflected in the 
regulation of many physiological processes by a group of transcription factors named 
Hypoxia Inducible Factors (HIFs). HIFs become transcriptionally active when their oxygen-
dependent degradation is reduced during hypoxia or when production is enhanced 
by inflammatory signals32. In turn, HIF transcriptional activity may exert pro- and anti-
inflammatory effects, which are highly dependent on cell- and tissue type33. 
Furthermore, low levels of oxygen have been shown to result in higher levels of the purine 
nucleoside adenosine. In addition, hypoxia also leads to increased expression of adenosine 
receptors. Both enhanced adenosine levels and increased expression of adenosine 
receptors exert anti-inflammatory and tissue protective effects34. 
Concerning hyperoxia, epidemiologic studies have shown conflicting data on the effect of 
high levels of oxygen at ICU admittance5,6,35. Although oxygen is essential for life, hyperoxia 
may be toxic to the lungs, as it has been associated with a pulmonary inflammatory 
response and lung injury36. Increased levels of reactive oxygen species have been shown 
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to play an important role in this process37. However, hyperoxia has also shown to exert 
protective anti-inflammatory effects in vitro38 and in murine studies39–41.
Data on the effects of both hypoxia and hyperoxia on the immune response in humans in 
vivo are lacking. An understanding of oxygenation-dependent immunomodulatory effects 
could provide insight into the epidemiologic observations in patients and could provide 
a foundation for tailored immunomodulatory therapy in patients with sepsis- or critical 
illness-induced dysregulation of the immune response. 
The interplay between platelets and the immune response
The primary function of platelets is to facilitate primary hemostasis, by forming large 
aggregates when blood vessels are damaged42. However, adhesion and aggregation of 
platelets are also important in the formation of atheromatous plaques in cardiovascular 
disease42. Consequently, antiplatelet therapy is the cornerstone of secondary prevention 
in patients with cardiovascular disease43. Inhibition of platelet function with acetylsalicylic 
acidreduces the risk of recurrent myocardial infarction and death44. Addition of an additional 
anti-platelet drug that inhibits the P2Y 12-receptor in the first year after myocardial infarction 
has shown to augment beneficial effects on outcome45,46. Although the archetypal function 
of platelets is to facilitate primary hemostasis, their interactions with the immune response 
are increasingly recognized. Platelets can be activated by the inflammatory response, as 
inflammation stimulates thrombin formation and endothelial activation47. This results in 
increased concentrations of plasma tissue factor and von Willebrand Factor, which both 
stimulate platelet activation. The platelets respond with the release of the contents of their 
granules with chemokines48 and membrane expression of P-selectin and CD40 ligand, 
which are important regulators of platelet-leukocyte interactions49. Platelets can bind to 
leukocytes, and these aggregates can affect the immune function of these cells50. Indeed, 
in vitro studies have shown that pharmacologic interventions on platelet function have 
immunomodulatory effects on leukocytes. Therefore, it appears plausible that anti-platelet 
therapy may also affect the immune response in vivo. Human studies on the effects of anti-
platelet therapy on inflammation is scarce. The few studies conducted only investigated 
the effects a single platelet inhibitor10,51, whereas most patients receive dual platelet 
inhibitory therapy43. In addition, the question remains whether the potential beneficial 
effect of antiplatelet therapy is only present when these drugs are used prior to hospita-
lization, or if they can also be achieved when started following admission to the ICU. 
Investigating the immune response in humans in vivo: the human experimental endotoxemia 
model
As dysregulation of the immune response is thought to be the root cause of impaired out-
come in patients with sepsis and an important factor in other critical illnesses, it is pivotal 
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to understand how this response develops, what factors may affect it, and how it can be 
modulated. However, studying the course of the immune response in patients is com-
plicated by the large heterogeneity in patients, causative pathogens and course of disease. 
Furthermore, uncertainty concerning the time of onset of inflammation obscures the 
interpretation of temporal changes. To overcome these obstacles, several models of systemic 
inflammation have been developed. Although there are several animal models that mimic 
sepsis, translating results from animal studies to a human situation is difficult, as there are 
distinct differences and similarities in the immune response between man and labo ra tory 
animals52,53. For the last six decades, the experimental human endotoxemia model has 
been used to study systemic inflammation in humans in vivo. This model consists of the 
administration of purified E. coli-derived endotoxin (lipopolysaccharide [LPS]), which results in 
a controlled, reproducible and transient acute systemic inflammatory response. This response 
is characterized by the development of fever, flu-like symptoms, changes in circulating 
leukocytes and increased plasma levels of cytokines and chemokines54. The experimental 
human endotoxemia model provides an opportunity to study the innate immune response 
and to evaluate interventions aimed to modulate the immune response in vivo. However, the 
model should not be mistaken for actual sepsis or other critical illnesses, as there is no organ 
injury and the inflammatory response is short-lived. Patients with sepsis are usually exposed 
to an inflammatory stimulus for a prolonged period, as opposed to the bolus injection of LPS 
in the classic experimental human endotoxemia model. Therefore, a continuous infusion of 
endotoxin may better resemble the temporal changes of the immune response as observed 
during sepsis. Such a sustained infusion of endotoxin has been described previously, but only 
using very low doses of endotoxin55, resulting in mild inflammation that is used to model 
chronic low-grade inflammation as observed in cardiovascular disease55. Higher dosed 
continuous infusion of endotoxin that results in a more profound systemic inflammatory 
response as observed in sepsis patients has not been described before. 
Endotoxin administration does not only result in a temporary systemic inflammatory 
response, but also in relative tolerance to a subsequent endotoxin administration56,57. This 
phenomenon is called ‘endotoxin tolerance’, and it may be used to model immunoparalysis 
as observed in critically ill patients. After an initial endotoxin administration, a second 
endotoxin administration will result in fewer flu-like symptoms, a less pronounced increase 
in temperature and a blunted cytokine response. Therefore, using repeated endotoxin 
administrations enables studying interventions aimed at restoring immunocompetence in 
immunoparalyzed patients58.
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Aim and outline of thesis
The aim of this thesis was to perform translational studies aimed at identifying potential 
interventions for critically ill patients suffering from conditions characterized by a dys-
regulated immune response. In epidemiologic studies, oxygenation status and anti-platelet 
therapy are both associated with altered outcomes in critically ill patients. Furthermore, 
both oxygenation and anti-platelet therapy are known to affect the immune response in 
vitro. This thesis aims to shed light on whether these readily available therapies may affect 
the innate immune response in vivo and to decipher what the underlying mechanisms of 
action of these observed effects are. 
Part I of this thesis focuses on the relationship between oxygenation and the innate 
immune response. Chapter 2 comprises a review describing how low levels of oxygen may 
affect the innate immune response in vitro and in animal studies and potential underlying 
mechanisms of hypoxia-induced immunomodulation. As the effects of hypoxia on the 
innate immune system have not been explored in humans, the potential effects and 
applications of oxygen-dependent immunomodulation in patients are discussed as well. 
In Chapter 3, the effects of short-term hypoxia on the in vivo innate immune response in 
endotoxemic mice and men are presented, and the underlying mechanisms of hypoxia-
induced immunomodulation are unraveled. As iron homeostasis and platelet function are 
both thought to be affected by hypoxia, as well as inflammation, effects of hypoxia during 
inflammation on iron homeostasis and platelet function and coagulation are presented in 
Chapter 4 and Chapter 5, respectively. Patients with von Hippel-Lindau (VHL) disease have 
a genetic deficiency in the VHL protein, which is involved in HIF degradation. In Chapter 6, 
the effects of this VHL deficiency on the ex vivo immune response are described. The effects 
of hyperoxia on the in vivo innate immune response elicited by endotoxin administration in 
mice and men are described in Chapter 7.
In Part II the effects of common clinically used platelet inhibition in the context of systemic 
inflammation are evaluated. Chapter 8 describes the influence of common combinations 
of anti-platelet therapy on the innate immune response using the experimental human 
endotoxemia model. In Chapter 9, the hypothesis that prehospital use of acetylsalicylic 
acid may improve outcome in patients with infections due to its immune system-enhancing 
characteristics is proposed. Chapter 10, describes the potential of acetylsalicylic acid to 
prevent or reverse endotoxin tolerance in healthy volunteers challenged with endotoxin 
twice, as a possible novel treatment for sepsis-induced immunoparalysis. 
Part III consists of methodological studies into the experimental human endotoxemia 
model. In Chapter 11, the response elicited by different doses and modes of endotoxin 
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administration are compared. Chapter 12 describes the comparison of the innate immune 
response in humans in vivo elicited by continuous infusion and bolus administration of 
three different batches of endotoxin. Furthermore, an analysis on the in vivo potency of a 
single batch of endotoxin over 12 years is provided.
This thesis is completed by a summary in Chapter 13 and a general discussion and 
consideration of future perspectives in Chapter 14. 
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Abstract
Hypoxia and immunity are highly intertwined at clinical, cellular, and molecular 
levels. The prevention of tissue hypoxia and modulation of systemic inflammation 
are cornerstones of daily practice in the intensive care unit. Potentially, immunologic 
effects of hypoxia may contribute to outcome and represent possible therapeutic 
targets. Hypoxia and activation of downstream signaling pathways result in 
enhanced innate immune responses, aimed to augment pathogen clearance. On 
the other hand, hypoxia also exerts antiinflammatory and tissue-protective effects 
in lymphocytes and other tissues. Although human data on the net immunologic 
effects of hypoxia and pharmacologic modulation of downstream pathways are 
limited, preclinical data support the concept of tailoring the immune response 
through modulation of the oxygen status or pharmacologic modulation of hypoxia-
signaling pathways in critically ill patients.
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Introduction
Optimization of oxygenation to prevent tissue hypoxia is one of the cornerstones of critical 
care. Concurrently, in the majority of patients admitted to the Intensive Care Unit (ICU), 
inflammatory processes take place which may affect outcome. As hypoxia and immunity 
are highly interdependent at the molecular, cellular and clinical levels, immunologic effects 
of hypoxia may represent therapeutic targets in critically ill patients. At the cellular level, 
hypoxia activates distinct hypoxia-signaling pathways, including a group of transcription 
factors known as Hypoxia Inducible Factors and adenosine signaling. In vitro and animal 
studies have shown that these pathways are involved in modulation of inflammatory 
responses, and animal studies have demonstrated that these pathways are relevant 
to inflammatory conditions that are frequently encountered in critically ill patients, 
such as sepsis1,2 and lung injury3,4. In addition, inflammatory conditions are frequently 
characterized by tissue hypoxia due to enhanced metabolic demand as well as decreased 
metabolic substrates resulting from edema, microthrombi, and atelectasis, in turn causing 
“inflammatory hypoxia”5,6. As such, aiming for specific tissue oxygenation levels could 
be favorable in a range of inflammatory conditions in critically ill patients. Alternatively, 
these effects may also be achieved with pharmacologic interventions targeting hypoxia-
signaling pathways. 
In the current review, we provide an overview of the immunologic consequences of hypoxia. 
We focus on in vitro, animal, and human studies concerning inflammatory conditions 
relevant to critically ill patients, including a discussion of oxygen-dependent signaling 
pathways and intermediate signaling systems (e.g. the HIF system and adenosine 
meta bolism)2,7. Furthermore we discuss the clinical potential of intervening in these 
mechanisms, including evidence on potential drawbacks of hyperoxia, feasibility of thera-
peutic permissive hypoxia, and pharmacologic therapies that act on oxygen-dependent 
pathways. The role of hypoxia and HIFs outside the scope of inflammatory conditions in 
critically ill patients is reviewed elsewhere2,7–9.
Immunologic effects of hypoxia
Evidence for immunologic effects of hypoxia have mainly been established in in vitro 
studies using myeloid cells (Table 1)10–12. Long-term hypoxia has been shown to represent 
an inflammatory stimulus in itself, as prolonged hypoxia results in production of cytokines 
in a human macrophage cell line13. In addition, hypoxia increases the production of 
pro-inflammatory cytokines upon stimulation with the toxins lipopolysaccharide or 
phytohemagglutinin in primary human mononuclear cells14,15. In contrast, other studies have 
demonstrated that hypoxia skews the pro-inflammatory character (M1-like) of macrophages 
toward an anti-inflammatory M2-like phenotype16,17. In addition to these contradictory 
findings, these in vitro studies are difficult to interpret, as the control condition is usually 
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room air, which has a higher PaO2 compared to physiologic tissue PaO2. Nevertheless, these 
in vitro studies demonstrate that oxygenation exerts immunologic effects, although the 
direction of this response may depend on the cell type and activation state. 
Healthy volunteers subjected to hypoxia in vivo display enhanced ex vivo neutrophil 
chemotaxis, phagocytosis, and reactive oxygen species production24, and increased activity 
of the key inflammatory transcription factor nuclear factor κB (NFκB) in monocytes25. 
Furthermore, exposure of healthy subjects to high altitude hypoxia (SaO2 75-90%) for four 
days results in increased plasma levels of the pro-inflammatory interleukin-621,22, while 
shorter periods of hypoxia do not induce such systemic responses19,23 (Table 1). Taken 
together, in vivo, prolonged hypoxia increases inflammatory responses of myeloid cells ex 
vivo and elicits a systemic immune response. 
Reference Model
Inflammatory 
stimulus/
model
Oxygen 
intervention
Timing 
oxygen 
intervention
Inflammatory 
effect of oxygen 
intervention
in vitro 14 Primary human 
monocytes
LPS or PMA  1% O2 24h ↑ TNFα and 
IL-1β 
13 Monocyte/
macrophage cell 
line (THP-1)
- 1% or 9% O2 Up to 24h ↑ TNFα 
15 Primary human 
monocytes
PHA 2% O2 16h and 40h ↑ IL-2, IL-4,  
IL-6, and IFNγ 
↓ IL-10 
18 Monocyte/
macrophage cell 
line (U937)
- 2.8% O2 24h ↑ adhesion of 
leukocytes to 
endothelium 
10 Primary human 
dendritic cells, 
monocytic (MM6), 
endothelial (HMEC-
1) and intestinal 
epithelial (Caco-2) 
cell lines 
- 2% O2 6h ↑ TLR2 and TLR6
19 Murine bone 
marrow-derived 
dendritic cells
LPS 1% O2 24h ↑ costimulatory 
molecules, TNFα, 
and IL6
17 Rat alveolar 
macrophages
LPS 1.3% O2 1.5h ↓ TNFα and 
IL-1β
16 Murine peritoneal 
macrophages and 
monocytic cell lines 
(U937 and THP-1)
LPS <0.3% O2 24h ↑ TNFα
16 TG-elicited 
murine peritoneal 
macrophages 
and LPS-primed 
monocytic cell lines 
(U937 and THP-1)
LPS <0.3% O2 24h ↓ TNFα
Table 1, continues on next page
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Reference Model
Inflammatory 
stimulus/
model
Oxygen 
intervention
Timing 
oxygen 
intervention
Inflammatory 
effect of oxygen 
intervention
animal 
model
20 Mice LPS i.p. at days 
11 and 27
12% O2 28 days ↑ TNFα 
(pre)
clinical 
human 
studies
21 Healthy volunteers none Altitude 
hypoxia 
(4350m, SaO2 
78.6-83.4%)
4 days ↑ IL-6
22 Healthy volunteers none Altitude 
hypoxia 
(3458-4559m, 
SaO2 75-90%)
4 days ↑ IL-6, IL-1RA, 
and CRP
23 Healthy volunteers none Altitude 
hypoxia 
(4500m)
2 h per day  
for 7 con-
secutive days
Neutrophilia, 
↑ neutrophilic 
superoxide 
production
24 Healthy volunteers ex vivo 
stimulation of 
neutrophils 
with fMLP 
12% O2 2 h ↑ chemotaxis, 
phagocytosis 
and ROS 
production
25 Healthy volunteers ex vivo 
stimulation 
of T-cells and 
monocytes 
with PMA, 
phagocytosis 
of zymosan
SaO2 78% 2 h = cytokines, 
↑ neutrophil 
phagocytosis
11 Healthy volunteers none SaO2 80% 1h per day  
for 10 con-
secutive days
= cytokines 
12 Healthy volunteers none 11% O2 30 or 60 min = cytokines 
Table 1. In vitro and (pre)clinical studies on the effects of hypoxia on immunity 
LPS: Lipopolyssacharide; PMA: phorbol myristate acetate; h: hours; TNFα : Tumor Necrosis Factor alpha; IL-1β: Interleukin-
1β; PHA: Phytohemagglutinin; IL-2: interleukin-2; IL-4: Interleukin-4; IL-6: Interleukin-6; IFNγ: Interferon γ; IL-10: 
Interleukin-10; TLR2: Toll Like Receptor 2; TLR6: Toll Like Receptor 6; i.p.: intraperitoneal; IL-1RA: Interleukin-1 receptor 
antagonist; CRP: C-Reactive Protein; fMLP: N-formyl-Met-Leu-Phe; ROS: reactive oxygen species; SaO2: arterial oxygen 
saturation; min: minutes. Control condition was room air unless specified otherwise, pressure is normobaric unless 
specified otherwise. 
Concerning the underlying mechanisms, hypoxia in vitro induces an expansive cascade of 
cellular processes, regulated by oxygen-sensitive pathways consisting of prolyl hydroxylases 
(PHDs), the transcription factors Hypoxia Inducible Factors (HIFs) and NFκB, adenosine 
signaling pathways, and other oxygen-sensitive processess. These cellular mechanisms 
provide adaptation towards conditions of limited oxygen availability, and each pathway 
contributes in different ways to the immunologic effects of hypoxia. This may explain why 
hypoxia causes both, pro- and anti-inflammatory, as well as tissue-protective effects, as 
further detailed below.
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Regulation of Hypoxia Inducible Factor-1α
HIFs represent a group of transcription factors that mediate a plethora of cellular adap-
tations in response to hypoxia26. HIFs are heterodimers consisting of HIF-β and one of 
the three O2-dependent transcriptionally active α subunits: HIF-1α, HIF-2α, and HIF-3α, 
of which HIF-1α is the most widely studied isoform. The cellular mechanisms responsible 
for the regulation of HIF-1α protein stabilization and signaling under normoxic, hypoxic, 
and inflammatory conditions are detailed in Figure 1. Under normoxic conditions, the 
oxygen-dependent prolyl hydroxylases (PHD)-1, PHD2, and PHD3, and the asparaginyl-
hydroxylase factor-inhibiting HIF (FIH) hydroxylate HIF-1α, after which hydroxylated HIF-1α 
binds to the Von Hippel Lindau (VHL) complex. Binding of HIFs to VHL ultimately results in 
ubiquitination and degradation in the proteasome. Under hypoxic conditions, the oxygen-
dependent hydroxylases are inactive, which prevents degradation of HIF-1α. As such, 
hypoxia regulates HIF-1α in a posttranslational manner. A second, oxygen-independent, 
posttranslational mechanism of HIF-1α regulation involves Heat Shock Protein (HSP) 90. 
HSPs are key players in the response to cellular stress, functioning as chaperone proteins 
that facilitate conformation, localization, and function of a diversity of proteins. HSP90 
blocks the oxygen-independent degradation of HIF-1α and thereby results in stabilization 
of HIF-1α27–29. Furthermore, HSP90 binding to HIF-1α facilitates coupling with HIFβ and 
subsequent transactivation29. 
Finally, the transcription and translation of HIF-1α are increased by inflammatory stimuli. 
There fore, hypoxia, cellular stress, and inflammation (synergistically) enhance HIF-1α 
stabilization2,7. 
HIF-1α stabilization facilitates transcription of >100 hypoxia-responsive genes30, many of 
which result in hypoxia-adaptation, e.g. erythropoietin and vascular endothelial growth 
factor31. Although the autoregulatory system of HIF-1α has not been fully elucidated, there 
appears to be a negative feedback system32. In vitro, hypoxia induces HIF-1α expression in 
a dose-dependent fashion, but prolonged hypoxia results in downregulation of HIF-1α, 
mediated by a microRNA which targets HIF (aHIF), of which levels increase over time under 
hypoxic conditions33. In contrast with in vitro data, where hypoxia has only been shown to 
prevent HIF-1α degradation, hypoxia in vivo stimulates transcription of HIF-1α, followed 
by a decrease to baseline levels, possibly resulting from the aHIF-mediated negative 
feedback34. Human studies revealed a large interindividual variability in leukocyte HIF-1α 
expression35 and downstream target gene expression36 in response to hypoxia, implicating 
phenotypical differences in HIF regulation.
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Figure 1. HIF-1α regulation and signaling under normoxic, hypoxic, and inflammatory conditions
HIF-1α subunits are constantly produced but rapidly degraded under normoxic conditions. Several pathways of HIF-1α 
regulation have been described. First, under normoxic conditions, HIF-1α subunits are rapidly hydroxylated by oxygen-
dependent prolyl-hydroxylase domain enzymes (PHDs), which are subsequently captured by the ubiquitin ligase Von 
Hippel-Lindau (VHL) protein and degraded by the proteasome. Second, the oxygen-dependent asparginyl hydroxylase 
Factor Inhibiting HIF (FIH) hydroxylates a conserved asparaginyl residue, preventing the recruitment of co-activators 
p300 and CBP, in turn inhibiting dimerization with HIFβ. During O2-deficiency, PHD and FIH activities decrease, resulting 
in accumulation of HIF-1α subunits in the cytosol. The Receptor for Activated C Kinase 1 (RACK1) and Heat Shock Protein 
90 (HSP90) regulate HIF-1α in an oxygen-independent manner: RACK facilitates oxygen-independent proteasomal 
degradation of HIF-1α, while HSP90 competes with RACK, thereby stabilizing HIF-1α, and facilitates its transactivation. 
Upon accumulation, HIF-1α is co-activated by p300/CBP and dimerizes with HIFβ to form stable HIF1αβ dimers. These 
dimers translocate to the nucleus and bind to Hypoxia Response Elements (HREs) in promoter enhancer regions of genes, 
resulting in transcriptional activity. HIF-1α stabilization results in transcription of many (>100) hypoxia responsive genes. 
As FIH remains active at lower oxygen concentrations than PHDs, FIH suppresses the activity of HIF-1α proteins that 
escape destruction during moderate hypoxia. Not only hypoxia, but also exposure to bacteria and bacterial products 
such as LPS results in HIF-1α accumulation.
Involvement of HIF-1α and adenosine signaling  
in the immunologic effects of hypoxia 
The molecular interplay between hypoxia, HIFs and NFκB
The regulation of HIF-1α and NFκB, the latter considered the master regulator of inflammatory 
responses, is highly intertwined37,38. In the inactivated state, NFκB is bound to the inhibitory 
protein IκBα in the cytosol. Not only inflammatory stimuli, but also other signals activate 
the enzyme IκB kinase (IKK), resulting in phosphorylation of IκBα. Subsequently, NFκB 
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translocates into the nucleus and an inflammatory response characterized by production 
of inflammatory cytokines is generated39. Another downstream effect of NFκB activity is 
enhanced HIF-1α transcription40–42. Conversely, HIF-1α activity enhances NFκB activity by 
increasing abundance of IKK and the NFκB subunit p6541,43. Moreover, hypoxia prevents 
PHD-dependent IKK-degradation44. In vitro studies confirmed this effect, as combined 
inhibition of PHD-1 and FIH enhanced basal NFκB activity in a HIF-1α independent fashion45. 
Paradoxically, PHD-1 and FIH inhibition suppress NFκB activity under inflammatory 
conditions45. These data illustrate that there is extensive interplay between hypoxia, 
oxygen-dependent hydroxylases, HIF-1α, and NFκB. Furthermore, as alluded to before, 
effects are dependent on the cellular activation state. 
Cellular and in vivo immunologic effects of HIF-1α 
At the cellular level, HIF-1α stabilization in immune cells results in a differentiated response, 
highly depending on the cell type. In neutrophils, the induction of β2-integrin involved 
in epithelial neutrophil binding18, regulation of pathogen-binding neutrophil extracellular 
traps, and anti-bacterial activity46 are all HIF-1α-dependent46. HIF-1α stabilization inhibits 
apoptosis of macrophages and neutrophils43,47 and is involved in the differentiation of 
monocytes to macrophages as well as in macrophage maturation48. HIF-1α also results 
in increased expression of Toll-like receptor (TLR)-449 as well as in enhanced macrophage 
phagocytosis50 and bacterial killing51. 
A wide diversity of animal studies using cell-specific transgenic knockout mice and 
pharmacologic HIF-1α modulation also demonstrate the cell type-specific effects of HIF-
1α. Myeloid HIF-1α knockout mice have a higher morbidity in streptococcal skin infections 
than their wild type littermates, which indicates that HIF-1α in myeloid cells is essential 
to mount an inflammatory response required to clear local infection51. In severe systemic 
inflammation induced by LPS (to mimic Gram negative infection)52 or lipoteichoic acid and 
peptidoglycan (to mimic Gram positive infection)53, myeloid HIF-1α deficient mice display 
an attenuated inflammatory response, associated with less tissue damage and improved 
survival52. In accordance, HIF-1α gain of function results in an overwhelming inflammatory 
response in sterile and bacterial peritonitis, with aggravated organ damage and impaired 
survival1. As such, in myeloid cells, HIF-1α is essential for the generation of an effective 
inflammatory response to clear infections, while simultaneously, HIF-1α overexpression 
leads to the clinical picture of the early, pro-inflammatory phase of sepsis in mice. 
In contrast to the pro-inflammatory effects observed in myeloid cells, HIF-1α activity 
induces anti-inflammatory and tissue-protective effects in lymphocytes. For instance, HIF-
1α induction results in increased numbers of regulatory T-cells, with subsequent tissue 
protection due to attenuation of inflammation54. Furthermore, in a murine bacterial peritonitis 
model, T-cell-specific HIF-1α deficiency results in increased levels of pro-inflammatory 
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cytokines55. Suggestive of anti-inflammatory effects of HIF-1α in B-cells, PHD-inhibition 
with dimethyloxyallyl glycine before lipopolysaccharide-administration in mice resulted 
in enhanced interleukin-10 production by B1-cells, which skewed macrophages towards 
an anti-inflammatory M2-like phenotype56. Moreover, other studies demonstrate that the 
transcriptional program that drives anti-inflammatory regulatory T-cell differentiation is 
under the control of HIF via the induction of the HIF-target gene FoxP354.
Apart from effects in dedicated immune cells, HIF-1α stabilization also exerts immunologic 
effects in other cells, e.g. intestinal and alveolar epithelium and myocytes. Pharmacologic 
stabilization of HIF-1α through PHD-inhibition in murine chemical-induced colitis results in 
reduced levels of TNFα, interleukin-6, and interleukin-1β, while levels of anti-inflammatory 
interleukin-10 increase57, and clinical outcome improves58,59. Similarly, pharmacologic PHD-
inhibition in ventilator induced lung injury results in HIF-1α dependent reduced lung injury 
and prolonged survival, whereas HIF-1α inhibition aggravates lung injury and shortened 
survival4. The tissue-protective effects of HIF-1α are also involved in protection against 
ischemic injury. For instance, myocardial protection by remote ischemic preconditioning 
is dependent on increased interleukin-10 production mediated through HIF-1α60,61, and 
myocardial HIF-1α expression mediates a metabolic switch to glycolysis, which is crucial for 
adaptation to ischemia62. An overview of the immunologic effects of PHD-inhibition in in 
vitro and animal studies is provided in Table 245,46,71–73,63–70.
Altogether, HIF-1α activity in myeloid cells is involved in the orchestration of immune 
responses aimed at pathogen clearance, whereas HIF-1α activity in lymphocytes, 
epithelium, and myocytes induces anti-inflammatory and tissue protective effects (an 
overview is provided in Figure 2). Although these opposing effects may seem contradictory, 
studies in the field of oncology have shown that myeloid HIF-1α activity suppresses T-cell 
responses77. Therefore, it is conceivable that, in the context of inflammation and infection, 
local interplay between different immune cells is required to optimize infection control and 
simultaneously prevent tissue damage78. 
Reference Model
Inflammatory 
stimulus/model Intervention
Inflammatory effect  
of PHD-inhibition
in vitro 74 Microgial cell line 
(BV2)
LPS EDHB ↓ mRNA TNFα and IL-6
  63 Keratinocyte cell 
line (HaCaT)
LPS AKB-4924 ↑VEGF, IL-6, IL-8
  64 Monocyte/ 
macrophage cell 
line (U937) and 
neutrophils from 
healthy donors
Various Gram 
positive and negative 
bacteria
AKB-4924 ↑bactericidal activity
  65 Endothelial cell 
line (5A32)
TNFα dimethyloxalylglycine ↓VCAM-1
Table 2, continues on next page
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Reference Model
Inflammatory 
stimulus/model Intervention
Inflammatory effect  
of PHD-inhibition
 in vitro 66 Macrophage cell 
line (RAW264.7)
LPS dimethyloxalylglycine ↓TNFα
  75 HeLa cell line IL-1β dimethyloxalylglycine ↓NFκB activity
animal 
model
58 Mice TNBS
(chemical colitis)
FG-4497 ↓ colonic TNFα, 
weight loss, histologic 
inflammation
  59 Mice DSS
(chemical colitis)
dimethyloxalylglycine ↓ colonic IL-1β, TNFα, 
IL-12, IL-6, disease activity 
index, weight loss, 
histologic inflammation 
  73 Rats DNBS
(chemical colitis)
dimethyloxalylglycine ↓ neutrophil infiltration 
  76 Mice TNBS and DSS
(chemical colitis)
TRC160334 ↓ disease activity index, 
weight loss, histologic 
inflammation 
  57 Mice TNBS
(chemical colitis)
AKB-4924 ↓ serum IL-1β, TNFα, 
IL-6, weight loss, disease 
activity
↑ IL-10
  68 Mice TNBS
(chemical colitis)
AKB-4924 ↓ colonic IL-1β, TNFα, 
IL-12, IL-6, weight loss, 
histologic inflammation
  69 Mice TNFΔARE/+ mice  
(spontaneous chronic 
terminal ileitis)
dimethyloxalylglycine ↓ histologic inflammation
  70 Mice LPS intraperitoneal
(endotoxemic shock)
dimethyloxalylglycine ↓TNFα, mortality 
↑IL-10
4 Mice Ventilator induced 
lung injury
dimethyloxalylglycine ↓ BAL MPO, pulmonary 
edema
↑gas exchange, survival 
time 
  64 Mice S Aureus 
(cutaneous infection)
AKB-4924 ↓lesion size, bacterial 
load, disease severity
  71 Mice E Coli 
(urinary tract 
infection)
AKB-4924 ↓bacterial load, IL1-β, IL-6, 
KC, MPO activity
  74 Mice MPTP
(neurotoxicity)
EDHB ↓ striatal IL-6
  72 Rabbits LPS and 
methylprednisolone 
(osteonecrosis)
EDHB ↓ osteonecrosis
Table 2. In vitro and preclinical studies on the effects of PHD-inhibitors on immunity
LPS: Lipopolyssacharide; EDHB: ethyl-3,4-dihydroxybenzoate; TNFα : Tumor Necrosis Factor alpha; IL-6: Interleukin-6; 
VEGF: Vascular Endothelial Growth Factor; IL-8:Interleukin-8; VCAM-1:Vascular Cell Adhesion Molecule-1; IL-1β: 
Interleukin-1β; NFκB: Nuclear Facor of kappa-light-chain-enhancer of activated B cells; TNBS: 2,4,6-trinitrobenzene 
sulfonic acid; DSS: dextran sulfate sodium; IL-12: Interleukin-12; DNBS: dinitrobenzene sulfonic acid; IL-10: Interleukin-10; 
TNFΔARE/+ mice: mice with gene targeted alterations in untranslated region of TNFα mRNA leading to development of 
severe ileitis; MPO: Myeloperoxidase; BAL: bronchial alveolar lavage; S Aureus: Staphylococcus Aureus; E Coli: Escherichia 
Coli; KC: keratinocyte-derived chemokine; MPTP: 1-methyl-4-fenyl-1,2,3,6-tetrahydropyridine
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Figure 2. The interaction between hypoxia and inflammation
Hypoxia enhances the immune response, and is an inflammatory stimulus by itself. Hypoxia leads to cellular stabilization 
of Hypoxia Inducible Factor 1α (HIF-1α), resulting in a synergistic effect with the key inflammatory transcription factor 
NFκB. In addition, inflammation enhances transcription and translation of HIF-1α, leading to a synergistic effect in case of 
hypoxia and inflammation. In myeloid cells, such as neutrophils and monocytes, HIF-1α activity exerts pro-inflammatory 
effects, aimed at clearance of pathogens. Conversely, in many other cells, such as T-cells, pulmonary and interstitial 
epithelium, and myocytes, HIF-1α activity has anti-inflammatory effects. Furthermore, hypoxia exerts anti-inflammatory 
effects through the adenosine pathway, as it increases the availability of adenosine progenitors adenosine triphosphate 
(ATP) and adenosine diphosphate (ADP), upregulates the converting enzymes CD39 and CD73 to enhance adenosine 
production, and increases the expression of the anti-inflammatory adenosine 2A and 2B receptors (A2A and A2B). The 
upregulation of CD73 and adenosine receptors is HIF-1α-dependent. 
 
HIF-1α in sepsis
The role of HIF-1α in sepsis is of particular interest, as inflammation and tissue hypoxia 
often co-exist, the latter due to a mismatch of oxygen demand and availability. The 
immunologic host response during early sepsis is characterized by (over)production of 
pro-inflammatory cytokines, which is aimed at pathogen clearance but also results in the 
clinical syndrome of septic shock. However, an anti-inflammatory reaction is mounted 
simultaneously, presumably to curtail the pro-inflammatory response and thereby prevent 
collateral tissue damage. When too pronounced and/or sustained, this anti-inflammatory 
response results in a profoundly suppressed state of the immune system. It is increasingly 
recognized that this phenomenon, known as “sepsis-induced immunoparalysis”, renders 
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patients more vulnerable towards secondary infections and is a major contributor to late 
mortality in septic patients79. 
Based on the data described earlier, HIF-1α activity may enhance pro-inflammatory effects 
and innate immune functions, which could be beneficial in sepsis-induced immuno-
paralysis. This concept is supported by the observation that endotoxin tolerance, which 
bears similarities to sepsis-induced immunoparalysis, was partially reversed by chronic 
mild hypoxia in mice20. However, this single animal study does not fully reflect the complex 
dynamics of HIF-1α during human sepsis. Furthermore, it needs to be emphasized that 
the abovementioned studies on (the interplay between) inflammation and hypoxia have 
been conducted in vitro and in animals. The translation from animal studies to the human 
situation is an important topic of debate80,81. Fortunately, two recent observational studies 
in sepsis patients have increased our understanding of the dynamics of HIF-1α during 
sepsis. In one of these, samples were obtained within 2-4 hours after admission, and HIF-1α 
mRNA expression in monocytes was increased82. Furthermore, HIF-1α induced the negative 
Toll-like receptor regulator IRAK-M, resulting in immunosuppression82. In contrast, the other 
study found reduced leukocytic HIF-1α protein and mRNA expression, but samples were 
obtained at later time points (i.e. within 24 hours after admission)83. Although one has to 
be cautious when interpreting data from preclinical work in the context of clinical patient 
studies, it could be envisioned that the early pro-inflammatory response drives increased 
HIF-1α expression, resulting in the induction of negative regulators such as IRAK-M to 
counteract excessive inflammation,ultimately resulting in reduced HIF-1α levels later in the 
course of sepsis. 
Tissue-protective and anti-inflammatory effects through the adenosine pathway
Hypoxia can also exert anti-inflammatory and tissue-protective effects through the ade-
nosine pathway, of which some elements have been reported to be HIF-1α dependent84,85. 
Cellular distress (e.g. hypoxia86) results in increased availability of the adenosine progenitors 
adenosine triphosphate (ATP) and adenosine diphosphate (ADP)87. Hypoxia leads to 
upregulation of CD39 (ecto-apyrase)88,89, which converts ATP and ADP into AMP, and to 
HIF-1α-dependent upregulation of CD73 (5’ecto-nucleotidase), which converts AMP into 
adenosine84. The tissue-protective effects of these enzymes have been demonstrated in 
studies using knockout mice. For example, mice lacking either CD39 or CD73 display increased 
morbidity and mortality after inflammatory or ischemic injury90–92. Correspondingly, genetic 
overexpression of HIF-1α results in increased epithelial expression of CD73 and improves 
outcome in murine chemically induced colitis93. Finally, hypoxia increases the expression 
of the adenosine 2A (A2A) and 2B (A2B) receptors, the latter in a HIF-1α dependent 
manner85. Stimulation of these receptors results in systemic anti-inflammatory effects in 
murine models of ischemia-reperfusion91, hypoxia94, and inflammation95. Furthermore, 
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permissive hypoxia (FiO2 10%) attenuated lung damage and improved survival in a murine 
model of acute lung injury in an A2A receptor-dependent manner96, and induction of the 
A2B-receptor in type 1 alveolar cells during ventilator-induced lung injury was shown to 
be dependent on HIF-1α3. Similarly, hypoxic preconditioning protected mice from liver 
ischema and reperfusion injury in an A2B receptor-dependent manner97.
The limited human data available substantiate that hypoxia results in enhanced adenosine 
availability. For instance, exposure to short-term hypoxia (20 min, SaO2 80%) in healthy 
volunteers increases plasma adenosine levels98. Furthermore, several experimental 
human studies have demonstrated anti-inflammatory effects of adenosine signaling, 
as intravenous adenosine administration99 as well as oral treatment with the adenosine 
uptake inhibitor dipyridamole100 attenuated the pro-inflammatory interleukin-6 response 
during experimental human endotoxemia, and dipyridamole treatment also augmented 
anti-inflammatory interleukin-10 production100. However, increased adenosine availability 
in these latter studies was not induced by hypoxia. Finally, a proof-of-concept clinical study 
revealed that interferon-β-1a enhances CD73 expression in human lung tissue and that 
administration of this cytokine to ARDS patients is associated with reduced interleukin-6 
and interleukin-8 levels as well as improved PaO2/Fio2 ratios and survival
101.
In addition to HIF-1α, NFκB, and adenosine metabolism and signaling pathways, other 
oxygen-sensitive transcription factors have been identified although the exact oxygen-
dependent mechanisms and downstream effects are not fully elucidated (reviewed in102).
A schematic overview of the complex interplay between hypoxia and inflammation is 
depicted in Figure 2. 
Hypoxia in critically ill patients
Hypoxic respiratory failure is a common condtion in ICU patients, with an incidence of 22-
33%103,104, depending on the definition (usually the need for mechanical ventilation and/or 
a PaO2/FiO2 ratio of <300 mmHg
103–105), and is associated with a mortality of 31-52%103–105. A 
subcategory of hypoxic respiratory failure is Acute Respiratory Distress Syndrome (ARDS), 
comprising 3-70% of patients with respiratory failure103–105. ARDS severity can be classified 
according to the Berlin definitions as mild (200-300 mmHg), moderate (100-200 mmHg), 
or severe (<100 mmHg), with mortality ranging from 32 to 65%105–111. It is important to 
differentiate between the diagnosis of hypoxic respiratory failure (i.e. an indication for 
intubation and mechanical ventilation due to hypoxia) and actual hypoxia (i.e. low PaO2 ), 
as patients with hypoxic respiratory failure can have normal PaO2 levels. The occurrence of 
hypoxia (i.e. PaO 2 <80 mmHg) at ICU admission is frequent (40%)
112, and in a retrospective 
cohort study in Dutch ICU patients, hypoxia at ICU admission or during ICU stay was shown 
to be associated with increased mortality, even after correction for disease severity and 
other confounders 112. The association between hypoxia at ICU admission and increased 
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mortality was confirmed in a similar analysis in Australian and New Zealand ICU patients113. 
However, these studies are observational in nature, and although efforts have been made 
to eliminate bias, confounding factors may still play a role. Therefore, these studies cannot 
be used to guide oxygen therapy. Currently, oxygenation targets for critically ill patients 
are lacking. Since the landmark study on tidal volumes in ARDS, a target of 55-80 mmHg or 
SaO2 88-95% is used in ARDS studies
114, even though there is no solid evidence supporting 
these targets115.
Results of clinical trials on the effects of oxygenation in ICU patients are necessary to 
deter mine optimal oxygenation targets in diverse subsets of patients. Currently, the O2-
ICU study randomizes ICU patients with systemic inflammation to either a target PaO2 of 
120 mmHg or 75 mmHg (Clinicaltrials.gov Identifier NCT02321072). The Hyper2S study 
(Clinicaltrials.gov Identifier NCT01722422), in which patients with septic shock were 
rando mized in a 2x2 fashion to normoxia (SaO2 88-95%) vs. FiO2 100% for 24 hours and 
resuscitation with isotonic saline vs. hypertonic saline, was preliminary terminated because 
of a borderline significant increase in mortality in the hyperoxic/hypertonic group116. 
Additionally, the Air Versus Oxygen in ST-segment Elevation Myocardial Infarction trial 
has showed that normoxic patients with ST-elevation myocardial infarction treated with 
supplemental oxygen exhibit increased creatine kinase levels and myocardial infarct sizes 
compared with normoxic patients who did not receive additional oxygen117. The putative 
harmful effects of hyperoxia have instigated further exploration of the safety and feasibility 
of conservative oxygenation targets. Two before-after studies in mechanically ventilated 
ICU patients applied SaO2 targets of 90-92%
118 and 92-95%119, respectively, which was not 
associated with adverse outcomes. The safety and feasibility of a conservative oxygenation 
strategy was recently affirmed by a randomized controlled pilot study comparing a liberal 
oxygenation strategy (SpO 2 > 96%) with a conservative strategy (SpO2 88-92%)
120.These 
results may pave the way for the exploration of a personalized oxygen target to influence 
inflammation in critically ill patients. 
The translation of preclinical data on hypoxia and 
inflammation towards treatment in critically ill patients
As illustrated by animal studies and the limited clinical data available, hypoxia and 
downstream signaling pathways may represent important and amendable factors in the 
pathophysiology of inflammatory conditions in critically ill patients such as sepsis and 
lung injury. However, many hurdles still have to be taken before we can translate these 
insights into clinical practice. The host-responses in inflammatory conditions in critically ill 
patients are complex, with considerable interindividual differences and changes over time. 
Nevertheless, it is conceivable that modulating the immune response towards a targeted, 
personalized, favorable immunologic phenotype, e.g. immunostimulatory therapy in 
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sepsis-induced immunoparalysis or anti-inflammatory therapy in acute lung injury, may be 
of clinical benefit121. As many specific therapeutic target interventions have failed to show 
benefit in clinical trials122, it would be naïve to assume that targeting hypoxia-dependent 
pathways is “the magic bullet”. Nonetheless, optimization of all amendable parameters to 
tailor the inflammatory host-response towards a more preferable profile should still be 
considered. As oxygen management is a daily practice in the ICU , the immunologic effects 
of oxygenation should therefore also be taken into account as a means of optimizing host-
responses. 
Although grossly based on in vitro and animal data, oxygenation-dependent immuno-
modulatory strategies could be envisioned as either pursuing a nullificiation of hypoxia-
induced immunologic effects by preventing hypoxia, or enhancing immunologic effects 
of hypoxia by preventing hyperoxia or even permitting or inducing hypoxia. For example, 
animal data suggest that averting hyperoxia and even permitting hypoxia is beneficial in 
acute lung injury96, apart from prevention of direct oxygen toxicity. Naturally, intentional 
or permissive hypoxia as a therapeutic strategy is only expedient when safety margins are 
taken into account, especially as PaO2  targets would be at the steep part of the oxygen-
hemoglobin dissociation curve. As previously proposed, a suitable oxygenation monitoring 
and control system should use real-time data on pulse oximetry, tissue oxygenation, and 
arterial oxygen tension to achieve a predefined oxygenation123, and should naturally be 
extensively tested for safety, feasibility, and efficacy. 
However, caution is warranted, as there is an association between long-term neuro cognitive 
impairment and the amount of time that ARDS patients were hypoxic (i.e. SaO2 <90%)
124. 
Therefore, short-term benefits of hypoxia, i.e. putative therapeutic effects in inflammation, 
and long-term effects, i.e. neurocognitive impairment need to be carefully weighed. 
Alongside hypoxia, or if permissive hypoxia does not prove to be feasible, HIF-1α-mediated 
effects could also be pursued through pharmacologic inhibition of PHDs. The PHD-inhibitor 
FG-4497 increased HIF-1α stabilization in mice, with subsequent resistance of stem 
cells to irradiation125, improved kidney transplantation survival126 and attenuated TNFα 
expression and weight loss during colitis58. A comparable PHD inhibitor (FG-2216) resulted 
in increased plasma EPO levels in hemodialysis patients127, however, due to a case of fatal 
hepatic necrosis and other patients developing abnormal liver enzyme tests, the FDA 
suspended this clinical trial and further development was discontinued128. Nonetheless, 
clinical trials with new drugs targeting PHDs for treatment of anemia in patients with 
chronic renal disease and dialysis are currently being performed26. Whether pharmacologic 
HIF stimulation affects the immune response in humans has not been established yet. 
Additionally, the frequently used PHD-inhibitor Dimethyloxallyl Glycine (DMOG) and the 
aforementioned FG compounds are pan-hydroxylase inhibitors, and are not specific for HIF-
1α stabilization, which may lead to undesired effects. For example, DMOG also stabilizes 
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HIF-2α, which results in increased EPO levels58,59 and could thus cause polycythemia. This 
can be circumvented by more specific PHD-inhibitors, such as the selective PHD-1 inhibitor 
AKB-4924, and/or local instead of systemic drug delivery68.
Taken together, although the concept of tailoring the immune response through oxy-
genation or pharmacologic modulation of hypoxia-signaling pathways is tempting, the 
question remains if this approach is feasible and will result in clinical benefits for the 
patient. Therefore, studies assessing the putative therapeutic potential of these effects are 
highly warranted. Furthermore, immunomodulatory therapy in inflammatory conditions 
in the ICU still faces many challenges. For example, anti-inflammatory strategies in sepsis 
have been unsuccessful in the past122, possibly because they render patients increased 
vulnerability to secondary infections, although it might also be due to the profound 
heterogeneity of this patient population. Immunostimulatory therapy to prevent and/or 
reverse immunoparalysis is currently under investigation for sepsis79. Meanwhile, a search 
for markers identifying the current “immune status” of ICU patients is ongoing, and may 
result in better identification of patients who could benefit from immunomodulating 
therapy129. 
Conclusion
There is extensive interplay between hypoxia and the immune system. Hypoxia and 
inflammation synergistically induce HIF-1α stabilization, resulting in cellular effects directed 
towards augmented pathogen clearance, of interest, simultaneously anti-inflammatory 
and tissue-protective mechanisms occur, for instance through enhanced adenosine meta-
bolism and signaling. The net effect of these effects is highly dependent on the cell type 
and activation state. Insights into these hypoxia-driven mechanisms promote the concept 
of personalizing oxygenation targets to tailor the immune response in inflamed critically ill 
patients. However, the development of such strategies requires exploration of the putative 
effects of hypoxia on the immune response in humans in vivo, as these data are currently 
lacking. Furthermore, additional studies on pharmacologic HIF-1α stabilizers and agents 
acting on the adenosine pathway are required. In any case, the optimal PaO2 and oxygen 
delivery in critically ill patients are likely to depend on diagnosis and comorbidities, and 
clinicians should be aware that their oxygen therapy may affect not only saturation, but 
also the inflammatory host response. As clinical guidelines on optimal oxygenation are 
currently not present, ongoing clinical trials exploring the feasibility of liberal vs. restrictive 
oxygenation are highly warranted and currently in progress; these could further pave the 
way towards individualized oxygenation therapy. 
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Abstract
Hypoxia and inflammation are closely intertwined phenomena. Critically ill patients 
often suffer from systemic inflammatory conditions and concurrently experience 
short-lived hypoxia. We evaluated the effects of short-term hypoxia on systemic 
inflammation, and show that it potently attenuates pro-inflammatory cytokine 
responses during murine endotoxemia. These effects are independent of hypoxia-
inducible factors (HIFs), but involve augmented adenosine levels, in turn resulting 
in an adenosine 2B receptor-mediated post-transcriptional increase of interleukin 
(IL)-10 production. We translated our findings to humans using the experimental 
endotoxemia model, where short-term hypoxia resulted in enhanced plasma 
concentrations of adenosine, augmentation of endotoxin-induced circulating IL-
10 levels, and concurrent attenuation of the pro-inflammatory cytokine response. 
Again, HIFs were shown not to be involved. Taken together, we demonstrate that 
short-term hypoxia dampens the systemic pro-inflammatory cytokine response 
through enhanced purinergic signaling in mice and men. These effects may contri-
bute to outcome and provide leads for immunomodulatory treatment strategies for 
critically ill patients. 
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Introduction
Hypoxia and inflammation are two closely linked phenomena that are encountered 
in many pathological processes; particularly in critical illness such as sepsis and trauma 
(reviewed in 1,2). Inflammation can lead to tissue hypoxia due to both enhanced demand 
and decreased availability of oxygen, the latter resulting from edema, microthrombi and 
changes in microcirculation (reviewed in 1). Conversely, in vitro studies have demonstrated 
that hypoxia influences the immune response as well, with either pro- or anti-inflammatory 
effects, depending on the cell type (reviewed in 3). In vivo data on immunomodulatory 
effects of hypoxia or hypoxia mimetics in animal models are conflicting. For instance, 
chronic hypoxia (11-27 days) in mice was reported to result in enhanced TNFα levels upon 
challenge with endotoxin4, whereas the hypoxia mimetic DMOG was shown to exert 
distinct anti-inflammatory effects in endotoxemic mice5. A recent study in mice revealed 
that long-term hypoxia (>12 hours) does not relevantly affect the immune response, 
but increases morbidity and mortality from skin and pulmonary infections6. Importantly 
however, hypoxia is often very short-lived in critically ill patients, as it is quickly corrected 
by oxygen supplementation and/or mechanical ventilation7, but the immunologic effects 
of short-term hypoxia are unknown. Furthermore, no human data on immunomodulatory 
effects of hypoxia are available. These are nevertheless of clinical relevance, because the 
majority of critically ill patients suffer from inflammation-related conditions, and putative 
immunomodulatory effects of short-term hypoxia might therefore contribute to the 
outcome of these patients.
Hypoxia may modulate the immune response through a group of transcription factors 
called hypoxia-inducible factors (HIFs)8. There are several HIF isoforms, of which primarily 
HIF-1α has been implicated in regulation of the inflammatory response8, although HIF-2α 
was also found to have immunomodulatory properties9. Moreover, hypoxia also induces 
enhanced signaling of the purine nucleoside adenosine10, which has been shown to exert 
anti-inflammatory and tissue-protective effects11. In addition, adenosine signaling is also 
augmented by inflammation, through enhanced plasma levels of adenosine and increased 
expression of adenosine receptors. Therefore, hypoxia and inflammation might have 
additive or even synergistic effects on adenosine signaling12. 
In the present work, we evaluated the immunologic effects of short-term hypoxia in vivo 
in mice. Furthermore, we investigated the involvement of HIFs and adenosine signaling in 
these effects, and translated our findings to the human setting using an in vivo model of 
systemic inflammation in healthy volunteers. 
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Materials and Methods
Murine studies
Animals and ethics 
Experiments were performed at the Experimental Centre at the University of Technology 
Dresden (Medical Faculty, University Hospital Carl-Gustav Carus), Germany, and the 
Radboud university in Nijmegen, the Netherlands. Experiments were in accordance with 
the facility guidelines at the University of Technology Dresden and were approved by the 
Landesdirektion Dresden, or with the requirements of the Dutch Experiments on Animals 
Act and the EC Directive 86/609, and approved by the Animal Ethics Committee of the 
Radboud university. Experiments were performed on male C57BL/6 mice (Charles River 
Laboratories International, Inc., L’Arbresle Cedex, France). For the experiments depicted in 
Figure S3, Vav:cre13, HIF1f/f14 and HIF2f/f15 transgenic mouse lines were obtained from the 
Jackson Laboratories (Bar Harbor, ME) and crossed in our facility. The obtained mouse lines 
are respectively: Vav:cre-HIF1αf/f (hematopoietic HIF1f/f) and Vav:cre-HIF2αf/f (hematopoietic 
HIF2f/f). The degree of HIF1α deficiency in hematopoietic cells of Vav:cre-HIF1αf/f mice 
versus WT littermates was defined by qPCR on CD45+ bone marrow cells, which revealed 
>90% reduction of WT HIF1α mRNA compared to WT littermates (Figure S1). Since HIF2α 
messenger was scarcely detectable in hematopoietic cells of WT mice, we performed 
genomic PCRs on DNA isolated from mature white blood cells. In samples displaying Cre-
recombinase, HIF2α PCRs revealed virtually full recombination of the floxed-HIF2α (Figure 
S1). For the experiments depicted in Figure 4 and 5, adenosine 2B receptorf/f (provided by 
Prof. Eltzschig), and B6.129P2-Il10tm1Cgn/J mice ((MGI Cat# 5470153, RRID:MGI:5470153) 
(IL-10−/−, The Jackson Laboratory, Bar Harbor, ME) and genetically matched controls were 
used (all C57BL/6 background). Due to the nature of the studies, blinding of the animal 
researchers was not possible. The laboratory analyses were performed by blinded 
personnel. 
Experimental protocol
After randomization using the sealed envelope method, mice were placed in an air-tight 
cage that was continuously flushed with either medical air (normoxia) or an hypoxic 
nitrogen/medical air mixture (fraction of inspired oxygen [FiO2] of 9%) at the same airflow 
rate. Endotoxin (E. Coli, serotype 0111:B4, Sigma-Aldrich, St Louis, MO, USA) dissolved in 
normal saline was administered intraperitoneally at a dose of 5 mg/kg. Mice were sacrificed 
by exsanguination through orbita extraction under deep isoflurane anesthesia. Blood 
was collected in ethylenediaminetetraacetic acid (EDTA)-containing tubes, centrifuged 
(14000g, 5 minutes, room temperature), was and plasma was stored at -80°C until analysis. 
Splenic tissue was snap-frozen in liquid nitrogen and stored at -80 °C until analysis. 
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Cytokine analysis
Plasma concentrations of TNF, IL-1β, IL-6, KC, and IL-10 were measured using a Luminex 
assay (Milliplex, Merck Millipore, Billerica, MA, USA) or ELISA (Duoset or Quantikine, R&D 
systems, Minneapolis, MN, USA).
mRNA expression analysis 
Spleen tissue was homogenized using a Tissuelyzer LT instrument (Qiagen, Venlo, the 
Netherlands) and RNA was isolated with the RNeasy kit (Qiagen). Up to 1 µg of RNA was 
used for cDNA synthesis with iScript (Bio-Rad, Veenendaal, the Netherlands).
qPCR was performed on a CFX96 (Bio-Rad, Hercules, CA, USA). The following primer-probe 
sets were used (all from Life Technologies, Carlsbad, CA, USA): TNF: Mm00443258_m1, IL-
1β: Mm00434228_m1, IL-6: Mm00446190_m1, KC: Mm04207460_m1, IL-10: Mm00439614_
m1, VEGF (Mm00437306_m1), B2M (Mm00437762_m1) and HRPT (Mm01545399_m1). 
ΔCt values were calculated as the difference between the Ct value of the target gene and 
the geometric mean of the Ct values of two housekeeping genes (B2M and HRPT). Fold 
regulation (2|ΔΔCt|) was determined by normalizing ΔCt to the reference group (normoxia-
saline). 
Tissue adenosine measurements
Nucleosides were extracted from spleen tissue by sonification in 850 uL of ice cold 0.4N 
perchloric acid. The mixture was vortexed and 10 uL of this solution was used for protein 
assay. The remaining volume was centrifuged at 14000 rpm at 4 °C for 10 minutes and 
710 uL of the supernatant was vortexed with 40 uL phenol red (0.1 mg/ml in water) and 
356ul 0.6N KHCO3/KOH. After addition of 111 uL ammonium phosphate and 50 uL of 0.18N 
H3PO4 the sample was vortexed, and centrifuged at 14000 rpm for 5 minutes. 1000 uL of the 
supernatant was used for adenosine measurements by HPLC16. 
Human studies
Subjects and study design 
The human experiments were carried out in two phases (ClinicalTrials.gov identifiers 
NCT01889823 and NCT01978158) for safety reasons. All experiments were in accordance 
with the declaration of Helsinki. After approval from the local ethics committee of the 
Radboud University Medical Center, thirty healthy, male volunteers gave written informed 
consent to participate in the experiments. Subjects were screened and had a normal 
physical examination, electrocardiography, and routine laboratory. Exclusion criteria were 
febrile illness during the 2 weeks before the experiment, high altitude exposure in the 
three months prior to the experiment, use of prescription drugs, history of spontaneous 
vagal collapse, and participation in a previous trial with endotoxin administration. 
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In the first phase, effects of short-term hypoxia in the absence of systemic inflammation 
were studied. Ten subjects were exposed to hypoxia for 3.5 hours by titration of FiO2 to a 
peripheral saturation (SaO2) of 80-85%, using an nitrogen/medical air mixture and an air-
tight respiratory helmet (CaStar, StarMed, Italy). The airflow was adjusted to prevent carbon 
dioxide rebreating and prevent hypercapnia. In the second phase, 20 subjects participated 
in endotoxemia experiments. These subjects were randomized using the sealed envelope 
method to hypoxia (n=10) as described above, or normoxia (medical air, FiO2 of 21%, also 
using the respiratory helmet and the same airflow rate as in hypoxic subjects, n=10). One 
hour after initiation of hypoxia or normoxia, 2 ng/kg U.S. Reference Escherichia coli endotoxin 
(serotype O:113, Clinical Center Reference Endotoxin, National Institute of Health, Bethesda, 
USA) was administered intravenously to elicit a systemic inflammatory response. Due to 
continuous monitoring of SaO2, blinding of the researchers performing the procedures on 
the healthy volunteers was not possible. All laboratory analyses were performed by blinded 
personnel. A depiction of the experimental setup is provided in Figure S2.
Procedures and recording of vital signs
Subjects refrained from caffeine and alcohol 24 hours before the experiment, and refrained 
from food and drinks 10 hours before the experiment. A venous cannula was placed for 
fluid infusion (prehydration with 1.5 L 2.5% glucose/0.45% saline in the hour preceding 
endotoxin administration followed by hydration with 150 mL/h for 6 h, and 75 mL/h for the 
rest of the experiment) and endotoxin administration. An arterial cannula was placed for 
monitoring of blood pressure and blood withdrawal. Heart rate and SaO2 were monitored 
using a three-lead electrocardiogram and a pulse oximeter connected to a Philips MP50 
patient monitor. Body temperature was measured every 30 minutes using an infrared 
tympanic thermometer (FirstTemp Genius 2; Covidien, Ireland).
Plasma cytokines and PaO2 measurements
Blood was collected in EDTA tubes and centrifuged immediately at 2000g at 4˚C for 10 
minutes after which plasma was stored at -80˚C until analysis by Luminex assay (Milliplex). 
PaO2 was analyzed in lithium heparin anticoagulated arterial blood using CG4+ cartridges 
and a point-of-care i-STAT blood gas analyzer (Abbott, Abbott Park, IL, USA). 
HIF-1α protein expression in leukocytes 
After lysis of erythrocytes in lithium heparin-anticoagulated blood using Pharm Lyse solution 
(Becton Dickinson, San Jose, CA), surface staining was performed using fluorochrome-
conjugated antibodies (CD15-FITC (Clone H198), CD3-PECγ7 (Clone HIT3a), CD14-APC 
(Clone M5E2) (BioLegend Cat# 301807, RRID:AB_314189) (all obtained from BioLegend, San 
Diego, USA) for neutrophils, lymphocytes, and monocytes, respectively. After fixation and 
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permeabilization with Transcription Factor Fixation/Permeabilization buffer (eBioscience 
Inc, San Diego, USA), PE-conjugated anti-HIF-1α and corresponding isotype control (Clone 
241812, RD Systems, Minneapolis, USA)were used to stain intracellular HIF-1α and correct 
for aspecific binding. Leukocytes were fixed and stored overnight in PBS containing 1% 
bovine serum albumin and 1% paraformaldehyde. The data were acquired with Cytomics 
FC500 (Beckman Coulter, Brea, CA, USA) and analyzed with Kaluza software (Beckman 
Coulter). Cell subtypes were identified by surface staining and sideward scatter. Mean PE 
fluorescence, after subtraction of isotype-fluorescence, was used as a measure of HIF-1α 
expression. The gating strategy used is depicted in Figure S3.
mRNA expression of HIF-1α, and hypoxia signaling-related genes
Blood was collected in PAXgene tubes (PreAnalytiX, Venlo, The Netherlands), which contain 
a proprietary reagent that immediately stabilizes leukocyte RNA at the moment of blood 
withdrawal, and kept at room temperature for 24 hours before storage at -80 °C. Total RNA 
was isolated using the PAXgene Blood RNA kit (PreAnalytiX) and up to 1 µg of RNA was 
reverse transcribed into cDNA using the i-script cDNA synthesis kit (Biorad), and stored 
at -20 °C until analysis. mRNA expression of HIF-1α was analyzed with qPCR on a Bio-Rad 
CFX96 (Bio-Rad). HIF-1α expression was normalized to the expression of the housekeeping 
gene B2M. The following primer-probe sets were used (from Life Technologies): HIF-1α: 
Hs00153153_m1 and B2M: Hs00984230_m1.
Expression of hypoxia signaling-related genes was analyzed in 3 subjects from each 
group using the RT2 Profiler hypoxia signaling Plus PCR Array (Qiagen) according to the 
manufacturer’s protocol on a CFX96 (Bio-Rad). The array plate was customized by replacing 
4 controls by 4 extra genes (Von Hippel Lindau [VHL], granulocyte macrophage colony-
stimulating factor [GM-CSF], granulocyte colony-stimulating factor [G-CSF] and soluble 
VEGF receptor [FLT1]. Genes of interest were normalized to 4 housekeeping genes (GAPDH, 
B2M, RPLP0 and ACTB) present on the PCR array. A <35 cycles cut off was applied. 
Plasma adenosine measurements
Plasma adenosine concentrations were measured using an in-house developed method 
described previously17. Briefly, blood was immediately mixed at the tip of the syringe with a 
2.5 ml solution containing pharmacological blockers of adenosine formation, transport and 
degradation. Blood samples were centrifuged for 10 minutes at 1000 g at 4°C and plasma 
was stored at -80°C until analysis. Plasma adenosine concentrations were determined by 
high performance liquid chromatography (HPLC). 
Whole blood stimulation experiments
After approval from the local ethics committee of the Radboud university medical center 
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(CMO 2010/10), lithium heparin-anticoagulated blood was obtained from 8 healthy 
volunteers who provided written informed consent. Blood was diluted 5 times in culture 
medium (RPMI [Invitrogen, Carlsbad, California, USA] supplemented with 10 μg/mL 
gentamicin, 10 mM Glutamax and 10 mM pyruvate) and incubated in 48-well plates in the 
presence of 1 or 10 μM PSB1115 (Tocris BioScience, Abingdon, UK) or vehicle (DMSO, final 
concentration of 0.1% in all experimental conditions) for 30 minutes at 37 °C and 5% CO2. 
Hereafter, 10 μM 5’-N-Ethylcarboxamidoadenosine (NECA) or vehicle (DMSO) was added 
and cultures were again incubated for 30 minutes. Subsequently, 10 ng/mL endotoxin 
(E Coli, serotype O55:B5, Sigma Aldrich) or vehicle (RPMI) was added and cultures were 
incubated for 24 hours, after which plates were centrifuged for 8 minutes at 1400 RPM at 
room temperature and supernatant collected and stored at -80 °C until analysis. Cytokine 
concentrations were measured using ELISA according to the manufacturer’s instructions 
(Human Duoset, R&D systems).
Calculations and statistical analysis
For both the human and murine experiments a power calculations were performed. 
In previous human endotoxemia experiments performed by our group, the standard 
deviation (s.d.) for peak plasma TNF concentration was 30% of the mean. Using an two-
sided α of 0.05, a power of 80% (β of 0.2), and an expected detectable contrast of 40% in an 
unpaired t-test design, 10 subjects per group were required. 
For the initial murine experiments, a provisional power calculations were based on 
previous murine endotoxemia experiments performed by our group, the s.d. for plasma 
IL-6 concentration was 25% of the mean. Using an two-sided α of 0.05, a power of 80% (β of 
0.2), and an expected detectable contrast of 40% in an unpaired t-test design, 8 animals per 
group were required. To reduce the number of animals needed, we used the data from the 
primary murine experiment to calculate the lowest number of animals necessary. Plasma 
IL-6 concentrations were normally distributed, with a mean of 38019 pg/ml in the normoxic 
group, and 11126 pg/ml in the hypoxia group, and a pooled standard deviation of 6994. 
A 2-group 2-sided power calculation with these actual data shows that n=2 would be 
sufficient to identify this difference. Nevertheless, we deemed this group size insufficient 
to draw robust conclusions and therefore have used a minimum of n=5 for all endotoxin-
treated groups. Because saline treatment was shown to not induce cytokine responses 
under normoxic or hypoxic conditions, we applied the ‘refinement’ dogma; by reducing the 
number of animals in this group to n=2-6. Data are presented as median and interquartile 
range, or mean (± s.e.m.) based on their distribution (calculated by the Shapiro-Wilk 
test). Differences between groups in demographic characteristics were calculated using 
Kruskall-Wallis tests. Except for demographic characteristics, all non-parametric data were 
log-transformed before statistical analysis The human in vivo cytokine data were analyzed 
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using unpaired Student’s t-tests on Area Under Curve (AUC) of time-concentration curves 
to assess differences in total amount of cytokines released. For other human in vivo data, 
repeated measures one-way analysis of variance (ANOVA) followed by Dunnett’s post-
hoc test was used to assess within-group differences over time and make comparisons 
to baseline, whereas between-group differences over time were assessed using repeated 
measures two-way ANOVA (interaction term). Independent groups were compared using 
Student’s t-test, multiple independent groups were compared using one way ANOVA 
with Dunnett’s post-hoc test to compare with control group. All tests were two-sided, 
and a p-value of <0.05 was considered statistically significant. Statistical calculations were 
performed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA). 
For the RT2 Profiler hypoxia signaling Plus PCR Array data, differences between groups 
were analyzed using repeated measures two-way ANOVA (interaction term) on ΔCT values. 
To analyze differences over time within one group or in the pooled dataset of hypoxic 
and normoxic endotoxemic subjects, paired Student t-tests were used on ΔCT values, 
comparing the different time-points against baseline (t=-1, just before initiation of hypoxia 
or normoxia using the respiratory helmet). A 2-fold change cut off compared to baseline 
was applied and p-values were corrected for the false discovery rate (FDR) using Benjamini 
Hochberg correction. qPCR array data were analyzed using TIGR Multiexperiment viewer 
4.0 (TMeV4.0) and are presented as fold change compared to baseline. 
Results 
Short-term hypoxia exerts anti-inflammatory effects during murine endotoxemia 
Binding of lipopolysaccharide (LPS, endotoxin) to Toll-like receptor 4 is a critical step in 
orchestrating of the inflammatory response in Gram-negative sepsis, and increased levels 
of plasma cytokines are one of the key hallmarks of this response. We used a murine 
model in which intraperitoneal injection with E coli-derived endotoxin was employed to 
elicit a systemic inflammatory response, and studied the effects of short-term hypoxia 
(fraction of inspired oxygen [FiO2] of 9%) on the systemic cytokine response (experimental 
design depicted in Figure 1a). Plasma levels of both pro- (tumor necrosis factor alpha 
[TNF], interleukin-1β [IL-1β], IL-6, and keratinocyte-derived chemokine [KC]) and anti- 
inflammatory (IL-10) cytokines were increased at both 1.5 and 3 hours after endotoxin 
administration (Figure 1b). Hypoxia initiated one hour before endotoxin administration 
resulted in profound augmentation of plasma IL-10 levels and attenuation of the pro-
inflammatory cytokine response (Figure 1b). These effects were most pronounced at 1.5h 
after endotoxin administration (Figure 1b), and were present to a similar extent when mice 
were challenged with lower doses of endotoxin (Figure 1c and d). 
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Figure 1. Short-term hypoxia exerts anti-inflammatory effects during murine endotoxemia 
(a) Experimental setup. C57BL/6 mice were randomized to short-term hypoxia or normoxia and intraperitoneally (i.p) 
injected with endotoxin (5 mg/kg) or saline. (b) Plasma concentrations of interleukin-10 (IL-10), tumor necrosis factor 
alpha (TNF), IL-1β, IL-6 and keratinocyte-derived chemokine (KC). n=4 in saline groups, n=8 in endotoxin groups. 
(c) Experimental setup. C57BL/6 mice were randomized to short-term hypoxia or normoxia and intraperitoneally injected 
with endotoxin (5, 0.5 or 0.05 mg/kg). (d). Plasma concentrations of IL-10, TNF, IL-1β, IL-6 and KC. n=5 per group. Data 
expressed as mean (± s.e.m.). *P < 0.05 ,**P<0.01, ***P < 0.001, # P=0.05-0.10 (unpaired Student’s t-test). 
 Hypoxia dampens inflammation in vivo | 57
3
The effects of short-term hypoxia are rapidly constituted and post-transcriptionally regulated
Subsequently, we assessed the time window during which hypoxia exerts the observed 
anti-inflammatory effects by varying the timing of hypoxia relative to endotoxin admini-
stration (experimental design depicted in Figure 2a). Except for TNF, which was not affected, 
the previously found anti-inflammatory phenotype was also observed when hypoxia was 
initiated at the time of endotoxin administration (“simultaneous” condition, Figure 2b). In 
contrast, anti-inflammatory effects were neither identified when hypoxia was applied only 
in the hour before endotoxin administration (hypoxia “pretreatment” condition), nor when 
it was initiated 0.5h after endotoxin administration (hypoxia “posttreatment” condition, 
Figure 2b). From these results, we infer that the first 30 minutes following endotoxin 
administration are critical for the anti-inflammatory effects of short-term hypoxia. To 
investigate whether these effects are transcriptionally regulated, we measured mRNA 
expression of IL-10, TNF, IL-1β, IL-6 and KC in splenic tissue (experimental design depicted 
in Figure 2c). In mice that were not challenged with endotoxin, hypoxia alone did not 
affect expression of any of the genes, except for a slight but significant decrease in TNF 
mRNA (Figure 2d). Expression of all cytokine genes was strongly induced by endotoxin 
administration, but was not attenuated by hypoxia (Figure 2d); TNF mRNA levels were even 
slightly enhanced. To ascertain that the spleen becomes hypoxic in our model, we also 
determined mRNA expression of the classic hypoxia-induced gene vascular endothelial 
growth factor (VEGF). As depicted in Figure S4, hypoxia significantly increased VEGF 
expression, both in the presence and absence of endotoxin-induced inflammation.
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Figure 2. The anti-inflammatory effects of short-term hypoxia are rapidly constituted  
and post-transcriptionally regulated
(a) Experimental setup. C57BL/6 mice were randomized to normoxia or one of the following hypoxia modalities: hypoxic 
control: hypoxia starting 1h before endotoxin administration until 1.5h thereafter; simultaneous: hypoxia starting 
simultaneous with endotoxin administration until 1.5h thereafter; pretreatment: hypoxia only in the hour before 
endotoxin administration; posttreatment: hypoxia starting 0.5h after endotoxin administration until 1.5h thereafter. 
Endotoxin (5 mg/kg) was injected intraperitoneally (i.p). (b) Plasma concentration of IL-10, TNF, IL-1β, IL-6 and KC. 
(c) Experimental setup. C57BL/6 mice were randomized to short-term hypoxia or normoxia and intraperitoneally injected 
with endotoxin (5 mg/kg) or saline. (d) mRNA expression of IL-10, TNF, IL-1β, IL-6 and KC measured in splenic tissue. n=8 
per group in all experiments. Data expressed as mean (± s.e.m.) or mean (± s.e.m.) fold change related to normoxic-saline 
condition on a 2log scale. *P < 0.05 , **P<0.01, ***P < 0.001 (compared to normoxia calculated using one-way ANOVA 
with post-hoc Dunnett’s test for panel b; unpaired Student’s t-test for panel d).
Hypoxia Inducible Factors are not involved in the anti-inflammatory effects of short-term hypoxia 
Previous studies have revealed that hypoxia-inducible transcription factors (HIFs) are 
involved in regulation of immune responses8. To evaluate the involvement of HIFs in the 
anti-inflammatory effect of short-term hypoxia, we performed hypoxia experiments in 
mice deficient for HIF1α or HIF2α in their hematopoietic system and wild type littermates 
(experimental design depicted in Figure 3a). As shown in Figure 3b, hematopoietic deletion 
of HIF1α or HIF2α did not relevantly affect the hypoxia-induced differences in cytokine 
responses compared to wild type mice. These results indicate no involvement of hemato-
poietic HIF1α or HIF2α in the anti-inflammatory effects of short-term hypoxia, which is in 
line with the previous finding that these effects are post-transcriptionally mediated. 
Short-term hypoxia augments adenosine levels and adenosine 2B receptor-dependent IL-10 
production
Purinergic signaling plays a critical role in adaptation to hypoxia. In vitro and ex vivo studies 
have shown that hypoxia as well as inflammation leads to increased levels of the anti-
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inflammatory and tissue-protective purine adenosine10,12,18–20. In addition, inflammation 
also increases the expression of adenosine receptors12. This may indicate that hypoxia and 
inflammation have additive or synergistic effects on adenosine signaling. Previous in vitro 
work revealed that stimulation of adenosine 2B (A2B) receptors results in increased IL-10 
production via a post-transcriptional mechanism21.
Figure 3. The anti-inflammatory effects of short-term hypoxia are not mediated through HIFs
(a) Experimental setup. Vav:cre HIF-1αf/f ,Vav:cre HIF-2αf/f and genetically matched wild type littermates (C57BL/6 
background) were exposed to short-term hypoxia and intraperitoneally (i.p.) injected with endotoxin (5 mg/kg). 
(b) Plasma concentration of IL-10, TNF, IL-1β, IL-6 and KC. n=6-7 in Vav:cre HIF-1αf/f and wild type groups, n=6-8 in 
Vav:cre HIF-2αf/f and wild type groups. Data are expressed as mean (± s.e.m.). * P<0.05, **P<0.01, ***P < 0.001 (unpaired 
Student’s t-test). 
Therefore, we hypothesized that short-term hypoxia results in a rapid increase in adenosine, 
leading to an early and profound increase in plasma IL-10 levels through enhanced A2B 
receptor signaling, ultimately resulting in dampening of the pro-inflammatory cytokine 
response. To test these hypotheses, we first measured tissue adenosine levels during 
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hypoxia, systemic inflammation and the combination of both conditions (experimental 
design depicted in Figure 4a). Hypoxia in the absence of inflammation enhanced splenic 
levels of adenosine within 30 minutes, further increasing after 1.5h of hypoxia (Figure 4b). 
Systemic inflammation also increased adenosine levels, and concurrent hypoxia resulted in 
a synergistic increase (Figure 4b). 
Figure 4. The anti-inflammatory effects of short-term hypoxia involve adenosine 2B receptor-
dependent augmentation of IL-10 levels
(a) Experimental setup. C57BL/6 mice were randomized to short-term hypoxia or normoxia and intraperitoneally (i.p.) 
injected with endotoxin (5 mg/kg) or saline. (b) Splenic tissue concentration of adenosine. n=6 in saline groups, n=8 in 
endotoxin groups. (c) Experimental setup. Adenosine 2B receptor (A2B) genetic deficient and genetically matched control 
mice (C57BL/6 background) were randomized to short-term hypoxia or normoxia and intraperitoneally injected with 
endotoxin (5 mg/kg) or saline. (d) Plasma concentration of IL-10, TNF, IL-1β, IL-6 and KC. n=2 in saline groups, n=6 in 
wild type endotoxin groups, n=8 in A2B -/- normoxic endotoxin group, n=7 in normoxic endotoxin A2B-/- group. Data are 
expressed as mean (± s.e.m.). * P<0.05, **P<0.01, ***P < 0.001, # P=0.05-0.1 (unpaired Student’s t-test).
Hereafter, we assessed the involvement of the A2B receptor in the observed enhanced IL-
10 levels and subsequent attenuation of the pro-inflammatory cytokine response using 
germline-deficient A2B receptor mice and genetically matched controls (experimental 
design depicted in Figure 4c). The hypoxia-induced increase in plasma IL-10 observed in 
wild type mice was nullified in A2B-deficient mice (Figure 4d). Furthermore, the hypoxia-
induced attenuation of IL-1β and KC was less pronounced and did not reach statistical 
significance in these mice, whereas the trend towards lower TNF levels was absent (Figure 
4d). Thus, the adenosine 2B receptor is crucial for the enhanced IL-10 levels induced by short-
term hypoxia. Because IL-10 potently attenuates pro-inflammatory cytokine production 
during endotoxemia in mice22 and humans23, we evaluated whether IL-10 is involved in the 
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hypoxia-induced attenuation of pro-inflammatory cytokines. To this end, we performed 
experiments in germline IL-10-deficient mice (experimental design depicted in Figure 5a). 
In these mice, the hypoxia-induced anti-inflammatory phenotype less pronounced for IL-1β 
and absent for IL-6 and KC (Figure 5b). 
Figure 5. Hypoxia-induced attenuation of pro-inflammatory cytokines involves IL-10
(a) Experimental setup. IL-10−/− and genetically matched wild type mice (C57BL/6 background) were randomized to 
short-term hypoxia or normoxia and intraperitoneally (i.p.) injected with endotoxin (5 mg/kg) or saline. (b) Plasma 
concentration of IL-10, TNF, IL-1β, IL-6 and KC. n=3 in wild type saline groups, n=4 in IL-10−/− saline groups, n=8 in all 
endotoxin groups. Data expressed as mean (± s.e.m.). **P<0.01, ***P < 0.001 (unpaired Student’s t-test). 
Short-term hypoxia dampens the endotoxin-induced pro-inflammatory cytokine response in 
humans in vivo
To translate our findings obtained in mice to humans, we performed hypoxia experiments 
in healthy volunteers who were intravenously injected with endotoxin. Thirty healthy 
subjects were exposed to either endotoxemia alone, hypoxia (target peripheral saturation 
[SaO2] of 80-85%) alone, or hypoxia combined with endotoxemia. (See Figure 6a for the 
experimental design, Figure S2 for a depiction of the experimental setup, and Table S1 
for demographic characteristics of the study subjects). Hypoxia (FiO2 of 11-12%) resulted 
in decreased arterial oxygen pressures accomplishing the peripheral saturation (SaO2) 
target of 80-85%, with a concurrent decrease in mean arterial pressure and an increase in 
heart rate (Figure 6b). Hypoxia was well-tolerated and no serious adverse events occurred 
during the study. In the hypoxia-only group, plasma cytokine concentrations were below 
the lower detection limit throughout the experiment, indicating that short-term hypoxia 
exerts no inflammatory effects by itself (Figure 6c). Endotoxin administration elicited a 
typical systemic inflammatory response characterized by an increase in body temperature 
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(Δ temperature 1.6±0 .2 °C in both groups, mean ± s.e.m.) and flu-like symptoms. 
Furthermore, plasma concentrations of TNF, IL-6, IL-8, and IL-10 increased profoundly after 
endotoxin administration (Figure 6c). Hypoxia during endotoxemia resulted in an early and 
two-fold increase of IL-10 compared with the normoxia group, while pro-inflammatory 
cytokine levels were attenuated by 30 to 50% (Figure 6c). 
Figure 6. Short-term hypoxia dampens the endotoxin-induced pro-inflammatory cytokine response 
in humans
(a) Experimental setup. Healthy volunteers were randomized to either short-term hypoxia or normoxia in combination 
with intravenous administration of 2 ng/kg endotoxin to elicit systemic inflammation, or to short-term hypoxia without 
endotoxin administration. (b) Arterial oxygen pressure (PaO2) peripheral oxygen saturation (SaO2), mean arterial 
pressure (MAP) and heart rate (HR). (c) IL-10, TNF, IL-6 and IL-8 plasma concentrations over time and area under the time-
concentration curves (AUC). The blue shaded box indicates the period of hypoxia. Data are expressed as mean (± s.e.m.). 
P-values indicate the difference between the AUCs of the normoxic endotoxemia and hypoxic endotoxemia groups, 
calculated using unpaired Student’s t-tests. *P < 0.05 , **P<0.01, ***P < 0.001. n=10 per group. 
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Hypoxia does not affect leukocyte HIF-1α mRNA and protein expression, and HIF activity  
in humans 
Although HIFs were not involved in the anti-inflammatory effects of short-term hypoxia 
in mice, we nevertheless assessed the possible involvement of these transcription factors 
in the human setting. To this end, we measured HIF-1α mRNA and protein expression in 
circulating leukocytes. HIF-1α mRNA in leukocytes and HIF-1α protein levels in neutrophils 
and lymphocytes, but not monocytes, increased after endotoxin administration (Figure 7a-
d). This endotoxin-induced increase in HIF-1α expression is in line with previous in vitro 
studies showing that endotoxin induces HIF-1α activity under normoxic conditions24. 
Hypoxia in the presence and absence of endotoxemia did not affect HIF-1α mRNA and 
protein expression (Figure 7a). In addition, we assessed hypoxia-induced transcriptional 
activity by determining the expression of 86 hypoxia-signaling-related genes in leukocytes, 
many of which are downstream targets of HIFs. This analysis revealed no significant changes 
in expression of any of the genes in the hypoxia only group. Furthermore, there were no 
significant differences in expression of any of the genes between hypoxic and normoxic 
endotoxemic subjects (Table S2). Taken together, short-term hypoxia neither results 
in enhanced HIF-1α levels, nor in HIF-dependent transcriptional activity in circulating 
leukocytes. 
Short-term hypoxia augments plasma adenosine levels in humans in vivo 
Plasma adenosine levels were measured to evaluate the role of this purine in the human 
experiments. Hypoxia in the absence of systemic inflammation resulted in a significant 
increase in plasma adenosine levels at the end of the hypoxic period (t=2.5h, Figure 7e), 
which normalized after reoxygenation. Systemic inflammation in the presence as well as 
the absence of hypoxia resulted in a more prolonged increase in plasma adenosine levels. 
A2B receptor stimulation in human whole blood mimics the anti-inflammatory effects  
of hypoxia 
Finally, to investigate the involvement of the A2B receptor in the human setting, we 
stimulated human whole blood with endotoxin in the presence or absence of the 
nonselective adenosine receptor agonist 5’-N-Ethylcarboxamidoadenosine (NECA) and 
the selective human A2B receptor antagonist PSB1115. As depicted in Figure 8a, NECA 
potently enhanced IL-10 production, while attenuating TNF and IL-6 release. A2B receptor 
blockade partially counteracted NECA’s effects on IL-10 and TNF. 
Taken together, our data reveal that short-term hypoxia dampens the endotoxin-induced 
systemic inflammatory response through a rapid increase in adenosine levels, resulting in 
an A2B-receptor dependent increase of IL-10 concentrations and subsequent attenuation 
of pro-inflammatory cytokines (Figure 8b).
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Figure 7. Short-term hypoxia neither affects leukocyte HIF-1α mRNA and protein expression, nor HIF 
transcriptional activity, and augments plasma adenosine levels in humans
Measurements were performed on samples obtained from the experiments depicted in Figure 6a. (a) Leukocyte HIF-1α 
mRNA change over time expressed as change from baseline (timepoint -1, just before initiation of hypoxia or normoxia 
using the respiratory helmet) on a 2log scale. (b, c and d) Change in neutrophil, monocyte and lymphocyte HIF-1α 
protein expression over time as measured by flow cytometry. Neutrophils, monocytes, and lymphocytes were identified 
with CD15, CD14, and CD3 fluorochrome-conjugated antibodies, respectively. Intracellular HIF-1α protein expression is 
expressed as the difference between mean fluorescence intensity (MFI) of HIF-1α antibody-stained and isotype control-
stained cells. The gating strategy is provided in Figure S3. (e) Plasma concentrations of adenosine. Data are expressed as 
median [IQR]. Within-group changes over time were analyzed using one way ANOVA followed by Dunnett’s post-hoc test 
on log-transformed data. Between-group differences over time were analyzed using repeated measures two-way ANOVA 
on log transformed data (interaction term). *P < 0.05 , **P<0.01, ***P < 0.001 compared to baseline (timepoint -1h). HE; 
hypoxic endotoxemia, NE; normoxic endotoxemia, H; hypoxia. MFI; mean fluorescence intensity. n=10 per group. 
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Figure 8. A2B blockade partially reverses the anti-inflammatory effects of the adenosine receptor 
agonist NECA in endotoxin-stimulated human whole blood
(a) Concentrations of IL-10, TNF and IL-6 in supernatants of whole blood cultures stimulated with endotoxin (10 ng/
mL) in the presence and absence of the nonselective adenosine receptor agonist 5’-N-Ethylcarboxamidoadenosine 
(NECA) and the selective human A2B receptor antagonist PSB1115. N=8, Data expressed as mean (± s.e.m.). **P<0.01, 
***P < 0.001 (compared with cultures incubated with the same dose of PSB1115 in the absence of NECA, calculated 
using paired Student’s t-tests). # P<0.05, ### P<0.001 (compared with cultures incubated with NECA in the absence of 
PSB1115, calculated using repeated measures one-way ANOVA with Dunnett’s post-hoc tests). (b) Proposed mechanism 
of hypoxia-induced anti-inflammation. Short-term hypoxia results in augmented adenosine levels and A2B receptor 
signaling. This results in enhanced IL-10 release via a post-transcriptional mechanism, in turn attenuating the pro-
inflammatory cytokine response.
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Discussion 
Hypoxia and inflammation are key characteristics of many pathological processes, and they 
influence each other considerably. Herein, we demonstrate that short-term hypoxia exerts 
profound anti-inflammatory effects during systemic inflammation in vivo in both mice and 
humans. The underlying mechanism involves enhanced adenosine release and stimulation 
of the adenosine A2B receptor, resulting in augmented IL-10 production and subsequent 
dampening of the pro-inflammatory cytokine response. Our data further demonstrate that 
HIFs are not involved in the immunologic effects of short-term hypoxia. 
Previous work demonstrated that hypoxia increases extracellular adenosine concentrations 
in vitro18 and ex vivo10,19,20. We show that clinically relevant levels of hypoxia result in a rapid 
increase of adenosine levels in vivo, in both humans and mice. Hypoxia can enhance 
extracellular adenosine levels through several pathways. During cellular stress, such 
as hypoxia or inflammation, precursor nucleotides (e.g. ATP) are released, and hypoxia 
enhances their conversion to adenosine25. In addition, hypoxia inhibits adenosine uptake 
of the equilibrative-nucleotide-transporter26. Nevertheless, both these processes take 
several hours to constitute, as they involve alterations of the transcription and translation 
of the proteins involved. However, in ex vivo experiments, hypoxia was shown to attenuate 
adenosine kinase activity within minutes, resulting in a rapid increase of extracellular 
adenosine10,20. It appears plausible that this mechanism accounts for the swift hypoxia-
induced increase of adenosine in the present work. 
We identify that the hypoxia-induced enhanced IL-10 production is mediated via an A2B 
receptor-dependent post-transcriptional mechanism; findings which are corroborated by 
our in vitro data obtained in human leukocytes. Furthermore, anti-inflammatory effects 
through A2B receptor signaling have been reported by others. For example, mice deficient 
for A2B display an augmented TNF response after renal ischemia and reperfusion27, and 
increased influx and delayed clearance of neutrophils in a lung injury model28. Along 
these lines, an important role for A2B receptors in improving outcome was demonstrated 
in murine models of pleural inflammation29, renal27, intestinal30, and hepatic31 ischemia-
reperfusion, and multimicrobial abdominal sepsis32. Previous human work is in support 
of the identified adenosine-induced IL-10-dependent anti-inflammatory effects. First, 
the infusion of recombinant IL-10 during human endotoxemia resulted in decreased 
plasma concentrations of pro-inflammatory cytokines33. Second, treatment with the 
adenosine reuptake inhibitor dipyridamole during human endotoxemia caused an early 
and pronounced increase of plasma IL-10 levels and attenuation of TNF and IL-6 plasma 
concentrations34. In contrast, intravenous infusion of adenosine during human endotoxemia 
did not result in a clear anti-inflammatory phenotype35. This may be explained by the fact 
that adenosine infusion started 30 minutes after endotoxin administration in these studies, 
whereas we show that the first 30 minutes are critical for its anti-inflammatorily effects. 
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In addition, plasma adenosine is known to have a very short half-life36, and the infused 
adenosine may therefore not have reached the target tissue. It needs to be acknowledged 
that although A2B and IL-10 deficient mice clearly display attenuation of the hypoxia-
induced anti-inflammatory phenotype, it was not completely abrogated, implying that 
other mechanisms may also contribute to hypoxia-induced anti-inflammatory effects, 
albeit to a much lesser extent.
We found no involvement of HIFs in the anti-inflammatory effects of short-term hypoxia. 
Our initial murine data revealed that the anti-inflammatory effects exerted by short-
term hypoxia are very rapid and post-transcriptionally regulated, already rendering the 
critical involvement of a transcription factor unlikely, and the subsequent experiments in 
hematopoietic HIF-1α- and HIF-2α-deficient mice confirm this. Nevertheless, it needs to 
be acknowledged that HIFs are known to exert immunomodulatory effects, but that these 
mainly appear to be of relevance in the setting of chronic hypoxia. For example, a recent 
murine study showed that prolonged hypoxia (12 hours up to several days) in the context 
of a concurrent skin or pulmonary infection leads to increased morbidity and mortality, 
in a HIF-dependent manner6. Another study, in which mice were exposed to hypoxia 
for 11-27 days, demonstrated an enhanced plasma TNFα response upon challenge with 
endotoxin4. These findings signify that distinctly different mechanisms underlie the effects 
of short-term and chronic hypoxia. Finally, administration of the hypoxia-mimetic DMOG, 
a prolyl hydroxylase inhibitor which stabilizes HIFs, resulted in a similar anti-inflammatory 
cytokine profile in endotoxemic mice as observed in the present study, although the in 
vivo involvement of HIFs was not determined and additional off-target effects cannot be 
excluded when using these pharmacological mimetics5. 
Our work demonstrates that short-term hypoxia attenuates the inflammatory response 
in vivo consistently across species. The relevance of hypoxia-induced anti-inflammation 
remains to be determined, but speculatively, it may represent a mechanism aimed at limiting 
inflammation-induced tissue injury, thereby improving outcome of severe infec tions 
with concurrent tissue hypoxia. Hosts can respond to invading pathogens by mounting 
an immunologic response, which may result in collateral damage known as immuno-
pathology37,38. Tolerance to the consequences of pathogen invasion and immuno pathology 
are mechanisms that provide an effective adaptation to disease. As such, hypoxia-induced 
anti-inflammation may represent a mechanism to improve the host’s tolerance to immuno-
pathology, and theoretically, accepting or inducing systemic hypoxia could therefore 
curtail excessive inflammation. Previous implementation studies39,40 and clinical trials41,42 
have demonstrated safety and feasibility of conservative oxygenation strategies in the 
intensive care unit (ICU), paving the way for further exploration of variable oxygenation 
targets. Intriguingly, recent work revealed that short-lived hypoxia at the emergency 
department appeared to be associated with a lower mortality compared to normoxia or 
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hyperoxia7. In that study, patients in the hypoxia group displayed a median PaO2 of 54 
mmHg (7.7 kPa) at the emergency department7, which is in the same range as what the 
hypoxic subjects were exposed to in our study. Based on the data presented in the present 
work, it is tempting to speculate that this observed beneficial effect on outcome is due to 
reduced immunopathology. Nevertheless, we wish to emphasize that caution should be 
taken in vulnerable patients due to the risk of inadequate tissue oxygenation and organ 
failure. The adenosine signaling pathway may therefore represent another therapeutic 
target. Unfortunately, direct systemic infusion of adenosine as an immunomodulatory 
therapy is limited by its short half-life36 and undesired cardiovascular side effects43. Direct, 
unselective pharmacologic stimulation of adenosine receptors may result in a similar 
harmful profile. Theoretically, allosteric modulation of the A2B receptor, thereby increasing 
its binding affinity and/or functional efficacy, may be more successful. Under physiologic 
conditions with low levels of adenosine, the adenosine receptor is not activated, preventing 
its disadvantageous systemic effects. Under local inflammatory or hypoxic conditions 
however, tissue levels of adenosine increase, and the allosterically modulated A2B receptor 
will be more sensitive to adenosine and/or cause stronger anti-inflammatory effects at 
similar adenosine concentrations, resulting in site-specific anti-inflammatory effects44 
without systemic side effects. Although the development of this class of drugs is in its 
infancy, efforts aimed at pharmacologic targeting of the adenosine signaling pathway to 
achieve anti-inflammatory effects are being made45,46.
In conclusion, we demonstrate that short-term hypoxia profoundly attenuates the pro-
inflammatory cytokine response during systemic inflammation in mice, and translate these 
findings to humans by showing identical results in healthy volunteers. The underlying 
mechanism involves increased adenosine levels and subsequent adenosine 2B receptor-
mediated enhanced release of IL-10. Hypoxia-induced anti-inflammation may constitute a 
mechanism to improve the host’s tolerance to immunopathology, but this requires further 
study. As short-term hypoxia is common in critically ill patients, its immunomodulatory 
effects may affect outcome. Finally, hypoxia and the adenosine pathway might represent 
promising therapeutic modalities to modulate the immune response. 
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Supplemental Figures and Tables
Supplemental Figure 1. Identification of hematopoietic-specific HIFα-deficient mouse lines 
(a) HIF1α mRNA level measured via qPCR using CD45+ BM from WT (HIF1αf/f) and Vav:cre-HIF1αf/f mice (n=3). Mean ± 
S.E.M. - * p<0.05. (b) HIF2α deficiency (excision of floxed-exon 2) was defined via genomic PCR (1 & 3: Vav:cre-HIF2αf/f; 2: 
HIF2αf/f; C: Control). 
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Supplemental Figure 2. Experimental setup during the human experiments
The subject wears an airtight respiratory helmet and is connect to a monitoring device. The upper monitor displays the 
ECG-signal (green), intra-arterial blood pressure (red), peripheral oxygen saturation (purple) and respiratory rate (white). 
The lower monitor displays the fraction of oxygen (FiO2) that flows through the efferent tube to the helmet (upper white 
line and number), and the concentration of carbon dioxide and oxygen within the helmet (green line and number and 
lower white line and number, respectively). The subject provided written informed consent to publish his picture. 
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Supplemental Figure 3. Gating strategy used for quantification of intracellular HIF-1α protein 
expression in various leukocyte subsets
Whole blood was surface stained using fluorochrome-conjugated antibodies (neutrophils: CD15-FITC [depicted in blue in 
the upper dot plot]; monocytes: CD14-APC [depicted in red in the upper dot plot], and lymphocytes: CD3-PECγ7 [depicted 
in green in the upper dot plot]). After fixation and permeabilization, a PE-conjugated anti-HIF-1α antibody (depicted 
in green in the lower dot plots) or the corresponding isotype control antibody (depicted in red in the lower dot plots) 
were used to stain intracellular HIF-1α and correct for aspecific binding. The mean fluorescence intensity (MFI) in the 
PE-channel for the isotype-stained cells was subtracted from the MFI in the PE-channel of the HIF-1α-stained cells to 
obtain the HIF-1α protein expression level. The representative data shown were obtained at 2.5 hours after endotoxin 
administration in the normoxic endotoxemia group (see Figure 6a for study design).
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Supplemental Figure 4. VEGF mRNA expression in splenic tissue
C57BL/6 mice were randomized to short-term hypoxia or normoxia and intraperitoneally injected with endotoxin (5 mg/
kg) or saline (experimental setup depicted in Figure 2c), and VEGF mRNA expression was measured in splenic tissue. n=8 
per group. Data expressed as mean (± s.e.m.) fold change related to normoxic-saline condition on a 2log scale. *P < 0.05, 
***P < 0.001 (compared to normoxia calculated using unpaired Student’s t-test). 
 
Hypoxia
(n=10)
Hypoxic endotoxemia
(n=10)
Normoxic endotoxemia
(n=10) p-value
Age [yr] 21 [19-23] 22 [20-22] 21 [20-23] 0.96
Height [cm] 183 [179-186] 183 [180-190] 185 [180-192] 0.80
Weight [kg] 75 [69-89] 75 [70-82] 75 [69-86] 0.99
BMI [kg/m2] 22.4 [20.9-25.6] 21.7 [21.0-24.6] 22.2 [20.5-24.2] 0.97
Supplemental Table 1. Demographic characteristics of healthy volunteers
Parameters measured during screening visit. Data are presented as median [interquartile range], p-values were 
calculated using Kruskall-Wallis tests. yr: years; cm: centimeter, kg: kilogram, BMI: body mass index, m: meter. 
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2.5 hours after endotoxin administration
Normoxic endotoxemia Hypoxic endotoxemia
Gene Fold regulation
Corrected
 p-value Fold regulation
Corrected
 p-value 2-way ANOVA
MMP9 63 .869 p>0.05 40 .542 p<0.05 0 .09
ADM 3 .214 p>0.05 5 .752 p<0.05 0 .86
APEX1 -3 .896 p>0.05 -5 .328 p<0.05 0 .84
HIF1A 4 .239 p>0.05 5 .300 p<0.05 0 .53
GPI -2 .904 p>0.05 -3 .354 p<0.05 0 .86
RUVBL2 -3 .502 p>0.05 -3 .877 p<0.05 0 .99
NAMPT 4 .047 p>0.05 5 .431 p<0.05 0 .41
CCNG2 1 .426 p>0.05 2 .096 p<0.05 0 .86
4 hours after endotoxin administration
Normoxic endotoxemia Hypoxic endotoxemia
Gene Fold regulation
Corrected
 p-value Fold regulation
Corrected
 p-value 2-way ANOVA
TP53 -5 .128 p<0.05 - 4 .762 p>0.05 0 .86
PFKFB3 14 .800 p<0.05 8 .034 p<0.05 0 .96
RPLP0 -3 .663 p<0.05 -4 .000 p>0.05 0 .91
TPI1 -2 .315 p<0.05 -1 .077 p>0.05 0 .24
MMP9 59 .200 p<0.05 20 .776 p<0.05 0 .09
SLC2A3 7 .669 p>0.05 4 .740 p<0.05 0 .86
GPI -4 .587 p>0.05 -3 .277 p<0.05 0 .86
BNIP3 -1 .446 p>0.05 -2 .092 p<0.05 0 .37
6 hours after endotoxin administration
Normoxic endotoxemia Hypoxic endotoxemia
Gene Fold regulation
Corrected
 p-value Fold regulation
Corrected
 p-value 2-way ANOVA
ADM 6 .357 p<0.05 5 .277 p>0.05 0 .86
SLC2A3 5 .889 p>0.05 3 .945 p<0.05 0 .86
PFKFB4 8 .625 p>0.05 2 .007 p<0.05 0 .96
APEX1 -3 .484 p>0.05 -3 .506 p<0.05 0 .84
GPI -3 .195 p>0.05 -2 .443 p<0.05 0 .86
MMP9 32 .791 p>0.05 9 .962 p<0.05 0 .09
NAMPT 8 .793 p>0.05 4 .208 p<0.05 0 .41
RBPJ 2 .622 p>0.05 2 .618 p<0.05 0 .96
BHLHE40 -2 .475 p>0.05 -2 .734 p<0.05 0 .99
BNIP3 -1 .244 p>0.05 -2 .019 p<0.05 0 .84
HIF1A 4 .000 p>0.05 2 .105 p<0.05 0 .53
BNIP3L 1 .019 p>0.05 -2 .890 p<0.05 0 .37
Supplemental Table 2. Changes in hypoxia-related gene expression in leukocytes of subjects that 
were exposed to short-term hypoxia or normoxia and were administered endotoxin
Data are expressed as fold regulation from baseline (time point -1, just before initiation of hypoxia or normoxia using 
the respiratory helmet, see Figure 6a for study design). Only genes that showed a >2-fold change in expression from 
baseline which was significant in either the normoxic endotoxemia of hypoxic endotoxemia group are listed. p-values 
calculated using paired Student’s t-test were false discovery rate (FDR)-corrected. Between-group differences over time 
were analyzed using 2-way ANOVA (FDR-corrected p-value of interaction term). There were no significant changes from 
baseline at 1h after endotoxemia. n=3 per group. 
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Dear editor, 
Hepcidin is the central mediator of iron homeostasis that limits iron availability in the 
extracellular compartment and causes iron-restricted erythropoiesis. Inflammation is a 
strong hepcidin inducer, which can lead to anemia of inflammation, whereas hypoxia can 
suppress hepcidin production. Inflammation, hypoxia and anemia are often encountered 
in critically ill patients. In the present study, we determined the effects of hypoxia on 
parameters of iron regulation and homeostasis in humans in vivo during systemic 
inflammation induced by endotoxin administration. We report that systemic inflammation 
results in increased plasma hepcidin levels and a subsequent decrease in serum iron levels. 
Hypoxia attenuates these endotoxaemia-induced effects on hepcidin and iron parameters, 
likely through increased production of erythropoietin and erythroferrone. 
Hepcidin binds to the iron exporter ferroportin expressed on macrophages and duodenal 
enterocytes, leading to its internalization and degradation, thereby reducing iron export 
into the extracellular compartment1. Hepcidin regulation is mainly driven by body iron 
status and systemic inflammation, which is a major inducer of hepcidin production. The 
redistribution of iron into iron-storing cells as a result of increased hepcidin production 
during infection is regarded as a part of the innate immune response against extracellular 
proliferating pathogens, as iron is a vital nutrient for microbial growth and replication. 
In contrast to inflammation, hypoxia is regarded as a strong suppressor of hepcidin 
production2. Hypoxia promotes increased transport of iron from storage sites to facilitate 
erythropoiesis in the bone marrow3,4. Erythropoiesis is induced by erythropoietin, which 
increases the production of erythroferrone, a known suppressor of hepcidin synthesis5. 
A great majority of critically ill patients suffer from inflammatory conditions such as 
sepsis, major surgery and trauma, and also develop anemia6. This so-called “anemia of 
inflammation” is related to worse outcome7,8. As such, efforts have been made to develop 
therapies that inhibit hepcidin production or mitigate its downstream effects9. Next to 
causing anemia, pronounced systemic inflammation often leads to concurrent tissue 
hypoxia in critically ill patients. Therefore, there may be interplay between both phenomena 
with regard to hepcidin production and iron homeostasis, but this has not yet been studied 
in humans. Herein, we investigated the effect of hypoxia on erythropoietin, erythroferrone 
and hepcidin production and iron homeostasis parameters in healthy volunteers during 
experimental endotoxaemia, a standardized controlled model of systemic inflammation in 
humans in vivo.
Data were obtained from subjects participating in an open-label, randomized, parallel 
group intervention study (registered at ClinicalTrials.gov: #NCT01978158) aimed at 
investigating the effects of modulation of oxygen status during systemic inflammation on 
immunologic (primary outcome) and many other parameters, including haemodynamic 
effects, coagulation, the endocrine response, and renal function (complete list provided 
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at https://clinicaltrials.gov/ct2/show/NCT01978158). The primary outcomes have been 
published elsewhere and are freely accessible10. The trial was approved by the local ethics 
committee and carried out according to GCP standards and the declaration of Helsinki 
including current revisions. The methods are detailed elsewhere10. Briefly, after written 
informed consent was obtained, subjects were declared eligible based on a screening 
including a full medical history, physical examination, ECG and routine laboratory tests. 
Twenty male non-smoking subjects, between 18 and 35 years of age, were randomized 
to receive either hypoxia (n=10) or normoxia (n=10) during experimental endotoxaemia. 
Hypoxic exposure (peripheral oxygen saturation [SaO2] 80-85%) started 1 hour before, and 
continued until 2.5 hours after endotoxin administration, and was attained by feeding 
a nitrogen/medical air mixture into an air-tight respiratory helmet (CaStar, StarMed, 
Italy). Normoxic subjects were fitted with the same respiratory helmet fed with medical 
air (FiO2 21%). Purified standard reference Escherichia coli O:113 LPS (Clinical Center 
Reference Endotoxin, National Institutes of Health, Bethesda, MD, USA) was administered 
intravenously at a dose of 2 ng/kg body weight to elicit a systemic inflammatory 
response. Blood samples were obtained from an arterial catheter (up to eight hours 
after endotoxin administration) or venipuncture (at 24 hours post-endotoxin). Plasma 
erythropoietin and erythroferrone concentrations were determined by ELISA (eBioscience, 
Vienna, Austria, and MyBioSource, San Diego, CA, USA, respectively). Plasma hepcidin 
levels were measured using a specifically designed competitive ELISA11 with a lower 
limit of detection of 0.42 nmol/L. None of the measured concentrations fell below this 
lower limit. Serum iron and transferrin were determined using routine analysis methods 
(Architect c16000, Abbott Diagnostics, Lake Forest, USA), as was haemoglobin (Sysmex 
XE 5000, Sysmex Corp., Kobe, Japan). Total iron binding capacity (TIBC) was calculated 
as: TIBC (μmol/L)=25 (µmol/g) x transferrin (g/L). Transferrin saturation was calculated as 
serum iron (μmol/L) / TIBC (μmol/L)) x 100. Plasma cytokine levels were determined by 
Luminex assay (Merck Millipore, Billerica, MA, USA).
Data are expressed as mean ± SD, and between-group differences over time (baseline to 
8 hours after endotoxin administration) were analyzed with repeated measures two-way 
analysis of variance (ANOVA, interaction term). Differences between groups at baseline and 
24 hours after endotoxin administration were evaluated using unpaired Student’s t-tests. A 
p-value of <0.05 was considered statistically significant.
As detailed elsewhere10, a SaO2 of 80-85% was attained using a mean FiO2 of 11.4±0.7% 
in the hypoxia group. All subjects experienced typical flu-like symptoms that peaked 
90 minutes after endotoxin administration and subsided within the following hours. 
Hypoxia resulted in increased plasma erythropoietin concentrations from 90 minutes 
after endotoxin administration onwards (Figure 1A). In normoxic subjects, erythropoietin 
levels were increased only at 24 hours post-endotoxin administration, and at that time-
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point, concentrations were similar as those observed in subjects who had previously 
been exposed to hypoxia. In both groups, circulating erythroferrone and hepcidin levels 
increased over time (Figure 1B-C). Hypoxia augmented the endotoxaemia-induced 
increase in erythroferrone and attenuated the increase in hepcidin levels, of which the 
latter effect manifested later on, at six hours after endotoxin administration. Baseline 
serum iron concentrations were comparable in both groups (21 ± 7.1 vs. 17.4 ± 5.9 µmol/L 
in the hypoxia and normoxia groups, respectively, p=0.23). In line with previous work12,13, 
endotoxaemia resulted in an initial increase in serum iron, peaking 3 hours after endotoxin 
administration, followed by a decrease below baseline values that was most pronounced 8 
hours post-endotoxin administrations (Figure 1D). Transferrin saturation showed virtually 
the exact same profile as serum iron concentrations with no differences between the 
treatment groups up till 8 hours post-endotoxin administration (data not shown). However, 
24 hours after endotoxin administration, significantly higher levels of serum iron (16.8 ± 4.1 
vs. 10.6 ± 3.4 µmol/L, p=0.002) and transferrin saturation (28.8 ± 8.5 vs. 17.8 ± 5.5, p=0.003) 
were observed in the hypoxia group compared with the normoxia group. No clear effects 
of either endotoxaemia or hypoxia were observed on total iron binding capacity (TIBC) 
(Figure 1E). Baseline haemoglobin levels were higher in the hypoxia group (149.4 ± 6.6 vs. 
143.3 ± 5.4 g/L, p=0.04), and an initial decrease was observed in both groups due to our 
prehydration protocol14 (Figure 1F). Furthermore, haemoglobin concentrations over time 
differed significantly between groups. In either group, baseline haemoglobin levels did not 
correlate with baseline or peak hepcidin levels, or with serum iron or TSAT at baseline or 
t=24h (all p-vales >0.10). Plasma cytokine levels markedly increased in all subjects after 
endotoxin administration10. Hypoxia resulted in a two-fold increase of concentrations of 
the anti-inflammatory cytokine interleukin (IL)-10, and a 30-50% reduction in levels of pro-
inflammatory cytokines Tumor Necrosis Factor α, IL-6 and IL-810. There were no significant 
correlations between cytokine responses (area under the concentration-time curve [AUC]) 
and peak or AUC hepcidin concentrations (all p-vales >0.10).
Taken together, our data demonstrate that exposure of healthy volunteers to hypoxia during 
experimental endotoxaemia enhances erythropoietin and erythroferrone concentrations, 
and partially suppresses inflammation-induced hepcidin production. Furthermore, 
hypoxia mitigates the inflammation-induced decrease in serum iron levels and transferrin 
saturation at later timepoints. 
Since its discovery in 2000, many regulatory pathways concerning hepcidin production 
have been discovered. The main hepcidin production-enhancing pathways are the BMP-
SMAD pathway, activated by high iron stores, and the JAK-STAT3 pathway induced by 
inflammatory mediators such as IL-615, which accounts for the phenomenon known 
as anemia of inflammation16,17. Anemia of inflammation occurs in both chronic (e.g. 
autoimmune conditions) and acute (e.g. sepsis) inflammatory conditions18. Previous studies 
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revealed that hepcidin levels are increased in septic patients, and that this is associated 
with the development of anemia18. Our data shows that hypoxia can partially reverse the 
effects of acute inflammation on hepcidin production and its downstream effects on serum 
iron levels and transferrin saturation. 
Figure 1. Parameters of iron regulation and homeostasis 
(A) Plasma erythropoietin (B) Plasma erythroferrone (C) Plasma hepcidin (D) Serum iron (E) Total iron binding capacity 
(F) Haemoglobin. The grey box indicates the period of hypoxic exposure, endotoxin was administered at 0 hours. Data 
are expressed as mean ± SD. Between-group differences over time (baseline to 8 hours post-endotoxin administration) 
were analyzed with repeated measures two-way ANOVA (interaction term displayed in each panel). ** indicates p<0.01, 
calculated using an unpaired Student t-test. 
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Hypoxia has been described to suppress hepcidin production through various mecha-
nisms, many of which involve a group of transcription factors called Hypoxia Inducible 
Factors (HIFs). Although HIFs do not directly affect hepcidin levels19, HIF induction 
results in increased erythropoietin production, in turn leading to increased synthesis of 
erythroferrone, a known suppressor of hepcidin production5. This cascade is also observed 
in this study. An alternative explanation for the observed change in hepcidin is that HIF 
induction also increases levels of furin, a protease that cleaves haemojuvelin and thereby 
produces soluble haemojuvelin, an inhibitor of the BMP-SMAD pathway20. The relevance of 
HIFs for hepcidin regulation and for iron mobilization and utilization in vivo is supported by 
the notion that patients who use pharmacologic HIF-inducers (named prolylhydroxylase 
inhibitors) for renal anemia display decreased hepcidin and ferritin levels, and an increase 
in total iron binding capacity and haemoglobin (e.g. for vadadustat21). Finally, hypoxia may 
decrease hepatic hepcidin transcription via induction of platelet derived growth factor-BB22. 
Due to the nature of this study, we cannot ascertain a cause-effect relationship between 
hepcidin levels at 6 hours and iron levels at 24 hours. Nevertheless, a murine study has 
shown that exogenously administered hepcidin affects iron levels for up to 48 hours, long 
after hepcidin levels had returned to baseline23. Therefore, such a cause-effect relationship 
may be present in humans as well. 
It deserves to be mentioned that experimental human endotoxaemia is a relatively mild 
model of systemic inflammation. As such, our results may not be directly applicable to 
critically ill patients. In addition, long-term effects of hypoxia on iron parameters remain 
to be determined, as we did not obtain blood samples from the study subjects later than 
24 hours following endotoxin administration. Finally, there were significant between-
group differences in baseline haemoglobin levels and in the change in haemoglobin 
concentrations over time, which can only be explained by an unbalanced randomization. 
Although no relationships between baseline haemoglobin level and peak levels of, or 
changes in hepcidin or iron levels were identified, we cannot exclude it as a confounding 
factor.
In conclusion, we demonstrate that hypoxia augments erythropoietin and erythroferrone 
levels, partially attenuates the inflammation-induced increase in hepcidin concentrations, 
and mitigates the decrease in serum iron levels and transferrin saturation. These results 
provide proof-of-concept that hypoxia is relevant in the context of hepcidin regulation and 
iron metabolism in vivo, and may be of special relevance to critically ill patients, in whom 
inflammation and hypoxia often coincide. 
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Abstract
Systemic inflammation and hypoxia frequently occur simultaneously in critically 
ill patients, and are both associated with platelet activation and coagulopathy. 
However, human in vivo data on the effects of hypoxia on platelet function and 
plasmatic coagulation under systemic inflammatory conditions are lacking. In the 
present study, twenty healthy male volunteers were randomized to either 3.5h 
of hypoxia (peripheral saturation 80-85%) or normoxia (room air), and systemic 
inflammation was elicited by intravenous administration of 2 ng/kg endotoxin. 
Various parameters of platelet function and plasmatic coagulation were determined 
serially. Endotoxemia resulted in increased circulating platelet-monocyte com-
plexes and enhanced platelet reactivity, effects which were attenuated by hypoxia. 
Furthermore, endotoxin administration resulted in decreased plasma levels of 
platelet factor 4 levels and increased concentrations of Von Willebrand factor. 
These endotoxemia-induced effects were not influenced by hypoxia. Neither endo-
toxemia nor hypoxia affected thrombin generation. In conclusion, our data reveal 
that hypoxia attenuates the endotoxemia-induced increases in platelet-monocyte 
formation and platelet reactivity, while leaving parameters of plasmatic coagulation 
unaffected. 
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Introduction
Systemic inflammation is a commonly observed phenomenon in critically ill patients, for 
instance in sepsis or following trauma. Systemic inflammation induces the activation of 
platelets and coagulation, ultimately resulting in coagulopathy, organ dysfunction, and 
worse outcome1. Hypoxia is also frequently encountered in these patients, possibly due to 
the fact that tissue hypoxia can be one of the consequences of systemic inflammation, and 
is associated with adverse outcome as well. Hypoxia has also implied to directly activate 
coagulation. For instance, it has been associated with an increased risk of thrombotic 
events2, and was shown to increase platelet reactivity in rats3 and to enhance procoagulant 
activity of human endothelial cells in vitro4. Therefore, next to systemic inflammation, 
hypoxia may also contribute to altered platelet function and coagulopathy in critically 
ill patients, thereby increasing their risks for organ dysfunction. Human in vivo data on 
the effects of hypoxia on platelet function and plasmatic coagulation during systemic 
inflammation are currently lacking. In the present study, we describe the effects of hypoxia 
on platelet function and plasmatic coagulation during experimental human endotoxemia, 
an in vivo model of systemic inflammation. 
Methods
Study design, population, and procedures
Data were obtained from healthy male volunteers participating in an randomized inter-
vention study (registered at ClinicalTrials.gov: #NCT01978158) aimed at investigating the 
effects of oxygenation during systemic inflammation on immunologic (primary outcome) 
and many other parameters (provided at https://clinicaltrials.gov/ct2/show/NCT01978158). 
The primary outcomes have been published elsewhere and are freely accessible [5]. 
The trial was approved by the local ethics committee and carried out according to GCP 
standards and the declaration of Helsinki, including current revisions. Detailed methods 
are provided elsewhere5. Briefly, after providing written informed consent, subjects were 
randomized to normoxia (room air) or hypoxia (titration of fraction of inspired oxygen to a 
peripheral oxygen saturation of 80-85%) for 3.5 hours using an air-tight respiratory helmet. 
One hour after initiation of hypoxia or normoxia, at timepoint t=0, two ng/kg E. coli-derived 
endotoxin was administered intravenously. Blood was collected in 3.2% citrate-containing 
vacutainers at several time points.
Assays
Platelet counts were determined using an automated hematology cell counter. Platelet 
monocyte complexes (PMCs) were flow cytometrically analyzed after incubating whole 
blood with PE-labeled anti-CD14 (BD Biosciences) and FITC-labeled anti-CD42b (Bio-
Legend). PMCs were defined as CD14+ cells positive for CD42b. Platelet reactivity was 
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determined by measuring membrane expression of CD62P (P-selectin) in unstimulated 
whole blood and after ex vivo stimulation with seven increasing concentrations of 
adenosine diphosphate (ADP; Sigma Aldrich) for 20 minutes. Antibodies used were PE-
labeled anti-CD62P (Bio-Legend) and PC7-labeled anti-CD61 (Beckman Coulter). The mean 
fluorescent intensity (MFI) of CD62P on CD61-postive platelets was determined by flow 
cytometry for each ADP concentration, and the area under the ADP-response curve was 
used as a measure for platelet reactivity. Thrombin generation was determined by means 
of calibrated automated thrombography, as described elsewhere6. Plasma concentrations 
of von Willebrand factor (vWF), platelet factor-4 (PF4) and thrombin-antithrombin (TAT) 
complexes were measured using ELISA, as described previously7.
Statistical analysis
Within-group changes over time were analyzed using one-way analysis of variance 
(ANOVA), and p-values are reported in the figure legends. Between-group differences over 
time were analyzed using general linear mixed models, and p-values are indicated in the 
figures. Data were analyzed with SPSS version 22 (IBM). A p-value of <0.05 was considered 
significant. 
Results
As published elsewhere5, endotoxin administration resulted in transient flu-like symptoms 
(i.e. fever, headache, muscle ache, nausea) and increased plasma cytokines levels in all 
subjects. Hypoxia enhanced plasma concentrations of the anti-inflammatory cytokine 
interleukin-10 by 230%, whereas levels of pro-inflammatory mediators Tumor Necrosis 
Factor-α, interleukin (IL)-6 and IL-8 were attenuated by 41, 39, and 37%, respectively5.
Platelet-associated parameters 
Platelet counts decreased slightly, but significantly, in normoxic endotoxemia subjects, an 
effect which was less pronounced in hypoxic subjects (Fig 1A). Percentages of circulating 
PMCs increased following endotoxin administration in both groups, but to significantly 
lesser extent in hypoxic subjects (Fig 1B). In both groups, platelet reactivity showed a 
very similar pattern as PMCs (Fig 1C). Plasma levels of PF4 in normoxic subjects tended to 
decrease and normalize afterwards, and hypoxia did not modulate this effect (Fig 1D). 
Von Willebrand factor levels and plasmatic coagulation
Endotoxemia resulted in increased plasma concentrations of the endothelial activation 
marker vWF, with a trend towards slightly higher levels in the hypoxia group (Fig 1E). 
Plasmatic coagulation was evaluated by measuring thrombin generation and TAT 
complexes. Thrombin generation was unaffected following endotoxin administration 
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(Fig 1F), while TAT complex concentrations gradually increased (Fig 1G). Both measures of 
plasmatic coagulation were not influenced by hypoxia. 
Figure 1. Time course of platelet function and coagulation parameters during experimental 
endotoxemia in normoxic and hypoxic healthy volunteers 
(A) Whole blood platelet counts. Changes over time: normoxia p<0.0001, hypoxia p<0.0001. (B) Percentage of platelet 
monocyte complexes (PMCs). Changes over time: normoxia p=0.0006, hypoxia p=0.03. (C) Platelet reactivity expressed 
as the change from baseline of the area under the adenosine diphosphate dose-response curve. Changes over time: 
normoxia p<0.0001, hypoxia p=0.41. (D) Plasma concentrations of platelet factor 4 (PF4). Changes over time: normoxia 
p=0.08, hypoxia p=0.001. (E) Plasma concentrations of von Willebrand Factor. Changes over time: normoxia p<0.0001, 
hypoxia p<0.0001. (F) Endogenous thrombin generation. Changes over time: normoxia: p=0.08 , hypoxia p=0.10. (G) 
Plasma concentrations of thrombin-antithrombin (TAT) complexes. Changes over time: normoxia p=0.03, hypoxia 
p=0.007. The grey box indicates the period during which subjects were exposed to hypoxia. Endotoxin was administered 
intravenously at t=0 hours. Data are expressed as the estimated mean with error obtained from the mixed linear model, 
and p-values reported in the panels express the difference between the normoxic and hypoxic endotoxemia model. 
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Discussion
In the present study, we demonstrate that hypoxia mitigates the effects of systemic 
inflammation on platelet-associated parameters, as endotoxemia-induced decreases in 
platelet counts, and increases in PMCs and platelet reactivity were attenuated in hypoxic 
subjects. Hypoxia did not significantly influence the endotoxemia-induced increase in 
plasma levels of vWF and TAT-complexes. Furthermore, concentrations of the platelet 
degranulation marker PF4 and ex vivo thrombin generation, a measure of plasmatic 
coagulation, were also unaffected by hypoxia. 
In accordance with our results, previous work has consistently demonstrated that 
experimental human endotoxemia results in decreased platelet counts8, and increased 
PMCs9, platelet reactivity10, and plasma levels of vWF8,10 and TAT complexes11. 
Correspondingly, increases in platelet activation markers are observed in sepsis patients12. 
Thrombin generation has not been previously assessed during endotoxemia, and our 
data reveal that it is not relevantly influenced by either systemic inflammation or hypoxia. 
The discrepancy between TAT complexes and thrombin generation may indicate that 
endotoxemia induces enhanced in vivo thrombin production, but that this does not result 
in a functional tendency towards hypercoagulation13. 
The few human studies that have investigated the influence of hypoxia on platelets under 
non-inflammatory conditions reported no effects of either eight hours of mild hypoxia14 or 
seven minutes of deep hypoxia15 on soluble P-selectin levels, PMCs, and platelet reactivity. 
In contrast, deeply hypoxic rats displayed increased platelet activation and aggregation3. 
Previous studies on the effects of hypoxia on plasmatic coagulation have yielded conflicting 
results. Some have reported increased concentrations of prothrombin fragments 1+2 
(F1+2) and TAT complexes (both markers of thrombin formation) during hypoxia
16, whereas 
others found no effects on either F1+2, TAT complexes, endogenous thrombin generating 
potential, or several other measures of plasmatic coagulation14,15,17. Taken together, most 
studies have not demonstrated procoagulant effects of hypoxia in humans in vivo, which is 
consistent with our current findings. Therefore, the assumption that hypoxia per se results 
in a procoagulant state is not supported by experimental data. 
Several potential mechanisms may explain the effects of hypoxia on the endotoxemia-
induced changes in platelet counts and coagulation parameters observed. Although 
platelets express Toll Like Receptor-4, the archetypal receptor for endotoxin, it is debated 
whether it can be directly activated by endotoxin12. Therefore, it is plausible that the 
endotoxemia-induced effects on platelets are mediated by secondary mechanisms, for 
example through the release of cytokines. In this context, it is important to emphasize that 
the hypoxic subjects in this study exhibited approximately 40% lower circulating levels 
of pro-inflammatory mediators5, which may explain the attenuated effects on platelets. 
Clearly, our work is limited by the fact that the experimental human endotoxemia model 
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does not fully represent the inflammatory response observed in critically ill patients. 
Nevertheless, given the paucity of human in vivo data on this subject, our study does provide 
valuable insights into the complex interactions between inflammation, hypoxia, platelets, 
and coagulation. We report that hypoxia does not augment, but rather attenuates systemic 
inflammation-induced increases in PMC formation and platelet reactivity in humans in vivo, 
whereas it does not affect parameters of plasmatic coagulation. 
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Dear Editor, 
Patients with Von Hippel-Lindau disease (VHLd) have a monoallelic germ line mutation 
in the Von Hippel-Lindau (VHL) gene. The Von Hippel-Lindau protein (pVHL) facilitates 
degradation of the transcription factor Hypoxia Inducible Factor(HIF)-1α1. When a second 
hit affects the only well-functioning VHL gene left, HIF-1α is no longer degraded and its 
transcriptional activity can contribute to the development of highly vascularized benign 
and malignant tumors in VHLd1. 
HIF-1α appears to play an important role in innate immunity. For instance, mice with a 
myeloid HIF-1α deficiency show an attenuated in vivo cytokine responses upon admini-
stration of lipopolysaccharide (LPS)2. 
These observations have led us and others3 to hypothesize that VHL haploinsufficiency may 
result in a more pro-inflammatory phenotype of myeloid cells. Such a pro-inflammatory 
phenotype may contribute to tumorigenesis, as an inflammatory environment created by 
tumor-associated macrophages promotes tumor growth4. Herein, we evaluated whether 
ex vivo LPS-induced cytokine production is altered in patients with VHLd. 
All procedures were approved by the local ethics committee (CMO 2010/104) and in 
accordance with the declaration of Helsinki. We included VHLd patients and age-matched 
healthy subjects in a 1:2 ratio. PMBCs were isolated and stimulated with 10 ng/ml LPS (E. 
Coli, serotype 0111:B4, Sigma Aldrich, St Louis, MI, USA) or medium (RPMI) for 24 and 48 
hours5. Concentrations of the pro-inflammatory cytokines Tumor Necrosis Factor (TNF)-α, 
interleukin (IL)-1β , IL-6 andIL-8 after 24 hours of stimulation and of the anti-inflammatory 
cytokine IL-10 after 48 hours of stimulation were determined in supernatants using ELISA 
(DuoSet, R&D Systems, Oxford, United Kingdom). 
The study population consisted of 7 VHLd patients (1 male and 6 females) and 14 controls 
(4 males and 10 females). Median [interquartile range] age was 49 [31-67] and 41 [31-52] 
years in patients and controls, respectively (p=0.33). There were no differences in TNFα, 
IL-1β, IL-8 and IL-10 production between patients with VHLd and controls, while IL-6 
production was lower in patients (Figure 1). 
These results indicate that a haplodeficiency in VHL does not augment ex vivo cytokine 
production capacity. These results are in contrast with the hypothesis that VHL haplo-
deficiency results in enhanced HIF-1α activity and a subsequent increased pro-inflammatory 
response. Previous work has shown that transcriptional HIF-1α activity is associated 
with pro-inflammatory effects in myeloid cells, as myeloid HIF-1α deficiency resulted in 
an anti-inflammatory phenotype in murine models of skin infection6, and after systemic 
administration of LPS2 or lipoteichoic acid and peptidoglycan7. The similarities in cytokine 
production of controls and patients with VHLd may therefore be due to sufficient monocytic 
pVHL residual function to accommodate adequate HIF-1α degradation. Alternatively, these 
similarities may be explained by the finding that mutant pVHL retains its E3 ligase function 
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necessary for HIF degradation8. Finally, as stimulation with LPS potently enhances HIF-1α 
transcription9, the resultant profoundly increased HIF-1α production may also overrule 
subtle differences in degradation between patients and controls. 
In conclusion, the LPS-induced ex vivo cytokine production of patients with VHLd is not 
augmented. Tumors-associated macrophages with a monoallelic VHL defect in patients 
with VHLd are therefore unlikely to contribute to a tumorigenic environment more than in 
patients without VHLd.
Figure 1. Cytokine production 
Concentration of the pro-inflammatory cytokines Tumor Necrosis Factor (TNF)α, Interleukin (IL)-1β, IL-6, IL-8, and IL-10 in 
the supernatants of peripheral blood monocytic cells incubated with or without E Coli lipopolysaccharide (10 ng/ml) for 
24h (TNFα, IL-1β, IL-6 and IL-8) or 48h (IL-10). Data are expressed as box plots showing medians and 10-90th percentile. 
Statistical differences were analyzed with Mann Whitney tests * p<0.05. VHLd: patients with Von Hippel Lindau disease
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Abstract
Oxygen therapy to maintain tissue oxygenation is one of the cornerstones of critical 
care. Therefore, hyperoxia is often encountered in critically ill patients. Epidemio-
logic studies have demonstrated that hyperoxia may affect outcome, although 
mechanisms are unclear. Immunologic effects might be involved, as hyperoxia 
was shown to attenuate inflammation and organ damage in preclinical models. 
However, it remains unclear whether these observations can be ascribed to direct 
immuno suppressive effects of hyperoxia or to preserved tissue oxygenation. 
In contrast to these putative anti-inflammatory effects, hyperoxia may elicit an 
inflammatory response and organ damage in itself, known as oxygen toxicity. Here, 
we demonstrate that, in the absence of systemic inflammation, short-term hyperoxia 
(100% O2 for 2.5 hours in mice and 3.5 hours in humans) does not result in increased 
levels of inflammatory cytokines in both mice and healthy volunteers. Furthermore, 
we show that, compared with room air, hyperoxia does not affect the systemic 
inflammatory response elicited by administration of bacterial endotoxin in mice 
and man. Finally, neutrophil phagocytosis and ROS generation are unaffected by 
short-term hyperoxia. Our results indicate that hyperoxia does not exert direct anti-
inflammatory effects and temper expectations of using it as an immunomodulatory 
treatment strategy.
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Introduction
In critically ill patients, the treatment paradigm “treat first what kills first” emphasizes on 
the avoidance of hypoxia and liberal oxygen supply is often the first medical intervention 
to be initiated, frequently resulting in hyperoxia at ICU admission1–4. A recent meta-analysis 
of observational studies revealed an association between hyperoxia at ICU-admission and 
increased mortality, albeit this was mainly due to increased mortality in a large subgroup 
of patients with cardiac arrest5. On the contrary, hyperoxia might also exert beneficial 
effects, for instance as prophylactic treatment for surgical wound infections, although 
clinical trials have yielded conflicting results6. The mechanism through which hyperoxia 
might exert detrimental or beneficial effects and contributes to outcome in critically ill 
patients is largely unclear, but immunologic effects might play a role. In vitro, short-term 
hyperoxia was shown to attenuate cytokine production7, β2-integrin expression necessary 
for leukocyte adhesion8, and macrophage phagocytosis and killing9. Furthermore, animal 
studies have demonstrated that hyperoxia mitigates the inflammatory response and 
organ damage after administration of zymosan10 and cecal ligation and puncture (CLP)11,12. 
However, these beneficial effects of hyperoxia in vivo were found 20-48 hours after the 
inflammatory insult10–12. As such, it remains unclear whether these were due to direct 
immunosuppressive effects of hyperoxia, or resulted from preserved tissue oxygenation 
during severe hemodynamic instability, thereby preventing additional tissue damage and 
subsequent inflammation13,14. 
If hyperoxia has intrinsic anti-inflammatory effects, it could be a promising treatment 
option in inflammatory conditions in the ICU, as oxygen is affordable and widely available. 
However, evidence of direct immunologic effects of hyperoxia in animals and humans in 
vivo is lacking. In addition, there are concerns of oxygen toxicity in the lungs, characterized 
by a pulmonary inflammatory response and lung injury15,16. 
In the present study, we investigated the intrinsic immunologic effects of short-term 
hyperoxia in the presence and absence of systemic inflammation elicited by administration 
of LPS in mice and man, primarily reflected by circulating cytokine levels. To evaluate possible 
compartmentalization of immunologic effects of hyperoxia, we also determined cytokine 
concentrations in spleen, liver, and lung homogenates in mice. Furthermore, as hyperoxia 
has been reported to impair leukocyte functions (e.g. cytokine production7, phagocytosis 
and killing9), whole blood ex vivo cytokine production, neutrophil phagocytosis, and 
intracellular generation of reactive oxygen species (ROS) were assessed in humans.
Results
Effects of hyperoxia during murine endotoxemia
Hyperoxia was well tolerated and did not increase cytokine levels in plasma or tissue 
homogenates in placebo-treated mice (Figure 1). LPS administration resulted in increased 
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cytokine levels in tissue homogenates, with the exception of IL-6 in liver, and IL-10 in spleen, 
liver, and lung homogenates. Apart from a slight, but statistically significant, reduction in 
plasma KC, hyperoxia did not affect LPS-induced cytokine concentrations. 
Figure 1. Cytokine concentrations in different compartments in mice 
Plasma, spleen, liver, and lung concentrations of (a) TNF-α, (b) IL-6, (c) KC, and (d) IL-10 150 minutes after normoxia/
hyperoxia (90 minutes after LPS/placebo administration). Concentrations are represented as mean±SEM. * indicates 
p<0.05. 
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Effects of hyperoxia during experimental human endotoxemia
Demographic characteristics and safety
Demographic characteristics of the subjects are listed in Table 1 and were similar among 
the groups. Hyperoxia was well tolerated. No (serious) adverse events occurred during the 
study.
HYPER NORM-E HYPER-E p
Age [yr) 23 [20-24] 21 [20-23] 21 [20-24] 0.68
Height [cm) 182 [178-184] 185 [180-192] 182 [179-189] 0.60
Weight [kg) 76 [74-84] 75 [69-86] 72 [67-80] 0.61
BMI [kg/m2) 23.8 [22.8-24.8] 22.2 [20.5-24.2] 22.5 [18.8-24.3] 0.28
Table 1. Demographic characteristics 
Data obtained during screening visit and presented as median [interquartile range]. NORM-E: normoxic endotoxemia, 
HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia, yr: years; cm: centimeter, kg: kilogram, BMI: body mass index, m: 
meter. 
Oxygenation, hemodynamic parameters, temperature, and symptoms
During the hyperoxic/normoxic period, mean PaO2 was similar in the hyperoxia group 
and hyperoxic endotoxemia group (54.8±3.0 (411.7±22.8) and 54.1±4.1 (405.9±31.1) kPa 
(mmHg), p=0.89), whereas PaO2 in the hyperoxic endotoxemia group was higher than in 
the normoxic endotoxemia group (15.2±0.7 (114.3±5.5) kPa, p<0.0001, Figure 2A). PaCO2 
was 5.0±0.3 (37.8±1.9) kPa in the hyperoxia group, 5.5±0.2 (40.9±1.2) kPa in the hyperoxic 
endotoxemia group, and 5.3±0.2 (39.5±1.7) kPa in the normoxic endotoxemia group 
(Figure 2B). After an initial increase, PaCO2 decreased over time in the hyperoxia group. A 
similar pattern was observed in the normoxic endotoxemia and hyperoxic endotoxemia 
groups, with no differences between these groups (Figure 2B). Lactate levels were in the 
normal range (<2 mmol/L) throughout the experiment in all subjects. In all groups, mean 
arterial pressure (MAP) decreased over time, with no difference between the normoxic and 
hyperoxic endotoxemia groups (Figure 2C). 
In the hyperoxia group, the heart rate gradually increased during the day, while a pro-
nounced increase was observed in both endotoxemic groups (Figure 2D). Endotoxemia 
resulted in a typical increase in temperature of approximately 1.5 oC (Figure 2E), and flu-like 
symptoms (median [IQR] peak symptom scores 1.5 h after LPS administration of 5.9 [0.81] 
and 8.7 [1.7] in the normoxic and hyperoxic endotoxemia groups, p=0.20), both of which 
were not influenced by hyperoxia.
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Figure 2. Blood gas parameters, hemodynamics, and temperature in healthy volunteers
(a) arterial oxygen pressure (PaO2), (b) arterial carbon dioxide pressure (PaCO2), (c) mean arterial pressure (MAP), (d) heart 
rate, and (e) tympanic temperature. The period of hyperoxia or normoxia is indicated with a grey box. In the endotoxemia 
groups, LPS was administered at T=0 hours. Data are expressed as mean±SEM. NORM-E: normoxic endotoxemia, 
HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
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Plasma cytokines
Plasma cytokine concentrations were below the lower detection limit of the assay at 
all time-points in the hyperoxia group. LPS administration resulted in increased plasma 
concentrations of TNFα, IL-6, IL-8, and IL-10 in all subjects. No differences between the 
normoxic and hyperoxic endotoxemia groups were observed (Figure 3).
Figure 3. Plasma cytokine concentrations in healthy volunteers
Plasma concentrations of (a) tumor necrosis factor (TNF)α, (b) interleukin (IL)-6, (c) IL-8 and (d) IL-10. The period that 
subjects were fitted with the respiratory helmet and breathed hyperoxic or normoxic air is indicated with a grey box. In 
the endotoxemia groups, LPS was administered at T=0 hours. Data are expressed as median with interquartile range. 
NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
 
Circulating leukocytes 
Numbers of circulating neutrophils, monocytes, and lymphocytes changed significantly, but 
to no clinically relevant extent, over time in the hyperoxia group (Figure 4). LPS administration 
typically resulted in neutrophilia, with transient lympho- and monocytopenia. Hyperoxia 
did not affect LPS-induced changes in any of the leukocyte subsets.
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Figure 4. Circulating leukocytes in healthy volunteers 
Numbers of circulating (a) neutrophils, (b) monocytes and (c) lymphocytes. The period that subjects were fitted with the 
respiratory helmet and breathed hyperoxic or normoxic air is indicated with a grey box. In the endotoxemia groups, LPS 
was administered at T=0 hours. Data are expressed as mean±SEM NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic 
endotoxemia, HYPER: hyperoxia.
Ex vivo cytokine production 
In the hyperoxia group, ex vivo production of TNFα was slightly increased at several time-
points, but no clear relationship with the period of hyperoxia was evident (Figure 5A). 
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Furthermore, IL-6 production was unaffected (Figure 5B). As circulating monocytes decrease 
during endotoxemia, ex vivo cytokine production could not be assessed one to three hours 
after LPS administration. As expected, in both endotoxemic groups leukocyte cytokine 
production capacity was blunted four and eight hours after LPS-administration due to 
endotoxin tolerance, which fully recovered the subsequent day. There were no differences 
in ex vivo cytokine production between the normoxic and hyperoxic endotoxemia groups. 
Figure 5. Ex vivo whole blood stimulation in healthy volunteers
(a) Tumor necrosis factor (TNF)α and (b) interleukin (IL)-6 cytokine production in whole blood stimulated ex vivo with 
LPS. Data are expressed as median with interquartile range. NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic 
endotoxemia, HYPER: hyperoxia.
Neutrophil phagocytosis and ROS generation
Neutrophil phagocytosis was similar in the normoxic and hyperoxic endotoxemia groups, 
with no clear changes over time following LPS administration (Figure 6A). Intracellular ROS 
generation was not affected in the hyperoxia group at any time-point. Also, no differences 
were observed between both endotoxemic groups (Figure 6B). 
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Figure 6. Neutrophil phagocytosis and ROS generation in healthy volunteers 
(a) Neutrophil phagocytic index and (b) neutrophil intracellular ROS generation. Data are expressed as mean±SEM. 
NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
Discussion
In the present study, we demonstrate that short-term hyperoxia neither induces increased 
levels of cytokines in itself, nor modulates the cytokine response during systemic 
inflammation induced by endotoxin administration in mice and healthy volunteers. 
In addition, both in the presence and absence of systemic inflammation in humans, no 
relevant effects of short-term hyperoxia were observed on temperature, flu-like symptoms, 
leukocyte counts, ex vivo whole blood cytokine production, neutrophil phagocytosis, and 
neutrophil ROS generation. To the best of our knowledge, we are the first to investigate 
the intrinsic immunomodulatory effects of hyperoxia in a standardized and well-controlled 
model of systemic inflammation in humans in vivo. 
Our findings appear to be in contrast with previous animal studies reporting anti-
inflammatory effects of hyperoxia during systemic inflammation. Although exposure to 
100% oxygen for 20 hours or to 70% oxygen for 48 hours did not affect plasma TNFα levels 
after CLP in rats, intermittent exposure to 100% oxygen for 6 hours per day reduced plasma 
TNFα concentrations12. Similarly, intermittent hyperoxia for 2-3 hours attenuated plasma 
TNFα and IL-6 levels 24 hours after zymosan administration in mice10. Paradoxically, the 
same authors showed that both shorter and longer exposure to 100% oxygen nullified the 
anti-inflammatory effects, without a clear explanation10. The discrepant results between 
these studies and ours might be explained by the use of more prolonged and severe 
models of inflammation. Prolonged inflammation may lead to a vicious cycle by causing 
tissue hypoxia, which subsequently results in the release of danger associated molecular 
patterns (DAMPs), in turn leading to aggravation of the inflammatory response17. Along 
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these lines, in animal models of severe sepsis and septic shock, hyperoxia was shown to 
improve tissue oxygenation and organ function, ultimately resulting in better survival18,19. 
Therefore, the previously observed beneficial effects of hyperoxia on systemic inflammation 
might be attributable to the prevention of tissue hypoxia and therefore interruption of 
the vicious cycle, rather than intrinsic immunosuppressive effects. The short-term murine 
endotoxemia model used in the present study is very unlikely to have resulted in tissue 
hypoxia, and the human endotoxemia model is naturally too mild to cause significant 
hemodynamic instability and tissue hypoxia.
Human in vivo studies on the effects of hyperoxia on the inflammatory response are 
scarce, and have mainly been performed in the perioperative setting. In a trial in patients 
undergoing elective thyroid surgery, a perioperative FiO2 of 80% resulted in decreased 
levels of postoperative plasma C-reactive protein, IL-1β, and IL-6 compared with a FiO2 of 
30%. The authors suggest that hyperoxia prevented wound hypoxia and consequently 
attenuated inflammation20. In contrast, hyperoxic ventilation in coronary artery bypass graft 
surgery resulted in a small, but significant, increase in plasma IL-6 on the first postoperative 
day21. However, this could not be reproduced in an identical study performed by the same 
group, where hyperoxia did not affect postoperative plasma concentrations of IL-6, IL-8, 
TNFα, IL-1a, IL-1β, and IL-1022. A number of randomized clinical trials have been conducted 
investigating perioperative hyperoxia as a means to prevent surgical site infections. Meta-
analyses of these studies report a slight beneficial effect in e.g. colorectal surgery6,23. 
Although in vitro, hyperoxia has been shown to enhance LPS-induced whole blood cytokine 
production7, we now demonstrate that hyperoxia in vivo does not affect ex vivo whole 
blood cytokine responses. As such, the present findings suggest that hyperoxia in vivo 
does not result in (lasting) leukocyte reprogramming that modifies cytokine production 
capacity. Previous studies have also described that hyperoxia inhibits phagocytosis of 
alveolar macrophages in vitro9 and in vivo in mice24, whereas neutrophil phagocytosis and 
ROS generation was shown to be enhanced in vitro25. In contrast, ex vivo neutrophil ROS 
generation and phagocytosis remained unaffected after exposure of healthy volunteers 
to hyperbaric hyperoxia26, which is in agreement with our findings. Taken together, these 
results suggest that the effects of hyperoxia on phagocytosis and killing is highly cell-type 
specific. 
The absence of immunomodulatory effects of hyperoxia in the present study tempers 
expec tations of utilizing therapeutic hyperoxia in acute inflammation. In addition, the con-
cept of therapeutic hyperoxia requires cautious consideration for several other reasons. 
First, an important drawback is the risk of oxygen toxicity27. The lungs, being the gas 
exchange interface, are at the greatest risk of hyperoxia-induced injury15. Pulmonary oxygen 
toxicity ultimately resembles the clinical and pathological characteristics of ARDS27, as 
demonstrated in mice exposed to 100% oxygen for up to 48 hours16. These mice developed 
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neutrophil infiltration and increased IL-6 and TNFα levels in the bronchial alveolar lavage 
fluid within 12 hours, followed by alveolar congestion, wall thickening, and hemorrhage16. 
Other animal studies have shown that especially in acute lung injury, high FiO2 levels 
are detrimental as well28. The current study was not primarily designed to assess oxygen 
toxicity, as this has only been described after long-term hyperoxia24,28,29. Nevertheless, we 
demonstrate that short-term hyperoxia neither causes pulmonary inflammation in itself, 
nor does it aggravate the pulmonary inflammatory response induced by systemic LPS 
administration in mice. 
A second concern is related to possible hemodynamic effects of hyperoxia, as it was shown 
to induce vasoconstriction and hence reduced tissue blood flow30,31 as well as reduced 
coronary blood flow and myocardial oxygen consumption32 in humans. Although we did 
not observe an effect of hyperoxia on gross hemodynamic parameters during human 
endotoxemia, we did not assess regional blood flow, oxygen consumption, or vascular 
resistance. Currently, the net effects of hyperoxia on hemodynamic parameters and oxygen 
delivery in patients with sepsis are unknown.
Finally, hyperoxia at ICU admission was shown to be associated with increased mortality in 
a meta-analysis of observational cohort studies5, which might be related to the issues raised 
in the previous points. Of note, this overall effect might be attributed to a large subgroup 
of cardiac arrest patients in the meta-analysis, in whom hyperoxia has obvious detrimental 
effects. Naturally, physicians may be tempted to treat the most severely ill patients with a 
higher FiO2, therefore, hyperoxia could represent a confounding factor instead of a direct 
cause of increased mortality in these observational studies.
This study has several strengths. First, results obtained in animals were confirmed in a 
human in vivo model of systemic inflammation. This is important, as the acute inflammatory 
response in human and animal models may differ considerably33. Second, it is unlikely 
that tissue oxygenation was compromised in our experiments. Therefore, conclusions can 
be drawn about the intrinsic effect of hyperoxia on the inflammatory response, without 
interference of tissue hypoxia effects or (other) alterations that might emerge during 
long periods of hyperoxia. Nevertheless, endotoxemia models do not reflect all aspects of 
the complex systemic inflammatory response encountered in many critically ill patients. 
Therefore, the effects of oxygenation on outcome in systemically inflamed ICU patients 
remain to be determined. Data from a recently preliminary terminated clinical trial in which 
sepsis patients were randomized to either hyperoxia or normoxia and hypertonic or isotonic 
saline in a 2x2 factorial design (HYPER2S, ClinicalTrials.gov identifier NCT01722422), and 
an ongoing study on liberal versus restrictive oxygenation in ICU patients with systemic 
inflammation (O2-ICU ClinicalTrials.gov identifier NCT02321072) will hopefully answer this 
important question.
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In conclusion, short-term hyperoxia does not affect the inflammatory response induced by 
administration of endotoxin in mice and man. These results indicate that hyperoxia does not 
exert direct anti-inflammatory effects, and suggest that the previously reported beneficial 
effects in animal models of more prolonged and severe inflammation are due to preserved 
tissue oxygenation. Our data tempers expectations of using hyperoxia as an immuno-
modulatory treatment strategy in patients. Intervention studies in patients are ongoing and 
are expected to provide evidence for tailoring oxygenation in critically ill patients. 
Materials and Methods
Effects of hyperoxia during murine endotoxemia
Animals
All procedures were in accordance with the requirements of the Dutch Experiments on 
Animals Act, the EC Directive 86/609 and approved by the Animal Ethics Committee of 
the Radboud University Medical Centre. A total of 32 male Balb/c mice (Charles River 
Laboratories International, Inc., L’Arbresle Cedex, France), aged six to eight weeks were 
used.
Reagents
Lipopolysaccharide (LPS, E. Coli, serotype 0111:B4) was obtained from Sigma–Aldrich (St 
Louis, MO, USA), dissolved in sterile 0.9% NaCl, and administered intraperitoneally at a dose 
of 5 mg/kg. Sterile 0.9% NaCl was used as placebo.
Experimental protocol
Mice were randomized into four groups (n=8 per group); 1. normoxia-placebo. 2. normoxia-
LPS. 3. hyperoxia-placebo. 4. hyperoxia-LPS. One hour before LPS/ placebo administration, 
mice were placed in an airtight cage with a continuous airflow of room air (21% oxygen, 
normoxia) or 100% oxygen (hyperoxia) to ensure a hyperoxic state during the initiation of 
inflammation. Ninety minutes after LPS/ placebo administration, when plasma levels of the 
archetypal pro-inflammatory cytokine TNFα (primary endpoint) reach their maximum34,35, 
mice were sacrificed by exsanguination through orbita extraction under deep isoflurane 
anesthesia. Blood was collected in ethylenediaminetetraacetic acid (EDTA)-containing 
tubes (MiniCollect, Greiner bio-one, Alphen a/d Rijn, the Netherlands), centrifuged (14000g, 
5 minutes, room temperature), and plasma was stored at -80°C until batch-wise analysis. 
Liver, spleen, and lungs were snap-frozen and stored at -80 °C until further analysis. 
Cytokine analysis
Liver, spleen, and lung tissue was homogenized for 5 minutes at 50Hz in Tissue Protein 
Extraction Reagent (Life Technologies, Bleiswijk, the Netherlands) containing protease 
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inhibitors (complete EDTA-free tablets, Roche, Woerden, The Netherlands) using a Tissuelyzer 
LT instrument and 5 mm stainless steel beads (both from Qiagen, Venlo, the Netherlands 
Plasma and tissue homogenate concentrations of Tumor Necrosis Factor (TNF)-α, 
interleukin (IL)-6,keratinocyte-derived chemokine (KC, murine homologue of IL-8), and IL-
10 were measured batch-wise using a Luminex assay (detection range 32-1000000 pg/mL) 
according to the manufacturer’s instructions (Milliplex, Merck Millipore, Billerica, MA, USA). 
Tissue cytokine concentrations were normalized to total protein content determined by 
bicinchoninic acid assay (BCA Protein Assay, Life Technologies, Bleiswijk, the Netherlands).
Effects of hyperoxia during experimental human endotoxemia 
Subjects and study design
Data was obtained from two larger trials on immunologic effects of oxygenation 
(ClinicalTrials.gov identifier NCT01889823 and NCT01978158). Experiments were in 
accordance with the declaration of Helsinki. After approval from the local ethics committee 
of the Radboud University Medical Center, 30 healthy male volunteers gave written 
informed consent to participate in the study. Subjects were screened before participation 
and had a normal physical examination, electrocardiography, and routine laboratory values. 
Subjects with febrile illness two weeks before the experiment, use of prescription drugs, or 
history of vagal collapse were excluded. The study was conducted in two phases. The first 
phase was designed to assess safety, feasibility, and immunologic effects of hyperoxia in 
the absence of systemic inflammation. In these experiments, 10 subjects were exposed to 
hyperoxia (fraction of inspired oxygen [FiO2] of 100%) using an air-tight respiratory helmet 
(CaStar, StarMed, Italy) for 3.5 hours. In the second phase, 20 subjects participated in 
endotoxemia experiments: they were randomized to either hyperoxia (as above, hyperoxic 
endotoxemia group, n=10), or normoxia (FiO2 of 21% using the same respiratory helmet, 
normoxic endotoxemia group, n=10). The period of hyperoxic exposure was chosen to 
assure a hyperoxic state at the initiation of the inflammatory response and throughout its 
acute phase, during which most inflammatory cytokines reach their maximum levels36,37. 
Apart from LPS administration, study protocols of the two phases were identical.
Study procedures
Experiments were conducted at the research unit of the intensive care department. Subjects 
refrained from caffeine and alcohol 24 hours before the experiment, and refrained from any 
intake of food and drinks 10 hours before the experiment. A venous and arterial cannula 
were placed for hydration, arterial blood pressure monitoring, and blood withdrawal. 
Heart rate was recorded with a three-lead electrocardiogram and peripheral saturation 
was measured using pulse oximetry. Hemodynamic data were recorded from a Philips 
MP50 patient monitor every 30 seconds using an in-house developed system. Every 30 
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minutes, temperature was measured using a tympanic thermometer (FirstTemp Genius 2; 
Covidien, Dublin, Ireland), and flu-like symptoms (headache, nausea, shivering, muscle and 
back pain) were scored on a six-point scale (0 = no symptoms, 5 = worst ever experienced), 
resulting in a total symptom score of 0–25.
After baseline measurements (t=-1h), subjects were fitted with the respiratory helmet 
and normoxia or hyperoxia was initiated. The inflowing gas composition and the gas 
composition within the helmet were continuously monitored (%O2 and %CO2) using gas 
analyzers (Philips Airway Gases analyser M1026A, Philips Medical Systems, Boebligen, 
Germany) connected to patient monitors (Hewlett Packard Model M1166A 68S, Geneva, 
Switzerland and Capnomac Ultima, DATEX-OHMED, Helsinki, Finland). To prevent carbon 
dioxide build up, airflow was titrated to assure an inspiratory CO2<1%. One hour after 
initiation of normoxia or hyperoxia (t=0h), purified LPS (US Standard Reference Endotoxin 
Escherichia Coli O:113) obtained from the Pharmaceutical Development Section of the 
National Institutes of Health (Bethesda, MD, USA) was administered intravenously at a dose 
of 2 ng/kg in both endotoxemia groups. After 3.5 hours of normoxia or hyperoxia (t=2.5h), 
the helmet was removed and all subjects breathed room air for the rest of the experiment.
Blood gas parameters, lactate, and leukocyte counts 
Blood gas parameters and lactate were analyzed in lithium heparin (LH)-anticoagulated 
arterial blood immediately after withdrawal using CG4+ cartridges and an i-STAT blood gas 
analyzer (Abbott, Libertyville, IL, USA). Analysis of leukocyte counts and differentiation was 
performed in EDTA-anticoagulated blood using routine patient sample analysis methods 
(flow cytometric analysis on a Sysmex XE-5000,The Netherlands). 
Plasma cytokine concentrations and ex vivo whole blood stimulation
EDTA-anticoagulated blood was centrifuged immediately after withdrawal (2000g, 10 
minutes, 4°C) and plasma was stored at -80°C until analysis. “Concentrations of TNFα, 
IL-6, IL-8, and IL-10 were analyzed batch-wise using a Luminex assay (detection range 3.2-
10000 pg/mL) according to the manufacturer’s instructions (Milliplex, Millipore, Billerica, 
MA, USA).” Leukocyte cytokine production capacity was assessed by ex vivo whole blood 
LPS stimulation using an in-house developed system38. Briefly, 0.5 mL LH-anticoagulated 
blood was added to pre-filled tubes with 2 mL culture medium or 2 mL culture medium 
supplemented with 12.5 ng/mL LPS (final LPS concentration: 10 ng/mL). After 24 hours 
of incubation at 37°C, samples were centrifuged, and supernatants were stored at -80°C 
until batch-wise analysis. Concentrations of TNFα and IL-6 were determined using ELISA 
according to the manufacturer’s instructions (Duoset, R&D systems, Minneapolis, MN, 
USA). Cytokine concentrations were normalized to monocyte counts (the main cytokine-
producing cells in whole blood stimulation assays39). 
118 | Chapter seven
Neutrophil phagocytosis assay
Neutrophil phagocytosis was measured using the pHrodo Red E. coli BioParticles Phago-
cytosis Kit for Flow Cytometry according to the manufacturer’s instructions (Life Techno-
logies, Bleiswijk, the Netherlands). Briefly, 100 μL LH-anticoagulated blood was incubated 
with pHrodo Red E. coli BioParticles for 15 minutes (at 37 0C or on ice). Thereafter, erythrocytes 
were lysed, the leukocyte pellet was washed and stored in 1% paraformaldehyde solution. 
Analysis was performed using a Cytomics FC500 flow cytometer and Kaluza Analysis 
Software (both from Beckman Coulter; Galway, Ireland). Neutrophils were gated based on 
forward and side scatter characteristics. Using the samples incubated on ice as negative 
control, the percentage pHrodo-positive neutrophils in the phycoerythrin channel was 
deter mined. Phagocytic index was calculated as the percentage of pHrodo-positive 
neutro phils multiplied by the Mean fluorescence intensity (MFI) of the pHrodo-positive 
neutrophil population. 
Neutrophil intracellular ROS generation
Neutrophil ROS generation was quantified using 2’,7’-dichlorofluorescein diacetate (DCFH-
DA; Sigma, St Louis, MO, USA), as described previously40. Briefly, LH-anticoagulated blood 
was incubated with 0.06 mM DCFH-DA (30 minutes, 37˚C, 400rpm), the reaction was stopped 
with 3 mM EDTA, and samples were centrifuged (430g, 5 minutes, 4˚C). Erythrocytes were 
lysed (BD Pharm Lyse, Beckton Dickinson, Breda, the Netherlands) and cells were washed, 
after which the leukocyte pellet was resuspended in 3 mM EDTA solution and stored 
overnight at 4˚, as pilot work showed that fluorescence remains stable overnight using this 
method. Analysis was performed the following day using a Cytomics FC500 flow cytometer 
and Kaluza Analysis Software (both from Beckman Coulter; Galway, Ireland). Pilot studies 
have shown that the fluorescence remains stable when stored overNeutrophils were gated 
based on forward and side scatter characteristics, and ROS generation was quantified by 
determining the mean fluorescence of the neutrophil population. ROS generation was 
normalized to baseline levels (t=-1h). 
Calculations and statistical analysis
Data are expressed as median [interquartile range] or mean±SEM based on their 
distribution (calculated by Shapiro-Wilk tests). Except for demographic characteristics, all 
non-parametric data were log-transformed before statistical analysis. Differences between 
groups in the murine experiments and between-group differences in mean PaO2, peak 
levels of flu-like symptoms, and demographic characteristics in humans were evaluated 
using unpaired Student’s t-tests or Kruskall-Wallis tests. Within-group differences over 
time in the hyperoxia group were analyzed using one-way analysis of variance (ANOVA). 
Two-way ANOVA (interaction term) was used to assess differences between endotoxemic 
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groups over time. A p-value of <0.05 was considered statistically significant. Statistical 
calculations were performed using GraphPad Prism version 5.03 (GraphPad Software, San 
Diego, CA, USA). 
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Abstract
The use of acetylsalicylic acid (ASA) is associated with improved outcome in 
patients with sepsis, and P2Y12 inhibitors have been suggested to also have 
immunomodulatory effects. Therefore, we evaluated the effects of clinically relevant 
combinations of antiplatelet therapy on the immune response in experimental 
endotoxemia in humans in vivo. 40 healthy subjects were randomized to seven days 
of placebo, placebo with ASA, ticagrelor and ASA, or clopidogrel and ASA treatment. 
Systemic inflammation was elicited at day seven by intravenous administration 
of Escherichia coli endotoxin. ASA treatment profoundly augmented the plasma 
concentration of pro-inflammatory cytokines, but did not affect anti-inflammatory 
cytokines. Addition of either P2Y12 antagonist to ASA did not affect any of the 
circulating cytokines, except for an attenuation of the ASA-induced increase in 
TNFα by ticagrelor. Systemic inflammation increased plasma adenosine, without 
differences between groups, and although P2Y12 inhibition impaired platelet 
reactivity, there was no correlation with cytokine responses. 
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Introduction
Platelet aggregation inhibitors are the pharmacological cornerstone in the primary and 
secondary prevention of cardiovascular events. In addition, it is increasingly recognized that 
platelets have potent immunomodulatory properties. Platelets respond to inflammatory 
stimuli by release of chemokines1, and expression of P-selectin and CD40 ligand, which 
are important regulators of platelet-leukocyte interactions2. The commonly used platelet 
aggregation inhibitors acetylsalicylic acid (ASA) and the P2Y12 receptor inhibitors (such as 
ticagrelor and clopidogrel) potentially interfere with these immunological effects and may 
thereby influence the clinical outcome of patients that encounter a severe infection. 
Several cohort studies have evaluated the association between acetylsalicylic acid treatment 
and outcome in patients with sepsis and pneumonia (summarized in Supplemental Table 
1). Acetylsalicylic acid (ASA) treatment has been associated with a reduced mortality in 
patients with sepsis admitted to the Intensive Care Unit (ICU) in four large cohort studies3–6. 
Furthermore, in a smaller study, the combination of ASA with macrolide treatment was 
associated with reduced mortality in patients with pneumosepsis7. Only one study did not 
identify an association of platelet inhibitory therapy with mortality in ICU patients with 
sepsis, but this study also included patients on alternative platelet inhibitors than ASA8. 
ASA treatment in patients with community acquired pneumonia has also been associated 
with a reduced need for ICU admission9 and mortality10.
Clinical data on the immunomodulatory effects of P2Y12 receptor inhibitors is sparse. 
Treatment with clopidogrel added to ASA is associated with attenuated inflammatory 
markers in patients following coronary interventions11,12 and other studies have demon-
strated that clopidogrel use is associated with increased incidence of pneumonia13 and 
post-coronary artery bypass surgical site infections14. A post-hoc analysis of the PLATelet 
inhibition and patient Outcomes (PLATO) trial suggested a reduced mortality after 
pulmonary infections and sepsis in patients treated with ticagrelor and ASA, compared to 
patients treated with clopidogrel and ASA15, although a beneficial effect on sepsis-related 
mortality of ticagrelor was not confirmed in a more recent randomized trial16. 
The immunomodulatory effects of platelet inhibitors have been investigated in more detail 
in experimental models of inflammation. Seemingly counterintuitive, inhibition of cyclo-
oxygenase (COX) augmented cytokine release. A three day treatment with 650 mg ASA in 
healthy volunteers augmented the ex vivo cytokine response of whole blood stimulated with 
lipopolysaccharide (LPS)17, and treatment with COX inhibitors amplified the pro-inflammatory 
response after in vivo LPS administration in mice18 and healthy volunteers19,20.
In contrast, P2Y12 inhibitors exert anti-inflammatory effects. A single dose of ticagrelor in 
healthy volunteers mitigated ex vivo cytokine production by LPS-stimulated leukocytes21. 
Similarly, treatment with ticagrelor or clopidogrel attenuated circulating levels of pro-
inflammatory mediators tumor necrosis factor (TNF)α, interleukin (IL)-6, and chemokine 
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ligand 2 during human endotoxemia22. Importantly, in contrast to clinical practice, the 
P2Y12 inhibitors were not combined with ASA treatment in this study.
Taken together, epidemiological data indicate that treatment with ASA is associated with 
a beneficial outcome after sepsis. For P2Y12-inhibitors, data shows less consistent effects. 
To gain more insight into the immunomodulating properties of the various antiplatelet 
agents that are used for cardiovascular prevention, we aim to study the effect of low-dose 
ASA alone and in combination with the P2Y12 inhibitors clopidogrel and ticagrelor in a well-
validated human in vivo model of systemic inflammation. 
Materials and methods
Study design, subjects and study procedures
This prospective randomized open-label, blinded endpoint study was performed according 
to the declaration of Helsinki, and registered by clinicaltrials.gov identifier NCT01978158. 
After approval of the local ethics committee (CMO Arnhem-Nijmegen, the Netherlands), 
forty healthy male volunteers aged 18-35 years, provided written informed consent and 
were included after screening. All subjects had normal physical examination, electro-
cardio graphy and routine laboratory values. The main exclusion criteria were medication 
use, recent febrile illness and increased bleeding risk. Randomization was performed after 
inclusion by opening of a sealed opaque envelope, prepared by a research nurse not 
involved in the study. Subjects were randomized to one of four study arms, i.e. ticagrelor 
(AstraZeneca, London, UK) and ASA (Apotex, Leiden, The Netherlands) (TA-group, n=10), 
clopidogrel (Sandoz, Berleben, Germany) and ASA (CA-group, n=10), dummy capsules 
(‘placebo’, Apotheek Radboudumc, Nijmegen, the Netherlands) and ASA (PA-group, n=10), 
or placebo only (P-group, n=10). A detailed description of the study protocol is provided in 
the Supplemental Methods. Briefly, subjects were treated for seven days after a loading dose 
on day one. Loading dosages were 180, 300, and 160 mg, and maintenance dosing schedules 
were 90 mg b.i.d., 75 mg q.d and 80 mg q.d for ticagrelor, clopidogrel, and ASA, respectively. 
Drug adherence was monitored by pill counts. The seventh day of study treatment, systemic 
inflammation was elicited by administration of purified lipopolysaccharide (US Standard 
Reference Endotoxin, Escherichia Coli O:113, Pharmaceutical Development Section of 
the National Institutes of Health (Bethesda, MD, USA)). Endotoxin was administered as a 
bolus of 1 ng/kg, followed by continuous infusion at 1 ng/kg/h for three hours. Blood was 
obtained before study treatment, immediately before LPS administration, and every hour 
until eight hours afterwards with an extra blood withdrawal at 1.5h after initiation of LPS 
administration.
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Cytokine measurement
Plasma concentration of the cytokines TNFα, IL-6, IL-8, IL-10 and IL-1 receptor antagonist 
(IL-1RA) and the chemokines macrophage inflammatory protein (MIP)-1α, MIP-1β and 
monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 
2 (CCL2), were determined batchwise in Ethylenediaminetetraacetic-(EDTA) anticoagulated 
plasma by a multiplex immunoassay assay according to the manufacturer’s instructions 
(Bio-Plex, BioRad, Hercules, USA and Milliplex, Millipore, Billerica, USA). 
Plasma adenosine
Plasma adenosine levels were determined as previously described23 (see Supplemental 
Methods). 
Assessment of P2Y12 inhibition and platelet activation and responsiveness
Specific effectiveness of P2Y12 inhibition was determined by the level of phosphorylation 
of vasodilator-stimulated phosphoprotein (VASP) in citrated blood using an ELISA-based 
assay (CY-QUANT VASP/P2Y12, BioCytex, Marseille, France) according to manufacturer’s 
instructions. P2Y12 inhibition is expressed as platelet reactivity index (PRI%), with a value 
<50% considered as adequate platelet inhibition. Platelet activation and responsiveness 
were assessed in whole blood (see Supplemental Methods). Briefly, platelet responsiveness 
was assessed by ex vivo stimulation with either adenosine diphosphate (ADP, 3.4 or 125 
μM) or crossed-linked collagen-related-peptide (CRP-XL, 39 or 625 ng/mL) and platelet 
expression of P-selectin, a measure of degranulation, was measured using flow cytometry. 
Platelet-leukocyte complexes
Platelet-leukocyte complex formation was determined using flow cytometry. Citrated whole 
blood was incubated with anti-CD61 (PC7; Beckman Coulter, Brea, CA, USA), anti-CD14 (ECD; 
DAKO, Heverlee, Belgium), anti-CD16 (FITC; Biolegend, San Diego, CA, USA) and anti-HLA-
DR (PC5; Beckman Coulter, Brea, CA, USA) within 2 hours after blood collection. Optilyse B 
(Beckman Coulter, Brea, CA, USA) was added after 20 minutes for fixation followed by distilled 
water for erythrocyte lysis. Monocytes and neutrophils were selected based on granularity 
(side-scatter, SS) and size (forward-scatter, FS) as well as their expression of CD16, CD14 
and HLA-DR (see Supplemental Figure 1 for gating strategy). The platelet-monocyte and 
platelet-neutrophil complex formation were quantified based on the % of cells expressing 
the platelet marker CD61 on respectively monocytes (CD14-positive) and neutrophils 
(CD16high,CD14low, HLA-DR negative). It is known that the amount of PMC’s measured 
depend on the time window between blood withdrawal and analysis. Due to variation in time 
from blood withdrawal to analysis between time points, data are only suitable to compare 
groups per time point, and not to evaluate changes in time within groups. 
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Plasma thromboxane
Plasma thromboxane B2 (the stable metabolites of thromboxane A2) was measured in 
citrated plasma in the placebo and placebo-ASA groups using an ELISA (Thromboxane B2 
EIA Kit, Oxford Biomedical Research, Oxford, USA). 
Leukocyte and platelet counts
Platelet and leukocyte counts and differentiation were performed in EDTA-anticoagulated 
blood using routine analysis methods (Sysmex XE-5000, The Netherlands).
Ex vivo monocyte stimulation
Monocytes were isolated from buffy coats obtained from healthy donors after written 
informed consent (Sanquin Blood Bank, Nijmegen, The Netherlands) as previously de-
scribed24 using both Ficoll-Paque and hyper-osmotic Percoll density gradient centri fugation 
and washing with warm PBS for purity and low platelet contamination. Washed platelets 
were isolated as previously described21,and pre-incubated with ASA (5 uM, Sigma) for 1 hour 
and washed to remove ASA. Supernatant and platelets were collected for co-incubation 
with isolated and adhered monocytes. Adhered monocytes (1.105) were incubated for 24 
hours with Escherichia coli LPS (10ng/mL; serotype 055:B5, Sigma), prostaglandin E2 (0.1 
uM or 1uM; Sigma), ASA (5-500uM), unexposed or ASA-exposed platelet supernatant (1:4 
dilution) and/or unexposed or ASA-exposed washed platelets (ratio 1:50 or 1:25). Hereafter, 
supernatants were collected and stored at -20 degrees. ELISA was used to determine TNFα.
Statistical analysis
Data are expressed as a mean ± SEM or as median [interquartile range], according to their 
distribution. Data were tested for normality using the Shapiro-Wilk test. To limit the number 
of statistical tests used, three hypotheses were hierarchically defined and sequentially tested 
by performing repeated measures two-way ANOVAs (interaction term of group and time) 
on specific pairs of groups: 1. To evaluate the effects of ASA, placebo-ASA was compared to 
placebo 2. To evaluate the effect of clopidogrel or ticagrelor added to ASA, clopidogrel-ASA 
and ticagrelor-ASA were compared to placebo-ASA. 3. In case of an effect of ticagrelor or 
clopidogrel added to ASA, a comparison of clopidogrel-ASA with ticagrelor-ASA was made 
to assess for differences between these P2Y12 inhibitors. In case no differences between 
groups were identified, no further statistical testing was performed. Statistical tests used 
are described in the figure legends and Supplement. All statistical analyses were performed 
using GraphPad Prism version 5.03 (GraphPad Software, San Diego, USA). A two-sided p 
value <0.05 was considered statistically significant. 
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Results
Subject inclusion and follow up, drug safety, compliance, and subject characteristics
The forty subjects that were included all completed the study (see CONSORT [Consolidated 
Standards of Reporting Trials] flow chart in Supplemental Figure 2). Study treatment 
was well tolerated. One subject treated with clopidogrel-ASA reported a spontaneous 
haematoma and one subject treated with ticagrelor-ASA experienced three days of mild 
dyspnoea with preserved exercise tolerance (both Grade I). Treatment compliance was 
100%. Demographic characteristics are listed in Table 1.
Placebo Placebo and 
acetylsalicylic acid
Ticagrelor and 
acetylsalicylic acid
Clopidogrel and 
acetylsalicylic acid
Age [y] 22 [20-28] 21 [19-24] 22 [21-24] 21 [20-21]
Height [cm] 183 [175-187] 186 [183-190] 180 [177-186] 186 [181-191]
Weight [kg] 77 [66-84] 83 [80-88] 72 [68-77] 83 [77-91]
BMI [kg/m²] 23 [21-25] 24 [23-26] 22 [21-24] 24 [22-25]
Table 1. Demographic characteristics
Data is presented as median [interquartile range]. y: years, cm: centimeter, kg: kilogram, BMI: body mass index, m: meter. 
Cytokine and chemokine response
Plasma cytokine and chemokine concentrations were below the lower detection limit of 
the assay before administration of LPS. LPS administration resulted in an increased plasma 
concentration of the cytokines Tumor Necrosis Factor (TNF)α, Interleukin(IL)-6, IL-8, IL-10, 
IL-1 receptor antagonist (IL-1RA), monocyte chemoattractant protein(MCP)-1, macrophage 
inflammatory protein(MIP)-1α and MIP-1β in all subjects (Figure 1). To evaluate the effects 
of low dose acetylsalicylic acid, we compared the cytokine response of subjects treated 
with ASA to the placebo treated group. 
Plasma levels of TNFα,IL-6, IL-8 and MIP-1α were increased to a greater extent in ASA treated 
subjects compared with the placebo group, and there was a trend towards enhanced levels 
of MCP-1. To evaluate whether addition of ticagrelor or clopidogrel further affected the 
systemic inflammatory response, we compared the cytokine response of the ASA group 
with the ticagrelor-ASA group and the clopidogrel-ASA group. Only for TNFα, addition of 
ticagrelor to ASA mitigated the ASA-induced augmentation, addition of clopidogrel to 
ASA did not alter any of the ASA-mediated changes in cytokines. Comparison of the ASA-
clopidogrel and ASA-ticagrelor group did not reveal any difference in TNFα levels between 
ticagrelor- or clopidogrel-treated subjects. None of the study treatments affected plasma 
concentrations of MIP-1β and the anti-inflammatory cytokines IL-10 and IL-1RA. 
132 | Chapter eight
Figure 1. Plasma cytokine concentrations
Plasma concentrations of (A) TNFα, (B) IL-6, (C) IL-8, (D) IL-10 and (E) IL-1RA during endotoxemia. Data are expressed 
as means with SEM. Effects of study treatment on the cytokine response were evaluated using a two-way ANOVAs 
(interaction term of group and time) on group pairs. P-values of significant differences are displayed in the figure. P: 
placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor and acetylsalicylic acid, CA: clopidogrel and acetylsalicylic 
acid.
Plasma adenosine
As adenosine is known to have potent anti-inflammatory effects25, and ticagrelor has 
previously been shown to increase extracellular adenosine by blocking reuptake26, we 
evaluated the effect of the study treatments on plasma adenosine. Plasma adenosine 
levels were comparable at baseline between groups. Endotoxemia significantly increased 
adenosine levels to a similar degree in all groups (Figure 2), and there were no differences 
between groups.
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Figure 2. Plasma adenosine
Plasma concentrations of adenosine before and 3h after initiation of endotoxin administration. Data are expressed as 
box and whiskers plots with median, minimal and maximal observed values. Baseline values were comparable between 
groups (Kruskal-Wallis test, p=0.13), and changes in adenosine after 3h were tested with the Wilcoxon signed rank test. 
* indicates p<0.05. 
Platelet P2Y12 receptor inhibition and platelet activation and responsiveness
To evaluate the specific inhibition of P2Y12, the level of phosphorylation of vasodilator-
stimulated phosphoprotein (VASP) was measured. There was no P2Y12 inhibition before 
the start of study treatment in any subject, and P2Y12 dependent platelet inhibition 
remained unaffected throughout the study in the placebo and placebo-ASA groups (Figure 
3). Ticagrelor treatment resulted in a VASP-PRI% <50% in all subjects, whereas platelet 
inhibition varied largely in clopidogrel-treated subjects.
In vivo platelet activation, as measured by unstimulated platelet P-selectin expression, 
was low in all subjects and was not affected by study treatment or endotoxemia (Figure 
4A). Platelet responsiveness to low and high concentrations of adenosine diphosphate 
and cross-linked collagen-related peptide remained unaffected by both experimental 
endotoxemia and ASA treatment (Figure 4B-E). Treatment with P2Y12 inhibitors diminished 
adenosine diphosphate-induced P-selectin expression in clopidogrel- and ticagrelor-
treated subjects similarly. P-selectin expression after stimulation with low concentration 
cross-linked collagen-related peptide was reduced in clopidogrel- and ticagrelor-treated 
subjects similarly. However, stimulation with high concentration cross-linked collagen-related 
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peptide fully surmounted the clopidogrel-, but not the ticagrelor-induced reduction in 
platelet responsiveness. Platelet responsiveness did not correlate with cyto kine responses 
(Supplemental Figure 3). 
Figure 3. VASP-P Platelet Reactivity Index
Platelet Reactivity Index (PRI), expressed as the percentage of phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP-P). Data are expressed as box and whiskers plots with median, minimal and maximal observed values. Baseline 
values were comparable among groups (Kruskal-Wallis test, p=0.53). Treatment with PA and P did not alter PRI (Friedman 
test, p=0.20 and p=0.16 respectively), treatment with TA and CA decreased PRI (Friedman test with post-hoc Dunn’s 
Multiple Comparison Test p=0.0004 and p=0.006). * indicates a difference with baseline value.
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Figure 4. Platelet activation and responsiveness
Mean fluorescence intensity as a measure of platelet P-selectin expression before study treatment and during 
endotoxemia of unstimulated platelets (A), and after stimulation with low (B) and high (C) concentrations of adenosine 
diphosphate (ADP, 3.4 or 125 μM) and low (D) and high (E) concentrations of cross-linked collagen-related-peptide 
(CRP-XL, 39 or 625 ng/mL). Data are expressed as box and whiskers plots with median, minimal and maximal observed 
values. Effects of study treatment on platelet activation status and reactivation were evaluated using a two-way ANOVAs 
(interaction term of group and time) on group pairs. P-values of significant differences between groups are displayed 
in the figure. P: placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor and acetylsalicylic acid, CA: clopidogrel and 
acetylsalicylic acid.
 
Platelet-leukocyte complexes
To evaluate whether antiplatelet agents affect platelet-monocyte and platelet-neutrophil 
interactions, the percentage of platelet-monocyte and platelet neutrophil complexes 
(PMC and PNC) was determined. Due to the endotoxin-induced transient monocytopenia, 
platelet-monocyte complexes were not measureable at 2 hours after onset of endotoxemia. 
Although there is a trend towards decreased PMC formation in the ticagrelor-ASA treated 
group at 4h, there were neither differences in formation of PMCs, nor of PNCs at any time 
point between groups (Figure 5). Again, there was no correlation between PMC and PNC 
formation and cytokine response (Supplemental Figure 4). 
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Figure 5. Platelet-leukocyte complexes
Percentage of platelet-monoycte complexes (A) and platelet-neutrophil complexes (B) during endotoxemia. Data are 
expressed as mean with SEM. Differences between study treatment groups were evaluated using a one-way ANOVA, 
there were no significant differences between groups. P: placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor and 
acetylsalicylic acid, CA: clopidogrel and acetylsalicylic acid.
Prostaglandins
To evaluate if COX-1 inhibition by ASA treatment was sufficient, plasma levels of throm-
boxane B2, the stable metabolite of the COX-1 product thromboxane A2, were determined. 
ASA treatment strongly reduced thromboxane B2 levels compared to placebo treatment 
(Figure 6).
Hemodynamic parameters, temperature and symptoms
Endotoxemia resulted in a decrease of mean arterial blood pressure of approximately 15 
mmHg (Supplemental Figure 5A) and an increased heart rate with approximately 35 bpm 
(Supplemental Figure5B). Body temperature increased with 2.5°C (Supplemental Figure 5C). 
Endotoxin-related symptoms peaked at 3 hours and resided six hours after the start of 
endotoxin infusion (Supplemental Figure 5D). There were no differences in these parameters 
between groups.
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Figure 6. Thromboxane B
Plasma concentration of thromboxane B before and after treatment with placebo (P) or placebo with acetylsalicylic 
acid (PA). Data are expressed as box and whiskers plots with median, minimal and maximal values. Baseline values 
were comparable among groups (Mann-Whitney test, p=0.80).Treatment with ASA mitigated plasma thromboxane B 
(Friedman test with post-hoc Dunn’s Multiple Comparison Test p=0.004). Endotoxemia did not affect thromboxane B 
levels (Friedman test p=0.83 and p=0.83 in P and PA groups, respectively). * indicates a difference with baseline.
 
Platelet and leukocyte count and differentiation
Platelet counts were comparable after study treatment (Supplemental Figure 6A) and 
endotoxemia resulted in a typical neutrophilia, and a transient thrombo-, mono- and 
lymphocytopenia (Supplemental Figure 6B-D), which were similar between groups. 
Ex vivo monocyte stimulation
In order to evaluate whether the ASA-induced augmentation of the inflammatory 
response is platelet-dependent, isolated, adhered monocytes were stimulated with LPS in 
different conditions. Incremental concentrations of ASA did not affect TNFα production 
upon LPS stimulation, whereas PGE2 attenuated TNFα production (Figure 7A).Therefore, 
we hypothesized that platelets mediated the ASA-induced pro-inflammatory response. 
Correspondingly, platelets pre-exposed to ASA augmented LPS-stimulated monocytic 
TNFα production, (Figure 7B), and similarly the supernatant of ASA-exposed platelets 
augments monocytic TNFα response (Figure 7C). These effects were abrogated in the 
presence of PGE2. 
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Figure 7. Ex vivo experiments with isolated monocytes, acetylsalicylic acid, prostaglandin E2  
and platelets
TNFα production of LPS-stimulated monocytes with incremental dosages of ASA and/or PGE2 (A). Treatment with ASA 
did not affect TNFα production (Wilcoxon signed rank test, p=NS), whereas PGE2 attenuated TNFα production compared 
to the condition without PGE2 (Wilcoxon signed rank test, * indicates p<0.05, n=9). TNFα production of LPS-stimulated 
monocytes in the presence of unexposed or ASA-exposed platelets (n=9) (B) or the supernatant of these platelets (n=12) 
and PGE2 (1 uM) (C). Treatment of platelets with ASA augmented TNFα production (Wilcoxon signed rank test, * indicates 
p<0.05), PGE2 abrogated this ASA-platelet mediated effect. Data are expressed as box and whisker plots with median, 
minimal and maximal values. TNFα; Tumor Necrosis Factor-α
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Discussion
We evaluated the effects of clinically relevant dosages of ASA, ticagrelor, and clopidogrel on 
systemic inflammation during human endotoxemia. A seven day course of low-dose ASA 
profoundly enhanced the pro-inflammatory response. Although the addition of ticagrelor 
attenuated the ASA-induced increase in TNFα levels, it did not affect the ASA-induced 
augmentation of other pro-inflammatory cytokines and chemokines. Further more, 
clopidogrel added to ASA did not affect the ASA-enhanced pro-inflammatory response 
during endotoxemia. There were no significant differences in immunomodulating effects 
between ticagrelor and clopidogrel added to ASA. 
The pro-inflammatory effects of low-dose ASA observed in this study mirror results from 
previous experimental studies on COX-inhibitors in humans. Single or multiple high 
dose(650 mg) treatment with a ASA augmented LPS-induced pro-inflammatory cytokine 
production ex vivo17,27 and treatment with the COX-inhibitor ibuprofen showed similar 
results during human endotoxemia19,20. Accordingly, ASA was shown to enhance plasma 
TNFα upon Salmonella typhi vaccination in healthy volunteers28. Interestingly, the timing of 
ASA treatment appears to be of importance, as a single dose of 1000 mg of ASA just before 
LPS administration did not affect the inflammatory response18. ASA, as a COX-inhibitor, 
abrogates the production of PGE2, and we and others have shown that PGE2 attenuates 
cytokine production29. Furthermore, the addition of exogenous PGE2 dose-dependently 
prevents the pro-inflammatory of ASA30. As such, ASA prevents PGE2 production and 
thereby abrogate it’s inhibitory effect on cytokine production. Of note, low dose ASA and 
ibuprofen treatment both have shown to attenuate the production of PGE2 during human 
endotoxemia in vivo31. Of note, the studies that assessed the effect of COX-inhibition on 
LPS-induced cytokine production were performed in whole blood or in vivo, and therefore 
in the presence of platelets17,27.To investigate whether the ASA-induced anti-inflammatory 
effect depends on a direct effect on myeloid cells or is platelet dependent, we performed ex 
vivo experiments on human isolated monocytes and platelets. The data shows that that the 
ASA induced pro-inflammatory effect is mediated by platelets. This is in correspondence 
with previous evidence obtained from experiments with murine bone marrow derived 
macrophages (BMDM), in which it was demonstrated that TNFα production of BMDM was 
shown to be attenuated in the presence of platelets or platelet supernatant32. Analogous 
to our experiments , pretreatment with ASA of platelets abolishes the anti-inflammatory 
effects. These authors further demonstrate that platelets exert anti-inflammatory effects 
through the activation of the COX-1-PGE2 pathway32. 
Taken together, it is conceivable that the mechanism of the ASA-induced pro-
inflammatory effects observed are caused by inhibition of PGE2 production by platelets. 
As a consequence, PGE2-induced dampening of pro-inflammatory cytokine responses is 
attenuated, ultimately resulting in increased cytokine levels.
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Although the addition of ticagrelor to ASA significantly affected plasma TNFα levels during 
endotoxemia, it did not influence other cytokines or chemokines, and clopidogrel added 
to ASA did not affect the cytokine response at all. Furthermore, there were no statistical 
significant differences in cytokine responses between ticagrelor- and clopidogrel-treated 
subjects. Animal studies evaluating the role of P2Y12 inhibition in various models of 
inflammation are sparse and have yielded conflicting results, showing pro-inflammatory33, 
anti-inflammatory34,35, or no effects36. Our results are in contrast with the scarcely available 
human data, as a single dose of ticagrelor reduced platelet-leukocyte interaction and 
ex vivo cytokine responses21, and ticagrelor and clopidogrel reduced pro-inflammatory 
cytokine levels during human endotoxemia22. Importantly, subjects did not receive 
concomitant treatment with ASA in these studies. The anti-inflammatory effects observed 
in these studies were suggested to be caused by a reduction in platelet reactivity and 
reduced platelet-leukocyte interaction22. However, in our study, there were no differences 
between groups in platelet-leukocyte interactions. In addition, although ADP-dependent 
platelet responsiveness was reduced by P2Y12 inhibitors, the degree of responsiveness did 
not correlate with cytokine responses. Therefore, it is most likely that the pro-inflammatory 
potential of ASA overshadows the previously observed immunomodulating effects of 
P2Y12 inhibitors. This is important, as most patients use a P2Y12 inhibitor in combination 
with ASA, and not as monotherapy. Various recent studies showed that ticagrelor increases 
the extracellular levels of endogenous adenosine37,38. Since adenosine is a potent anti-
inflammatory agent, it was proposed that this mechanism contributes to the beneficial 
effect of ticagrelor on endotoxemia, but adenosine levels were not measured in this 
study22.We found no effects of ticagrelor on plasma adenosine, which is consistent with 
our previous finding that ticagrelor does not inhibit ENT transport at clinically relevant 
dosages39. In conclusion, our findings indicate that ticagrelor and clopidogrel do not 
relevantly modulate the immune response when they are combined with ASA treatment. 
This implies that that the beneficial effects of ticagrelor and ASA compared with clopidogrel 
and ASA on mortality after sepsis and pneumonia in the PLATO trial are unlikely caused by 
immunomodulation15. 
The putative immunomodulating effects of antiplatelet therapy are important for two 
reasons. First, use of anti-platelet therapy in the ICU population is very common, with 
estimates ranging from 17-43%6,40–42. ASA treatment has consistently been associated 
with reduced mortality in patients with sepsis in several studies3–7, with the exception 
of one smaller study, which evaluated not only treatment with ASA, but also other anti-
platelet therapy8. In patients with community acquired pneumonia, pretreatment with ASA 
has been associated with a reduced need for ICU admission9 and mortality10. So, clinical 
data consistently support the association of ASA with beneficial outcomes in sepsis and 
pneumonia. However, due to the observational nature of these studies, no cause-effect 
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relationships can be identified. Therefore, these associations instigate the development 
of hypothesis concerning how anti-platelet therapy could contribute to these observed 
beneficial effects in sepsis. Two hypothesis on how the immune-enhancing effects of ASA 
may contribute to any survival benefit in patients with sepsis may be put forward. First, 
the augmented pro-inflammation caused by low-dose ASA may result in a more effective 
early clearance of bacteria, resulting in improved survival compared to patients with an 
initial less pronounced cytokine response43. Alternatively, the here described immune-
enhancing effects of ASA could also explain the observed beneficial outcomes in sepsis 
if ASA counteracts sepsis-induced immunoparalysis. Sepsis-induced immunoparalysis 
is a phenomenon receiving increasing attention, characterized by the inability to clear 
pathogens and an increased susceptibility to secondary (opportunistic) infections44. The 
immune-stimulating properties of ASA may partially compensate this immune refractant 
state. 
Second, as platelets are increasingly recognized as mediators in inflammation, modulating 
the immune response with anti-platelet therapy may represent a novel strategy to treat 
patients with sepsis. Although it is recognized that imbalances in the immune response 
itself result in the clinical syndrome of sepsis and sepsis-related mortality, until now, 
anti-inflammatory therapies have failed to improve outcome45. The host response in 
sepsis is complex, with interindividual differences in the inflammatory balance over time. 
Nevertheless, it is conceivable that modulating the immune response, depending on the 
inflammatory state, may be of clinical benefit45. Although randomized controlled trials have 
not shown beneficial effects of ibuprofen46 and lornoxicam47 in sepsis, this may be due to 
small sample sizes, patient selection and timing of treatment45. Currently, a randomized trial 
is recruiting patients to evaluate the effects of ASA in patients with severe sepsis or septic 
shock (Clinical Trials.gov identifier NCT02612480). Alternatively, the observed improved 
survival of ASA users in sepsis may be based on non-immunologic mechanisms, or despite 
efforts to correct for baseline differences between ASA and non-ASA users, even be related 
to other patient characteristics or chance. Therefore, the questions if and how ASA affects 
outcome in patients with sepsis still require definitive answers. 
In this study, we evaluated the effect of clinically relevant antiplatelet treatment schedules 
on systemic inflammation in a highly reproducible human model. In contrast to bolus 
administration in previous studies22, systemic inflammation was elicited with continuous 
infusion of endotoxin, which resulted in a prolonged inflammatory state and may therefore 
be more representative of ongoing inflammation as encountered in patients. Although 
we have ruled out that adenosine, platelet-reactivity or platelet-leukocyte interactions 
play a role in ASA/P2Y12 inhibitor related immunomodulation, we have not conclusively 
pinpointed the mechanism through which ASA augments the cytokine response. Never-
theless, human endotoxemia remains an experimental model of inflammation, although 
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well validated, and does not fully reflect the complexity of the pathogenesis of sepsis. 
Another potential limitation of our study is that, as opposed to patients with sepsis and 
pneumonia, subjects were young healthy males, limiting generalization to patients. 
Speculatively, platelet inhibition may have more pronounced effects in patients with 
activated platelets, as observed in atherosclerosis48 or Gram-positive sepsis49. 
In conclusion, seven days of treatment with low-dose ASA resulted in an enhanced pro-
inflammation during systemic inflammation in humans. Although the addition of ticagrelor 
to ASA treatment attenuated the TNFα response, ticagrelor and clopidogrel added to ASA 
did not relevantly alter the ASA-augmented inflammatory response. 
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Supplemental Methods
Study design, subjects and study procedures. 
This prospective randomized open-label, blinded endpoint (PROBE-design) study was 
performed according to the latest version of the declaration of Helsinki (2008), the Medical 
Research Involving Human Subjects Act (WMO) and Good Clinical Practice (GCP) and is 
registered at clinicaltrials.gov identifier NCT01978158. 
After approval of the local ethics committee from the Radboud university medical centre, 45 
males signed informed consent and were screened for eligibility. Forty healthy volunteers 
were included as they met all inclusion criteria and none of the exclusion criteria. Inclusion 
criteria were male sexe, age 18-35 years and no known current medical or psychiatric 
diseases. Exclusion criteria were history, signs or symptoms of cardiovascular disease, 
chronic obstructive pulmonary disease or asthma, hemorrhagic diathesis or disorders 
associated with increased risk of bleeding, pathological bleeding, history of intracranial 
haemorrhage, history of dyspepsia, quantitative bleeding assessment tool (BAT) score> 
350, immune deficiency, spontaneous vasovagal collapse, use of any medication, smoking, 
cardiac conduction abnormalities on electrocardiogram, hypertension (systolic blood 
pressure >160 mmHg or diastolic blood pressure >90 mmHg), hypotension (systolic blood 
pressure <100 mmHg or diastolic blood pressure < 50 mmHg), renal impairment (estimated 
glomerular filtration rate by Modification of Diet in Renal Disease formula < 60 ml/min), 
liver enzyme abnormalities (ALAT or ASAT > two times the upper limit of reference value), 
thrombocytopenia (thrombocytes < 150 x 109/L), anemia (heamoglobin < 8.0 mmol/L), 
febrile illness in the week before the endotoxin challenge, hypersensitivity to ticagrelor or 
any excipients and participation in another drug trial or donation for blood 3 months prior 
to, until 3 months after the planned endotoxin experiment. 
Subjects were randomized to one of four study arms, i.e. ticagrelor and ASA (TA), clopidogrel 
and ASA (CA), placebo and ASA (PA) or placebo. All subjects received a loading dose of the 
allocated treatment on day one, and continued with maintenance doses during the seven 
days preceding the endotoxemia experimental day. Ticagrelor loading dose was 180mg, 
with a maintenance dose of 90 mg twice daily, clopidogrel loading dose was 300 mg, and 
with a maintenance dose of 90 mg daily, ASA loading dose was 320 mg, with a maintenance 
dose of 80 mg daily. 
Subjects refrained from alcohol, nicotine and caffeine for 24 hours, and fasted overnight 
prior to the endotoxemia experiment. After admission to the intensive care research 
department, an arterial cannula (Angiocath; Becton Dickinson, USA) was placed in the 
radial artery and connected to a blood pressure monitoring system (Edward Lifesciences, 
Irvine, CA, USA) for blood pressure monitoring and blood withdrawal. A venous cannula 
provided access for intravenous hydration and endotoxin administration. Heart rate was 
monitored by a three-lead electrocardiogram and haemodynamic data was recorded from 
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a Philips M50 monitor (Eindhoven, The Netherlands) with an interval of 30 seconds using 
an in-house developed system. Subjects were prehydrated with intravenous (i.v.) infusion 
of 1.5L glucose 2.5%/0.45% NaCl in one hour. Purified lipopolysaccharide (LPS, US Standard 
Escherichia Coli O:113 endotoxin) was obtained from the Pharmaceutical Development 
Section of the National Institutes of Health (Bethesda, MD, USA). The lyophilized powder 
was reconstituted in 5 mL saline 0.9% for injection and vortex mixed for 20 min after 
reconstitution. An i.v. bolus of LPS was administered at a dose of 1 ng/kg at time point 0 
hours, continued by a continuous infusion at a dose of 1 ng/kg/ h for 3 hours. Hydration 
was continued with a rate of 150 ml/h for 6 hours, and 75 ml/h for the rest of the experiment 
to ensure optimal hydration. Blood was drawn at several time points throughout the 
experiment. All samples were processed within 3 hours after collection. Temperature was 
measured using a tympanic thermometer (FirstTemp Genius 2; Covidien, Dublin, Ireland). 
Endotoxin induced flu-like symptoms (headache, nausea, shivering, muscle and back pain) 
were scored on a six-point scale (0 = no symptoms, 5 = worst ever experienced), resulting 
in a total symptom score of 0–25.
Cytokine measurement
Ethylenediaminetetraacetic-(EDTA) anticoagulated blood was immediately centrifuged 
after withdrawal at 2000 g, 4°C for 10 minutes. The obtained plasma was stored at -80°C 
until further analysis. Plasma concentration of the cytokines Tumor Necrosis Factor (TNF)
α, Interleukin (IL)-6, IL-8, IL-10 and IL-1 receptor antagonist (IL-1RA) and the chemokines 
macrophage inflammatory protein (MIP)-1α, MIP-1β and monocyte chemoattractant 
protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), were determined 
batchwise in anticoagulated plasma by a multiplex immunoassay assay according to 
the manufacturer’s instructions (Bio-Plex, BioRad, Hercules, USA and Milliplex, Millipore, 
Billerica, USA). 
Plasma adenosine
Plasma adenosine levels were determined using an in-house developed method as 
described previously23. Blood was drawn with a special syringe system that immediately 
mixed the blood with a solution that consisted of pharmacological blockers of adenosine 
formation, transport and degradation at the tip of the syringe in a 1:1 ratio. Haematocrit 
values in the blocking solution-blood mixture and in whole blood were determined to 
correct for dilution. The mixture was centrifuged at 2000 g, 4°C for 10 minutes and stored 
at -80°C until further analysis. 
The blocker solution consisted of 40 μM dipyridamole (adenosine transport inhibitor), 
10 μM erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) (adenosine deaminase inhibitor), 
10 μM iodotubericidine (ITU) (adenosine kinase inhibitor), 13.2 mM Na2EDTA (disodium 
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ethylenediamine tetraacetate) (inhibits release from platelets and acts as a 5ʹ-nucleotidase 
inhibitor), 118 mM NaCl, and 5 mM KCl. Plasma adenosine concentrations were determined 
by high performance liquid chromatography (HPLC). In brief, 36 volumes of plasma were 
mixed with 1 volume of perchloric acid (70%) and 20 volumes of 0.5M trioctylamine in 
chloroform, followed by centrifugation (3 min, 13400rpm, RT). Four volumes of supernatant 
were mixed with 1 volume of chloroacetaldehyde (6x diluted in 1M acetate buffer, pH 4.5) 
followed by derivatization (60 min, 500rpm, 70 °C). Chloroform was added (3.3 volumes), 
the mixture was centrifuged (3 min, 13400 rpm, RT), the supernatant was transferred to 
a HPLC vial and injected. Adenosine was separated by HPLC system (Thermo Scientific, 
Rockford, USA) using a Polaris C18-A column (150 x 4.6 mm) with gradient elution using 
eluent A (50 mM NH4H2PO4, 5 mM sodium 1-hexanesulfonate monohydrate [pH 3.0], and 
2% MeOH) and eluent B (H2O: ACN: THF; 50:49:1). The retention time was approximately 
10 min. Quantification was based on peak areas of the samples and reference standards 
measured with fluorescence (excitation: 280 nm; emission: 420 nm).
Assessment of P2Y12 inhibition
Specific effectiveness of P2Y12 inhibition was determined by the level of phosphorylation 
of vasodilator-stimulated phosphoprotein (VASP) in citrated blood (3,2% sodium citrate, 
Vacutainer, Becton Dickinson) whole blood using an ELISA-based assay (CY-QUANT 
VASP/P2Y12, BioCytex, Marseille, France) according to manufacturer’s instructions. This 
test monitors the responsiveness to P2Y12 inhibitors, and P2Y12 inhibition is expressed 
as platelet reactivity index (PRI%), a value <50% is considered as adequate platelet 
inhibition. 
Platelet activation and responsiveness 
Platelet activation and responsiveness was assessed in citrated (3.2% sodium citrate, 
Vacutainer, Becton Dickinson) whole blood using flow cytometry within 3 hours. Whole 
blood (5µL) was added to a mix of hepes-buffered saline, saturating concentrations of 
FITC-labeled anti-fibrinogen (DAKO, Heverlee Belgium), PE-labeled anti-CD62p (anti-P-
selectin; BD Biosciences, San Jose, CA, USA) and PC7-labeled anti-CD61 (anti-glycoprotein 
IIIa; Beckman Coulter, Brea, CA, USA). Platelet reactivity was assessed by ex vivo stimulation 
with either platelet agonist adenosine diphosphate (ADP; 3.4 and 125 µM; Sigma-Aldrich, 
Zwijndrecht, The Netherlands) or cross-linked collagen-related-peptide (CRP-XL; 39ng/L or 
625ng/L). CRP-XL was a generous gift from Prof. dr. R. Farndale (Cambridge, UK) and was 
prepared as described previously51. After incubation for 20 minutes at room temperature a 
500µL fixative solution (0,4% formaldehyde) was added. Samples were directly measured 
on a FC500 flow cytometer (Beckman Coulter) and data were analyzed using Kaluza® 
software (Beckman Coulter). Platelets were gated on forward-scatter (FS), side-scatter (SS) 
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and CD61 positivity. Subsequently expression of CD62p, a measure of degranulation, and 
fibrinogen after ADP stimulation were expressed as median fluorescence intensity (MFI).
Leukocyte and platelet counts
Analyses of leukocyte counts, differentiation and thrombocyte counts were performed in 
EDTA anticoagulated blood using routine analysis methods also used for patient samples 
(flow cytometric analysis on a Sysmex XE-5000). 
Statistical analysis
Data are expressed as a mean ± SEM or as median [interquartile range], according to their 
distribution. Data were tested for normality using the Shapiro-Wilk test. To evaluate the 
effect of platelet inhibitors on cytokine responses, PRI and activity and responsiveness, 
repeated measures two-way ANOVAs (interaction term of group and time) were performed 
between specific pairs of groups: 1. To evaluate the effects of ASA, placebo-ASA was 
compared to placebo 2. To evaluate the effect of clopidogrel or ticagrelor added to ASA, 
placebo-ASA was compared to clopidogrel-ASA and ticagrelor-ASA. 3. In case of an effect 
of ticagrelor or clopidogrel added to ASA, a comparison of clopidogrel-ASA with ticagrelor-
ASA was made to assess for differences between these P2Y12 inhibitors. 
Baseline values of prostaglandins, plasma adenosine and VASP-P platelet reactivity index 
were compared with Students t-test or Mann-Whitney test. Differences in changes over 
time were analyzed with Friedman test with post-hoc Dunn’s Multiple Comparison Test 
(thromboxane B and VASP-P) or Wilcoxon signed rank test (adenosine). Haemodynamic 
parameters, temperature, symptom scores, platelet and leukocyte counts were analyzed 
for differences between all four groups using a repeated measures two-way ANOVA 
(interaction term of group and time). Correlation between platelet responsiveness and 
plasma cytokine levels were calculated using Pearson’s correlation. All statistical analyses 
were performed using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, 
USA). A two-sided p value <0.05 was considered statistically significant.
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Supplemental Figures
Supplemental Figure 1. Gating strategy platelet-leukocyte complexes
Gating strategy for platelet-monocyte and platelet-neutrophil complex formation in a representative sample. Monocytes 
(blue) were selected based on size (forward-scatter; FS), granularity (side-scatter; SS) and expression of CD16, CD14 and 
HLA-DR as shown in the upper scattergrams. Neutrophils were gated based on size (FS), granularity (SS) CD14, CD16 and 
HLA-DR as shown in the lower scattergrams. The markers were chosen to distinguish neutrophils and monocytes during 
experimental human endotoxemia. Platelet interaction was assessed using the % of CD61-positive events shown in the 
right overlay graph. An example of the different populations of monocytes (Blue) and neutrophils (green) are shown left 
in the scattergram. Kaluza Analysis 1.5 (Beckman Coulter, Brea, CA, USA) was used for analysis.
Supplemental Figure 2. CONSORT Flow chart of study inclusion and follow up
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Supplemental Figure 3. Correlations between cytokines and platelet reactivity
Correlations between tumor necrosis factor (TNF)α (panel A and B) and interleukin-6 (panel C and D) and platelet 
reactivity expressed as P-selectin expression upon stimulation with high doses of collagen related peptide (CRP-XL) (Panel 
A and C) or adenosine diphosphate (ADP) or at time of endotoxin administration. Cytokine production is expressed as 
the area under the concentration-time curve (ng/ml*h). Pearson’s correlation coefficients were not significant. ASA: 
acetylsalicylic acid.
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Supplemental Figure 4. Correlations between cytokines and platelet neutrophil complexes
Correlations between tumor necrosis factor (TNF)α and interleukin-6 and platelet monocyte complexes (PMC) or platelet 
neutrophil complexes (PNC). Cytokine production is expressed as the area under the concentration-time curve (ng/ml*h). 
Pearson’s correlation coefficients were not significant. ASA: acetylsalicylic acid.
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Supplemental Figure 5. Hemodyanmic parameters, temperature and symptoms
(A) Mean arterial pressure (MAP), (B) heart rate, (C) temperature and (D) symptom score during endotoxin-elicited 
systemic inflammation. Endotoxin administration started at t=0 hours and continued until t=3 hours. Data are expressed 
as mean and SEM. MAP decreased over time, with a concurrent increase in heart rate and temperature (1-way ANOVA 
in P group, p<0.0001 for all parameters). There was a small difference in MAP between groups (2-way ANOVA p=0.04), 
although post-hoc analysis did not point out what the discrepant group or time point was. There was no effect of study 
treatment on heart rate, temperature and symptom score. P: placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor 
and acetylsalicylic acid, CA: clopidogrel and acetylsalicylic acid. 
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Supplemental Figure 6. Platelets and leukocyte counts during endotoxemia
(A) platelet-, (B) neutrophil-, (C) monocyte-, and (D) lymphocyte counts during endotoxin-elicited systemic inflammation. 
Endotoxin administration started at t=0 hours and continued until t=3 hours. Data are expressed in box plots with minimal 
and maximal observed values. Platelets, monocytes and lymphocytes decreased temporarily due to endotoxemia (1-way 
ANOVA in P group, p<0.0001 for all parameters), without any effect of study treatment on cell counts. P: placebo, PA: 
placebo and acetylsalicylic acid, TA: ticagrelor and acetylsalicylic acid, CA: clopidogrel and acetylsalicylic acid.
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Dear Editor, 
With great interest we read the letter of Falcone et al.1 in which an independent association 
between the survival of septic shock from community-onset pneumonia and treatment 
with chronic low dose aspirin and macrolides is reported. The authors hypothesize that 
the anti-inflammatory effects exerted by these drugs may explain the decreased mortality. 
It is indeed conceivable that agents interfering with the pathogenesis of sepsis through 
modulation of inflammation and coagulation may improve the outcome in sepsis. However, 
for aspirin treatment we would like to argue that it is more likely that this is related to an 
augmented pro-inflammatory response rather than to anti-inflammatory effects.
Perhaps counter-intuitive, aspirin increases the pro-inflammatory cytokine response after 
whole blood stimulation with endotoxin in healthy volunteers2. Other non-steroidal anti-
inflammatory drugs, such as ibuprofen, have also shown to significantly augment levels of 
the pro-inflammatory cytokines TNFα, IL-6 and IL-8 following intravenous administration of 
endotoxin in healthy volunteers, by 3.9-, 3.1-, and 2.9-fold, respectively3. As prostaglandins 
are known to attenuate (innate) pro-inflammatory cytokine production at the transcriptional 
level4, it appears plausible that the pro-inflammatory effects of these COX-inhibitors are 
mediated by attenuation of prostaglandin production. Therefore, patients on chronic low 
dose aspirin may exhibit an augmented pro-inflammatory cytokine response to invading 
pathogens. This enhanced initial cytokine response likely results in more effective clearance 
of bacteria5, whereas an initially less pronounced pro-inflammatory cytokine response may 
result in ineffective microbial killing, leading to an increase of the bacterial load, ultimately 
causing more pronounced activation of the immune response, septic shock, organ failure, 
and increased risk of death6. 
Taken together, we propose that the observed association of chronic low dose aspirin 
use and improved survival in patients admitted to the ICU with infectious diseases may 
rather be the result of an augmented pro-inflammatory cytokine response and pathogen 
clearance, as opposed to the assumed anti-inflammatory effects. 
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Abstract
Objective: To investigate immunostimulatory effects of acetylsalicylic acid (ASA) 
during experimental human endotoxemia and in sepsis patients.
Design: Double-blind randomized placebo-controlled study in healthy volunteers 
and ex vivo stimulation experiments using monocytes of septic patients.
Setting: Intensive care research unit of an university hospital.
Subjects: 30 healthy male volunteers and 4 sepsis patients.
Interventions: Healthy volunteers were challenged intravenously with endotoxin 
twice, at a one week interval, with each challenge consisting of a bolus of 1 ng/kg 
followed by continuous administration of 1 ng/kg/hr during 3 hours. Volunteers 
were randomized to ASA-prophylaxis (80mg ASA daily for a 14-day period, starting 
7 days before the first endotoxin challenge), ASA-treatment (80mg ASA daily for 
the 7-day period in-between both endotoxin challenges), or the control group 
(receiving placebo). Furthermore, ASA pre-exposed platelets were co-incubated 
with monocytes of sepsis patients that were subsequently stimulated with 
endotoxin.
Measurements and Main Results: ASA-prophylaxis enhanced plasma TNFα con-
centrations upon the first endotoxin challenge by 50% compared with the control 
group (p=0.02), but did not modulate cytokine responses during the second 
endotoxin challenge. In contrast, ASA-treatment resulted in enhanced plasma 
levels of TNFα (+53%, p=0.02), IL-6 (+91%, p=0.03) and IL-8 (+42%, p=0.02) upon 
the second challenge, whereas plasma levels of the key anti-inflammatory cytokine 
IL-10 were attenuated (-40%, p=0.003). This pro-inflammatory phenotype in the 
ASA-treatment group was accompanied by a decrease in urinary prostaglandin E 
metabolite levels (-27%±7, p=0.01). Ex vivo exposure of platelets to ASA increased 
production of TNFα (+66%) and decreased production of IL-10 (-23%) by monocytes 
of sepsis patients. 
Conclusions: Treatment, but not prophylaxis with low-dose ASA partially reverses 
endotoxin tolerance in humans in vivo by shifting response towards a pro-
inflammatory phenotype. This ASA-induced pro-inflammatory shift was also ob-
served in septic monocytes, signifying that patients suffering from sepsis-induced 
immunoparalysis might benefit from initiating ASA treatment.
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Introduction
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host 
response to infection1. Despite decades of research, sepsis incidence is increasing2, 
the associated health care costs are enormous, and sepsis represents the leading cause 
of in-hospital mortality3. The pathophysiology of sepsis is highly complex, as the host 
response between patients is variable and can comprise both hyperinflammatory and 
immunosuppressive phenotypes4. The latter phenotype, often referred to as sepsis-induced 
immunoparalysis, is increasingly recognized as the overriding immune dysfunction in 
septic patients5,6. Sepsis-induced immunoparalysis is characterized by impaired innate 
and adaptive immune responses, including exhaustion and apoptosis of lymphocytes, 
diminished capacity of monocytes and macrophages to produce cytokines, and decreased 
HLA-DR expression on the cell surface of monocytes5,7,8. This suppressed immune function 
may contribute to adverse outcome, as the host is unable to control the primary infection, 
and is increasingly susceptible towards secondary infections6,9–13. As such, these patients 
might benefit from immune stimulatory therapy to restore host defence. 
In several large observational studies, prehospital use of low-dose acetylsalicylic acid (ASA) 
was associated with reduced mortality in patients admitted to the Intensive Care Unit (ICU) 
with sepsis14–21. The most recent meta-analysis performed in 17,065 patients showed a 7% 
reduction (range 2–12%) in mortality in patients taking aspirin prior to sepsis onset22. A 
large randomized controlled trial (ANTISEPSIS) is currently being conducted to evaluate the 
effect of prehospital ASA use on outcome in the sepsis population23. 
Although it is often proposed that anti-inflammatory properties of ASA may account 
for the observed beneficial effects, ASA has been shown to potentiate, not attenuate, 
leukocytic cytokine production. For instance, previous data of our group shows that a 
short course of oral aspirin in volunteers increases ex vivo cytokine production capacity24. 
Furthermore, a 7-day treatment with low-dose ASA in healthy volunteers resulted in a 
more pronounced increase in plasma levels of pro-inflammatory cytokines Tumor Necrosis 
Factor (TNF)α, Interleukin (IL)-6 and IL-8 during experimental human endotoxemia25. While 
subjectively counterintuitive, these findings are to be expected considering the inhibitory 
impact of aspirin on prostaglandins, a known negative regulator of (pro-inflammatory) 
cytokine production26,27. This indicates that low-dose ASA exerts pro-inflammatory 
effects during systemic inflammation. As a consequence, ASA may alleviate sepsis-
induced immunoparalysis, which could contribute to the improved survival found in the 
abovementioned observational studies. However, the effects of ASA on the development 
of immunoparalysis have hitherto not been investigated. 
In the present study, we investigated whether a course of low-dose ASA can prevent 
or reverse immunoparalysis in humans in vivo. Similar to previous work of our group, 
we used repeated experimental human endotoxemia as a model for sepsis-induced 
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immunoparalysis28. We investigated whether ASA can prevent immunoparalysis by treating 
subjects 7 days before the first challenge until the second endotoxin challenge. Also, ASA’s 
potential to reverse immunoparalysis was investigated by treating subjects after the first 
endotoxin challenge. Furthermore, we investigated whether this ASA-induced pathway is 
still amenable in monocytes of septic patients. 
Materials and Methods
Subjects
After approval of the local ethics committee (CMO Arnhem-Nijmegen; reference no. 
NL57410.091.16 and 2016-2550), 30 healthy male volunteers aged 18-35 years, were 
recruited. All subjects gave written informed consent and medical history, physical 
examination, laboratory tests and a 12-leads electrocardiogram did not reveal any 
abnormalities. Smoking, medication use (in particular the use of COX inhibitors), previous 
participation in experimental human endotoxemia, or signs of acute illness within 3 weeks 
prior to the start of the study were exclusion criteria. All study procedures were performed 
in accordance with the declaration of Helsinki, including the latest revisions. The study was 
registered at ClinicalTrials.gov (NCT02922673). For ex vivo stimulation experiments, we 
obtained monocytes from 4 patients with sepsis according to the Sepsis-3 criteria1 and 
platelets from 3 healthy volunteers. These experiments were approved by the local ethics 
committee (CMO Arnhem-Nijmegen; reference no. 2016-2923 and 2010-104). 
Endotoxemia study design
We performed a randomized double-blind placebo-controlled study, of which the design is 
depicted in Figure 1. All subjects were challenged intravenously with endotoxin twice, on 
study days 7 and 14. The second challenge was used to quantify the extent of endotoxin 
tolerance. Study medication was prescribed in two 7-day courses prior to both endotoxin 
challenges, and was encapsulated to maintain the double-blinded design. Subjects were 
randomized to one of three groups (n=10 per group). The ASA-prophylaxis group received 
80mg acetylsalicylic acid once daily starting one week prior to the first endotoxin challenge 
and continuing until the second endotoxin challenge. The ASA-treatment group received 
placebo once daily in the week prior to the first endotoxin challenge, and 80mg acetylsalicylic 
acid once daily in the week prior to the second endotoxin challenge. The control group 
received placebo in the weeks prior to both endotoxin challenges. In both the ASA-pro-
phylaxis and ASA-treatment groups, the first ASA dose administered was a loading dose of 
160mg, consistent with our previous work25 and clinical use of ASA. Therapy compliance was 
verified by diaries, pill counts, and urinary 11-dehydro-thromboxane B2 concentrations.
All additional study procedures, including ex vivo experiments with monocytes of sepsis 
patients, and analysis methods are provided in the Supplemental Digital Content.
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Figure 1. Endotoxemia study design 
Procedures on the day of the first and second endotoxin challenge are similar. ASA = acetylsalicylic acid;  
LPS = lipopolysaccharide. 
Results
Subject characteristics
Baseline demographic characteristics of the study population are listed in Supplementary 
Table 1 and reveal no significant differences between the three study groups. Apart from 
the well-known endotoxin-induced symptoms, no adverse events occurred during the 
study. There were no baseline differences in urinary 11-dehydro-TXB2 levels between 
groups (Figure S1). Therapy compliance was 100%, as verified by diaries and pill counts 
and confirmed by urinary 11-dehydro-TXB2 concentrations, which were greatly reduced 
in all ASA-treated subjects (before ASA: 184±28, after ASA: 41±8 pg/mL/creat, p<0.0001, 
Figure S1).
Plasma cytokines
The first endotoxin challenge resulted in a profound inflammatory response, illustrated by 
an increase in plasma levels of all cytokines (TNFα, IL-6, IL-8, IL-10, and IL-1RA are depicted 
in Figure 2, and MCP-1, MIP-1α, and MIP-1β in Figure S2). Individual data of the area under 
the time-cytokine concentration curves are depicted in Figure S3. Plasma levels of IL-1β, 
IL-4, and IL-13 were below the detection limit of the assay in the great majority of samples 
obtained on both endotoxemia days (data not shown). Prophylactic use of ASA enhanced 
plasma concentrations of TNFα by 50% compared with the control group upon the first 
endotoxin challenge (p=0.02, Figure 2A and S3A), but did not significantly affect the 
other cytokines measured. Following the second endotoxin challenge, the development 
of endotoxin tolerance was illustrated by a severely blunted plasma cytokine response 
upon the second endotoxin challenge in the control group (decrease in AUC of TNFα: 
58±11%, p=0.003, Figure 2A and S3A; IL-6: 73±11%, p=0.004, Figure 2B and S3B; IL-8: 
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65±10%, p=0.003, Figure 2C and S3C; IL-10: 56±11%, p=0.003, Figure 2D and S3D; IL-1RA: 
54±14%, p=0.003, Figure 2E and S3E; MCP-1: 38±11%, p=0.007, Figure S2A and S3F; MIP-
1α: 48±5%, p=0.001, Figure S2B and S3G; MIP-1β: 55±11%, p=0.01, Figure S2C and S3H). 
Prophylactic treatment with ASA did not significantly affect the development of endotoxin 
tolerance (Figure 2, S2 and S3). In the ASA-treatment group, endotoxin tolerance was less 
pronounced, illustrated by significantly higher plasma levels of TNFα (+53%, p=0.02, Figure 
2A and S3A), IL-6 (+91%, p=0.03, Figure 2B and S3B) and IL-8 (+42%, p=0.02, Figure 2C 
and S3C) upon the second endotoxin challenge compared with the control group. The 
shift towards a more pro-inflammatory phenotype in the treatment group was further 
exemplified by lower plasma levels of the key anti-inflammatory cytokine IL-10 compared 
with the control group (-40%, p=0.003, Figure 2D and S3D). No between-group differences 
were found upon the second endotoxin challenge for IL-1RA, MCP-1, MIP-1α, and MIP-1β 
(Figure 2E, S2 and S3E-H).
HLA-DR expression on monocytes
ASA-prophylaxis did not affect mHLA-DR expression in the absence of systemic inflamma-
tion (Figure 3A). The first endotoxin challenge expectedly resulted in decreased mHLA-DR 
expression in subjects not (yet) exposed to ASA (the control and treatment group, p<0.01 
and p<0.001), whereas no significant decrease was observed in the ASA-prophylaxis group. 
The second endotoxin challenge resulted in significantly attenuated mHLA-DR expression 
levels in all groups (p<0.001, Figure 3A).
PGE-M
We did not observe differences in baseline urinary PGE-M levels between the three groups 
(data not shown). Endotoxemia resulted in increased urinary PGE-M concentrations in 
all groups upon both endotoxin challenges, with peak levels observed in urine collected 
during the first three hours after the start of endotoxin administration. Peak PGE-M levels 
did not differ upon the first and second challenge in the control and ASA-prophylaxis groups 
(Figure 3B). In the ASA-treatment group, peak PGE-M concentrations were significantly 
attenuated upon the second challenge compared to the first (-27±7%, p=0.01, Figure 3B). 
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Figure 2. Plasma levels of cytokines during the first and second endotoxin challenge
Plasma levels of (A) Tumor Necrosis Factor (TNF)α, (B) Interleukin (IL)-6, (C) IL-8, (D) IL-10, and (E) IL-1 receptor antagonist 
(RA), upon the first and second endotoxin challenge. Cytokine concentrations over time are depicted as mean and SEM. 
The grey area indicates the three-hour endotoxin administration period. p-values represent the interaction term of 
repeated measures two-way ANOVA. ASA = acetylsalicylic acid.
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Figure 3. HLA-DR expression and prostaglandin concentration
(A) HLA-DR expression on monocytes before (baseline) and 6 hours after start of the first and second endotoxin challenge. 
(B) Peak urinary prostaglandin E metabolite (PGE-M) concentrations upon the first and second endotoxin challenge. 
Data are depicted as bar (mean) and scatter plots.** p < 0.01 and *** p < 0.001 compared with baseline in panel A 
(calculated using repeated measures one-way ANOVA with Dunnett’s post-hoc tests). Data in panel B were analyzed 
using paired Student’s t-tests. ASA = acetylsalicylic acid; NS = non significant. 
Oxidative stress
Plasma levels of malondialdehyde (MDA), a product of lipid peroxidation due to oxidative 
stress, increased upon both endotoxemia days. MDA concentrations did not differ between 
the first and second endotoxin challenges within any of the groups. Furthermore, no 
between-group differences were observed (Figure 4).
Figure 4. Oxidative stress expressed by plasma levels of malondialdehyde (MDA) upon the first and 
second endotoxin challenge
MDA concentrations over time are depicted as mean and SEM. The inserts depict the individual area under the 
time-concentration curves (AUC) data expressed as nmol * h/mL. The grey area indicates the three-hour endotoxin 
administration period. p-values represent the interaction term of repeated measures two-way ANOVA. ASA = 
acetylsalicylic acid.
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Hematologic and clinical parameters
Transient changes in hematologic parameters were observed during both challenges, 
however changes were less outspoken upon the second challenge. ASA-prophylaxis 
or treatment did not affect endotoxin-induced changes in cell counts or differentiation 
(Figure S4). The first endotoxin challenge caused a profound increase in body temperature, 
symptoms, and heart rate, and a decrease in MAP (Figure S5). The presence of endotoxin 
tolerance was characterized by less pronounced effects on clinical parameters upon the 
second challenge in the control group (peak body temperature of 39.3±0.3 vs. 38.1±0.2oC, 
peak symptom score of 7.9±0.8 vs. 3.4±0.9, peak heart rate of 102±3 vs. 91±2 bpm, and 
nadir MAP 69±2 vs. 75±3 mmHg, for the first and second endotoxin challenge, respectively). 
There were no differences in vital parameters between the ASA-prophylaxis or ASA-
treatment and the control group upon both endotoxin challenges. 
Ex vivo monocyte stimulation experiments
We previously showed that ASA potentiates monocytic TNFα production in healthy 
volunteers in a platelet-dependent manner25. We set out to investigate whether these 
effects also apply to monocytes of sepsis patients. Patient characteristics (n=4) are listed in 
Supplementary Table 2. Three patients exhibited mHLA-DR levels <12000 antibodies/cell, 
consistent with immune suppression29. Compared to co-incubation with naive platelets, 
co-incubation with ASA pre-exposed platelets resulted in enhanced production of TNFα 
(+66%, 1365 [333-2744] vs. 2272 [453-3800] pg/mL, p=0.02) by LPS-stimulated monocytes, 
whereas production of IL-10 was decreased (-23%, 363 [100-400] vs. 281 [70-347] pg/mL, 
p<0.001, Figure 5). Co-incubation of monocytes with ASA alone (without platelets) did not 
affect LPS-stimulated cytokine production (data not shown).
Figure 5. Cytokine production of monocytes obtained from septic patients after ex vivo 24 hour 
stimulation with LPS 
Differences in cytokine production of monocytes co-incubated with ASA pre-exposed platelets (ASA+) and naive platelets 
(ASA-) were analyzed using paired Student’s t-tests on log-transformed data. ASA = acetylsalicylic acid; TNF = Tumor 
Necrosis Factor; IL = Interleukin.
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Discussion
In the current study, we show that continuous administration of endotoxin to healthy 
volunteers results in the development of profound endotoxin tolerance, exemplified by a 
severely blunted cytokine response, fewer symptoms and less changes in vital parameters 
upon the second endotoxin challenge one week later. Prophylaxis with a clinically relevant 
dose of ASA (80mg) resulted in an augmented pro-inflammatory response upon the first 
challenge, but did not prevent or otherwise modulate the development of endotoxin 
tolerance observed during the second challenge. Treatment with a 7-day course of low-
dose ASA in-between both endotoxin challenges resulted in partial reversal of endotoxin 
tolerance, exemplified by a more pro-inflammatory phenotype upon the second endotoxin 
challenge compared to the control group. These data confirm previous reports that ASA 
augments the innate immune response24,25,30,31 and demonstrate that ASA-treatment 
partially reverses endotoxin tolerance in humans in vivo. Furthermore, our ex vivo results 
reveal that this pathway is still amenable in sepsis patients, as the ASA-induced pro-
inflammatory shift was also observed in monocytes obtained from these patients. 
ASA-treatment resulted in a distinct shift towards a more pro-inflammatory phenotype 
upon the second endotoxin challenge, exemplified by enhanced plasma levels of pro-
inflammatory cytokines TNFα, IL-6, and IL-8 compared to the control group, whereas 
the anti-inflammatory IL-10 response was further decreased. Levels of another anti-
inflammatory cytokine, IL-1RA, did not reveal a pattern similar to IL-10, but were also not 
enhanced like the pro-inflammatory mediators. Interestingly, an imbalance in the IL-6/IL-10 
ratio was shown to correlate with an increased risk towards secondary infections in sepsis 
patients, and this effect was already observed when levels of IL-6 and IL-10 deviated >30-
50% from the mean values obtained in sepsis patients32. In our study, the ASA-induced 
changes in cytokine levels/production in healthy volunteers in vivo (TNFα: +53%, IL-6: 
+91%, IL-8: +42%, and IL-10: -40%) and in septic patients ex vivo (TNFα: +66% and IL-10: 
-23%) were in the same order of magnitude or greater. Therefore, it appears plausible that 
the observed ASA-induced shifts are of clinical relevance. 
Although the beneficial effects of ASA are most frequently attributed to its anti-
inflammatory properties, pro-inflammatory characteristics of ASA were demonstrated 
decades ago in vitro24,30,31, but also more recently in vivo by our group25. These ASA-
mediated effects appear to be dose-specific, as in vitro work has revealed that low ASA 
dosages enhance cytokine responses, whereas very high dosages inhibit cytokine 
production33. Low-dose ASA potently acetylates the constitutively active enzyme COX-1, 
thereby irreversibly inhibiting the conversion of arachidonic acids into prostaglandins34. 
In addition, we have previously shown that platelets are critically involved in ASA’s pro-
inflammatory effects, as co-incubation of monocytes of healthy volunteers with ASA-
pre-exposed platelets augmented monocytic LPS-stimulated TNFα production, whereas 
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incubation of monocytes with ASA alone did not exert any effects25. In the current study, we 
show that this ASA-induced pathway is still amenable in monocytes of sepsis patients, and 
confirm that this effect is platelet-dependent, as incubation with solely ASA did not exert 
any effects on monocytic cytokine production. Others have shown that platelets exert anti-
inflammatory effects during sepsis via the COX-1-PGE2-patyway
35, and it is well established 
that PGE2 inhibits the release of TNFα and IL-6
27,36, whereas it stimulates production of 
IL-1026. In accordance, we previously demonstrated that addition of PGE2 attenuated the 
pro-inflammatory effects of ASA in a dose-dependent manner25. The present work reveals 
that the endotoxin-induced increase in urinary PGE-M concentrations (as a surrogate 
measure of in vivo systemic PGE2 synthesis) was significantly attenuated upon the second 
endotoxin challenge in the ASA-treatment group. Taken together, we hypothesize that the 
ASA-induced COX-1-inhibition results in decreased levels of PGE2, and thereby abrogates 
the suppressive effects on LPS-induced pro-inflammatory cytokine production, ultimately 
resulting in increased production of these mediators27. 
Beneficial effects of anti-platelet therapy, and in particular of ASA, in the context of 
sepsis have been extensively described18,20,37. In a recent meta-analysis using propensity 
matching, the use of low-dose ASA prior to sepsis onset was associated with a 7% reduction 
in mortality22. Similar results were found in a Bayesian network meta-analysis, where 
prehospital use of ASA was associated with lower hospital mortality in septic patients38. In 
accordance with previous work of our group25, the present study demonstrates that ASA 
prophylaxis enhances TNFα response upon the first endotoxin challenge. However, we now 
show that ASA-prophylaxis does not affect the development of endotoxin tolerance. This 
shift towards a more pro-inflammatory profile upon the initial challenge could nevertheless 
represent an explanation for the abovementioned beneficial effects observed in sepsis 
patients on pre-hospital low-dose ASA treatment, as a more potent host response may 
enhance clearance of pathogens39. In addition, ASA did not result in increased oxidative 
stress, this might indicate that the ASA-induced shift towards a more pro-inflammatory 
phenotype does not come at the expense of increased collateral damage.
Unfortunately, most epidemiological studies that have evaluated the effects of prehospital 
(low-dose) ASA on sepsis outcome merely assessed clinical parameters. To the best of 
our knowledge, only one study assessed circulating cytokine levels, and no effects of 
prehospital ASA use on host-response parameters were observed40. Clearly, assessment of 
ASA’s putative immunomodulatory effects from these retrospective patient data is difficult. 
Interpatient variability is extensive, and it could be argued that, due to an enhanced initial 
immune response, prehospital ASA use renders patients less vulnerable to develop a severe 
sepsis that requires hospitalization41. Therefore, it would be interesting to investigate the 
effects of prehospital ASA use on sepsis susceptibility. Interestingly, a large randomized 
clinical trial (ANTISEPSIS) is currently underway that will address this question23. 
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The effects of ASA in this study were mainly exerted at cytokine production capacity level, 
while other immune parameters were less strongly affected. In line with previous data of 
our group28, experimental endotoxemia resulted in decreased mHLA-DR expression. This 
effect was similar across all groups and during both endotoxin challenges, although it did 
not reach statistical significance in the ASA-prophylaxis group upon the first endotoxin 
challenge, which might be another reflection of the enhanced pro-inflammatory profile 
observed in this group. Despite the fact that the effects of ASA on HLA-DR expression were 
relatively small, they could still be of clinical relevance, as an increase of 4.8% in HLA-DR 
expression was shown to be associated with improved survival in patients suffering from 
severe sepsis42. 
The ASA-induced shift towards a more pro-inflammatory phenotype was not reflected in 
the assessed clinical parameters. This is likely explained by the fact that cytokine levels do 
not directly correlate with clinical parameters in the experimental human endotoxemia 
model, as we have shown before43. Rather, there appears to be a threshold effect, in which 
clinical parameters only show changes when cytokine responses are profoundly altered43.
This study has limitations which should be acknowledged. First, only male subjects and 
patients were studied. Pertaining to the endotoxemia results, females were previously 
shown to mount a more pronounced pro-inflammatory immune response upon endotoxin 
challenge44, meaning that including both sexes would result in more interindividual 
variation and impair statistical power of the study44. Furthermore, fluctuating hormone 
levels during the menstrual cycle are also known to influence immune parameters45,46, 
which would further increase variation. This would necessitate a larger sample size, which 
is undesirable for the very labor- and cost-intensive endotoxemia studies. Despite the fact 
that there are no indications that the immunologic response to ASA is different between 
males and females, the use of only males limits the generalisability of our work. Second, only 
young subjects were studied, whereas ASA therapy is used mostly in the aged, and sepsis 
patients are usually older as well. Again, there is no reason to assume that the immunologic 
response to ASA is different in older subjects, and our ex vivo experiments using monocytes 
of (also older) sepsis patients corroborate this. Third, it should be noted that endotoxin 
tolerance only partially resembles sepsis-induced immunoparalysis. For instance, in sepsis 
patients, also profound adaptive immune system derangements, such as lymphocyte 
apoptosis and dysfunction occur7,47. Administration of an endotoxin mainly results in 
activation of the innate immune system; there is no antigen presentation and no classic 
adaptive response, nor profound lymphocyte dysfunction and/or apoptosis as observed 
in sepsis. Nevertheless, human endotoxemia is the only human model available that 
captures several important hallmarks of both sepsis and sepsis-induced immunoparalysis, 
and the only human model to study these conditions. Furthermore, although our model 
mimics infection with Gram-negative bacteria, transcriptomic analyses have revealed 
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that most sepsis response pathways are common, and independent of pathogen or 
source of infection48. Both the considerable overlap in signaling pathways downstream of 
pathogen-specific pattern recognition receptors and inflammation-induced translocation 
of endotoxin from the gut to the circulation may explain these common responses49. This 
suggests that our findings may also be relevant for infections with other pathogens. Fourth, 
it has been reported that the efficacy of low-dose ASA varies between patients according 
to their lean body mass50. Whereas this is not relevant for our study results (BMI was equally 
distributed among groups), it might be relevant for patients. Moreover, a certain part of 
the population appears to be resistant to the anti-platelet aggregation effects of low-
dose ASA51, however, it remains to be determined whether this also applies to the pro-
inflammatory effects of ASA. 
Conclusions
Treatment, but not prophylaxis, with low-dose ASA partially reverses endotoxin tolerance 
in humans in vivo by causing a shift towards a more pro-inflammatory phenotype. This 
effect likely involves inhibition of PGE2. This ASA-induced shift towards a pro-inflammatory 
phenotype is also observed in monocytes of sepsis patients, which signifies that patients 
suffering from sepsis-induced immunoparalysis may benefit from initiation of ASA 
treatment in the hospital. While prophylaxis with ASA did not prevent the development 
of endotoxin tolerance, the ASA-associated survival benefits in observational studies 
might be related to an augmented pro-inflammatory response in the early phase of sepsis, 
resulting in improved bacterial clearance of their primary infection. As such, the current 
study provides an potential explanation of the benefits of ASA use in sepsis patients. If the 
upcoming ANTISEPSIS trial confirms the association between ASA use and survival benefits 
once again, a prospective trial with ASA in sepsis patients is highly warranted. 
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Supplemental Materials and Methods
Experimental human endotoxemia
On both endotoxin challenge days, subjects were admitted at the Intensive Care Unit of the 
Radboud university medical center for 10 hours. Subjects had to refrain from alcohol and 
caffeine (24 hours), and food and drinks (12 hours) before the administration of endotoxin. 
Subjects were weighted to determine the total dose of endotoxin to be administered (4 ng/
kg bodyweight). An intravenous cannula was placed in an antebrachial vein to administrate 
fluids and endotoxin. A radial artery catheter (BD Infusion Therapy Systems, Sandy, USA) 
was placed to withdraw blood and continuously monitor blood pressure. During the hour 
before endotoxin administration, prehydration fluid (1.5 L 2.5% glucose/0.45% NaCl) was 
administered to prevent vasovagal responses1. Hereafter, a bolus of 1 ng/kg endotoxin 
(lipopolysaccharide [LPS], E. Coli Type O113, Lot no. 94332B4; List Biological Laboratories, 
Campbell, USA) was administered, followed by continuous administration of 1 ng/kg/
hr endotoxin for three hours, analogous to our previous study2. Hydration fluid (2.5% 
glucose/0.45% NaCl) was administered at a rate of 150 mL/hr from start of endotoxin 
administration until discharge from the hospital.
Cytokine measurements
After withdrawal, ethylenediaminetetraacetic acid (EDTA-)anticoagulated blood was cen-
trifuged (10 min, 2000g, 4oC), and plasma was stored at -80oC until analysis. Concen trations 
of Tumor Necrosis Factor (TNF)α, Interleukin (IL)-1 receptor antagonist (RA), IL-1β, IL-4, 
IL-6, IL-8, IL-10, IL-13, Macrophage Inflammatory Protein (MIP)-1α, MIP-1β, and Monocyte 
Chemoattractant Protein (MCP)-1 were determined batchwise using a simultaneous 
luminex assay (Milliplex, Millipore, Billerica, USA).
HLA-DR expression on monocytes
HLA-DR expression on monocytes was determined in EDTA-anticoagulated whole blood 
before and six hours after both endotoxin challenges using the Anti-HLA-DR/Anti-Monocyte 
Quantibrite assay (BD Biosciences, San Jose, USA) on a CytoFLEX flow cytometer (Beckman 
Coulter, Indianapolis, USA). Flow data were analyzed using Kaluza Software (Beckman 
Coulter, Indianapolis, USA). Antibodies bound per cell were calculated by standardizing 
HLA-DR arithmetic mean fluorescence intensity (MFI) of monocytes to BD Quantibrite 
phycoerythrin (PE) beads (BD Biosciences, San Jose, USA). 
Prostaglandins
Urine was collected in containers placed on ice and thoroughly mixed at the end of the 
specified intervals, after which samples were taken and stored at -80oC until analysis. Because 
plasma thromboxane A2 is rapidly hydrolyzed to thromboxane B2, we measured the stable 
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urinary metabolite 11-dehydro-thromboxane B2 (11-dehydro-TXB2) to confirm therapy 
compliance and acetylsalicylic acid (ASA) efficacy using enzyme-linked immunosorbent 
assay (ELISA, Cayman Chemical, Ann Arbor, USA). Prostaglandin E2 production was 
assessed by measuring urinary Prostaglandin E metabolites (PGE-M) using ELISA (Cayman 
Chemical, Ann Arbor, USA). Urinary 11-dehydro-TXB2 and PGE-M values were corrected for 
urinary creatinine content, determined using a Cobas C8000 analyzer (Roche Diagnostics 
Operations, Indianapolis, USA) at the Department of Laboratory Medicine of the Radboud 
university medical center.
Oxidative stress
Lipid peroxidation was determined by measuring levels of malondialdehyde (MDA) in 
EDTA plasma using the Thiobarbituric Acid Reactive Substances (TBARS) Parameter Assay 
Kit (R&D Systems, Abingdon, UK) according to the manufacturer’s instructions. 
Hematological parameters
Platelet and leukocyte counts and differentiation were determined in EDTA-anticoagulated 
blood by the Department of Laboratory Medicine of the Radboud university medical center 
(Sysmex XE-5000, Sysmex Nederland B.V., Etten-Leur, the Netherlands).
Clinical parameters
During hospitalization, heart rate and intra-arterial blood pressure were monitored using 
a 4-lead electrocardiogram (M50 Monitor, Philips, Eindhoven, the Netherlands), and a 
pressure transducer (Edward Lifesciences, Irvine, USA) connected to the Philips monitor, 
respectively. Hemodynamic data were sampled every 30 seconds using in-house developed 
software. Every 30 minutes, core temperature was measured with a tympanic thermometer 
(FirstTemp Genius 2, Covidien, Dublin, Ireland) and flu-like symptoms (headache, nausea, 
cold shivers, muscle and back pain) were scored using a numeric six-point scale (0 = no 
symptoms, 5 = worst ever experienced) with addition of 3 points in case of vomiting, 
resulting in a total symptom score ranging from 0 to 28.
Ex vivo monocyte stimulation experiments
Peripheral blood mononuclear cells of sepsis patients (n=4) were isolated from EDTA anti-
coagulated blood using Ficoll-Paque (GE Healthcare, Chicago, Illinois, USA) as described 
previously3. Subsequently, (unlabeled) monocytes were obtained by magnetic beads 
depletion using a Pan monocyte isolation kit (MACS, Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. Purity of the monocyte fraction 
(>95% monocytes of leukocytes for all samples) was determined using a hematology 
analyzer (Sysmex XN450, Hamburg, Germany) prior to stimulation. Washed platelets 
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(WP) obtained from healthy donors (n=3) were isolated from citrated blood as described 
previously4 and pre-incubated with 10 µM ASA (Sigma, St. Louis, Missouri, USA) for 30 
minutes and subsequently washed to remove ASA. The ASA concentration used reflects the 
levels observed in vivo after repeated oral intake of 80mg ASA, and predominantly results 
in acetylation of platelet-derived cyclooxygenase (COX)-1, and not of COX-25,6. Thereafter, 
monocytes (5*104 cells) were incubated with WP (1:100 monocyte to platelet ratio) and 
stimulated with E. coli LPS (10 ng/ml; serotype 055:B5, Sigma, St. Louis, Missouri, USA) and 
Trombin Receptor Activator Peptide 6 (TRAP; 50 uM, Sigma, St. Louis, Missouri, USA). After 
24 hours, supernatants were collected and stored at -20°C. TNFα and IL-10 concentrations 
were measured using ELISA according to the manufacturer’s instructions (R&D systems, 
Minneapolis, Minnesota, USA). To assess the immune status of the patients, mHLA-DR 
expression was determined as described above.
Statistical analysis
In a previously performed experiment by our group using continuous endotoxin admini-
stration, the standard deviation of the area under the TNFα concentration time curve in the 
placebo group was 40% of the mean2. Using an α of 0.05, a power of 80% (β of 0.2), and an 
expected detectable difference of 50% between placebo and ASA groups in an unpaired 
design, 10 subjects per group were required. Normally distributed data, according to 
D’Agostino & Pearson omnibus normality test, are presented as mean ± standard error (SEM), 
and non-parametric data as median [interquartile range]. Significant outliers in normally 
distributed datasets were detected using the Grubbs’ test and excluded accordingly with 
a maximum of one exclusion per group. The area under the curve (AUC) was used as an 
integrated measure of responses over time. In the text, percentage difference in AUC are 
reported to illustrate differences in responses and, in case of paired measurements, the SEM 
is provided. One-way analysis of variance (ANOVA) was performed to compare baseline 
characteristics between groups, and repeated measures one-way ANOVA followed by 
Dunnett’s post-hoc test to analyze within-group changes over time. Repeated measures 
two-way ANOVA (interaction term) was used to compare data of the three groups over 
time within the same endotoxin challenge day. Differences in peak PGE-M levels between 
both endotoxin challenge days were tested using paired Student’s t-tests. Differences in 
ex vivo monocytic cytokine production were tested using paired Student’s t-test on log-
transformed data. A two-tailed p-value <0.05 was considered statistically significant. All 
statistical analyses were performed using GraphPad Prism version 5.03 (GraphPad Software, 
San Diego, USA).
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Supplementary figures
Figure S1. Urinary 11-dehydro-thromboxane (TX) B2 levels at baseline and prior to the first  
and second endotoxin challenge 
Data are depicted as bar (mean) and scatter plots. ** p < 0.01 and *** p < 0.001 compared with baseline (calculated using 
repeated measures one-way ANOVA with Dunnett’s post-hoc tests). ASA = acetylsalicylic acid.
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Figure S2.
Plasma concentrations of (A) Monocyte Chemoattractant Protein (MCP)-1, (B) Macrophage Inflammatory Protein (MIP)-
1α, and (C) MIP-1β upon the first and second endotoxin challenge. Cytokine concentrations over time are depicted 
as mean and SEM. The grey area indicates the three-hour endotoxin administration period. p-values represent the 
interaction term of repeated measures two-way ANOVA. ASA = acetylsalicylic acid.
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Figure S3. 
Area under the time-concentration curves (AUC) of (A) Tumor Necrosis Factor (TNF)α, (B) Interleukin (IL)-6, (C) IL-8, and (D) 
IL-10, (E) IL-1 receptor antagonist (RA), (F) Monocyte Chemoattractant Protein (MCP)-1, (G) Macrophage Inflammatory 
Protein (MIP)-1α, and (H) MIP-1β upon the first (1st) and second (2nd) endotoxin challenge. Data are depicted as scatter 
plots with the horizontal line indicating the mean value, and expressed as µg * h/mL. ASA = acetylsalicylic acid; PR = ASA-
prophylaxis; C = control; TR = ASA-treatment.
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(A) Neutrophil, (B) monocyte, and (C) lymphocyte counts upon the first and second endotoxin challenge (mean and 
SEM). The grey area indicates the three-hour endotoxin administration period. p-values represent the interaction term of 
repeated measures two-way ANOVA. ASA = acetylsalicylic acid.
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Figure S5. 
(A) Temperature, (B) symptom score, (C) heart rate, and (D) mean arterial pressure upon the first and second endotoxin 
challenge (mean and SEM). The grey area indicates the three-hour endotoxin administration period. p-values represent 
the interaction term of repeated measures two-way ANOVA. ASA = acetylsalicylic acid.
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Supplementary Tables
Parameters
Control 
(n=10)
ASA-treatment 
(n=10)
ASA-prophylaxis  
(n=10) p-value between groups
Age, yr 22 ± 2 23 ± 3 22 ± 3 0.84
Height, cm 184 ± 5 182 ± 6 183 ± 6 0.71
Weight, kg 79 ± 7 85 ± 9 80 ± 11 0.29
BMI, kg/m2 23 ± 2 26 ± 2 24 ± 3 0.08
HR, bpm 68 ± 10 64 ± 6 72 ± 9 0.12
MAP, mmHg 97 ± 6 94 ± 9 98 ± 4 0.35
Table S1. Baseline characteristics of the healthy volunteers enrolled in the endotoxemia experiments
Data are presented as (mean ± SD). p-values were calculated using one-way ANOVA.
ASA = acetylsalicylic acid; BMI = body mass index; HR = heart rate; MAP = mean arterial pressure.
Patient 1 Patient 2 Patient 3 Patient 4
Age 72 46 29 68
Gender M M M M
BMI 27.3 22.9 25.0 23.7
Focus sepsis Pneunomia Pneunomia Pneunomia Pneunomia
Noradrenaline dosage  
(µg/kg/min)
0.02 0.125 0.05 0
Highest noradrenaline 
dosage (µg/kg/min)
0.04 0.125 0.133 0
HLA-DR
(antibodies/cell)
11068 4285 32367 11980
Table S2. Characteristics of septic patients included in the ex vivo stimulation experiments 
BMI = body mass index; HLA-DR = Human Leukocyte Antigen – DR isotype.

PART III
Experimental endotoxemia 
as a model of systemic inflammation

CHAPTER 11
Characterization of a model of systemic 
inflammation in humans in vivo elicited by 
continuous infusion of endotoxin
D. Kiers, R.M. Koch, L. Hamers, J. Gerretsen, E.J.M. Thijs, 
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Abstract
Investigating the systemic inflammatory response in patients with critical illness 
such as sepsis, trauma and burns is complicated due to uncertainties about the 
onset, duration and severity of the insult. Therefore, in vivo models of inflammation 
are essential to study the pathophysiology and to evaluate immunomodulatory 
therapies. Intravenous bolus administration of endotoxin to healthy volunteers is 
a well-established model of a short-lived systemic inflammatory response, charac-
terized by increased plasma cytokine levels, flu-like symptoms and fever. In contrast, 
patients suffering from systemic inflammation are often exposed to inflammatory 
stimuli for an extended period of time. Therefore, continuous infusion of endotoxin 
may better reflect the kinetics of the inflammatory response encountered in these 
patients. Herein, we characterize a novel model of systemic inflammation elicited 
by a bolus infusion of 1 ng/kg, followed by a 3hr continuous infusion of 1 ng/
kg/h of endotoxin in healthy volunteers, and compared it with models of bolus 
administrations of 1 and 2 ng/kg of endotoxin. The novel model was well-tolerated 
and resulted in a more pronounced increase in plasma cytokine levels with different 
kinetics and more prolonged symptoms and fever compared with the bolus-only 
models. Therefore, the continuous endotoxin infusion model provides novel 
insights into kinetics of the inflammatory response during continuous inflammatory 
stimuli and accommodates a larger time window to evaluate immunomodulating 
therapies.
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Introduction
Systemic inflammation is a common hallmark of patients with sepsis1, trauma2, burns3, as 
well as those undergoing major surgery4. This inflammatory response follows the activation 
of specific receptors by pathogen-, or danger associated molecular patterns (PAMPs and 
DAMPs), and is characterized by the production of cytokines and chemokines. In turn, these 
cytokines and chemokines trigger complement activation and coagulation, leukocyte 
migra tion, and increased vascular permeability5. A dysregulated immune response can 
have detrimental effects, such as hemodynamic instability, organ dysfunction, and pro-
longed immune suppression6.
A comprehensive appreciation of the innate immune response is crucial to understand 
the pathogenesis of systemic inflammation observed in patients. However, investigating 
the innate immune response in patients is hampered by heterogeneity, uncertainties 
about the moment of onset and, in the case of sepsis, the accuracy of the diagnosis6. In 
order to overcome these impediments, models of systemic inflammation may facilitate 
investigations into the pathophysiological mechanisms and evaluate the effects of 
immunomodulatory interventions. As in vitro and animal models have obvious drawbacks 
concerning extrapolation to humans7, investigating systemic inflammation and immuno-
modulation is of great importance8. 
A controlled, transient and reproducible systemic inflammatory response in humans can be 
achieved with an intravenous (i.v.) bolus administration of endotoxin (lipopolysaccharide 
(LPS)), a compound derived from the cell membrane of Gram-negative bacteria. This 
inflammation is characterized by flu-like symptoms, fever, hemodynamic alterations and 
increased plasma levels of cytokines9. Previous studies have shown a dose-dependent effect 
of endotoxin on the magnitude of the inflammatory response, but largely unaltered kinetics 
with increasing endotoxin dosages10–12. Furthermore, repeated endotoxin administration 
studies have demonstrated the development of endotoxin tolerance, representing an 
immune suppressed state that resembles sepsis-induced immunoparalysis13. This experi-
mental human endotoxemia model has been frequently used to investigate the patho-
physiology of systemic inflammation, to assess a broad range of immunosuppressive and 
immunostimulatory drugs and non-pharmacological interventions14–17, and to evaluate the 
effects of inflammation on other biologic processes, such as iron homeostasis18. 
Patients suffering from systemic inflammation are in most cases exposed to inflammatory 
stimuli for extended periods of time19. Therefore, a bolus administration of endotoxin likely 
poorly reflects the kinetics of the inflammatory response observed in these patients9,19, 
and a continuous infusion of endotoxin may provide a more accurate representation. 
Furthermore, as the endotoxin-induced inflammatory response is rapidly orchestrated and 
waned after bolus administration, investigational treatments are typically initiated before 
endotoxin administration. Although this approach increases the likelihood to show efficacy 
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of the intervention in the experimental model, it does not reflect the clinical situation in 
which treatment is initiated after systemic inflammation has presented. An inflammatory 
model that develops over several hours may provide a larger time window to evaluate 
interventions once inflammation has developed. 
Taken together, the pathophysiology of systemic inflammation and immunomodulatory 
treatments are difficult to study in patients. The human endotoxemia model that is currently 
used is characterized by a rapid and short-lived systemic inflammatory response after a bolus 
administration of endotoxin. A continuous infusion of endotoxin may provide more insight 
into the kinetics of the inflammatory response in patients with ongoing inflammation.
Herein, we characterize a novel model of systemic inflammation elicited by continuous 
endo toxin infusion (an initial endotoxin bolus of 1 ng/kg followed by 1 ng/kg/h for 3 hours). 
Additionally, we provide a context to interpret the characteristics of the continuous infusion 
model by describing the characteristics of endotoxin models using 1 or 2 ng/kg bolus 
administrations and responses to placebo administration. We report the kinetics of plasma 
cytokines, hemodynamic alterations, symptoms and leukocyte changes, and explore the 
coherence between different cytokines and their association with clinical parameters. 
Results
Demographic characteristics, elicitation of systemic inflammation and safety
Eligible subjects were healthy, non-smoking male subjects, aged 18-35 years. Demographic 
characteristics of the subjects are listed in Table 1. All subjects were Caucasian. There were 
no differences in baseline characteristics between the groups. All subjects received a venous 
and arterial cannula to accommodate infusion of fluids and endotoxin and frequent blood 
withdrawal and continuous blood pressure monitoring. Systemic inflammation was elicited 
by either continuous endotoxin infusion (an initial endotoxin bolus of 1 ng/kg, followed 
by 1 ng/kg/h for 3 hours) or a bolus administration of 1 or 2 ng/kg bolus administrations 
of endotoxin. The placebo group received a comparable volume of NaCl 0.9%. No serious 
adverse events occurred and all subjects were well at the time of discharge, eight hours 
after initiation of endotoxin administration. 
Placebo
n=15
bolus
1 ng/kg
n=10
bolus
2 ng/kg
n=15
bolus 1ng/kg+ 
continuous 3ng/kg
n=10 p-value
Age [yrs] 21.5 ± 0.5 21.1 ± 0.9 21.7 ± 0.7 23.6 ± 1.6 0.30
Height [cm] 181 ± 2 185 ± 2 185 ± 2 182 ± 2 0.40
Weight [kg] 77 ± 3 78 ± 3 78 ± 3 77 ± 4 0.98
BMI [kg/m²] 23.4 ± 0.9 22.8 ± 0.7 23.0 ± 0.8 23.2 ± 0.7 0.96
Table 1. Demographic characteristics of subjects 
Data were obtained during screening visit and are presented as mean ±SEM. P-values were calculated using one-way 
ANOVAs. yrs: years, cm: centimeter, kg: kilogram, BMI: body mass index, m: meter
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Plasma cytokines and chemokines
To determine serial plasma levels of cytokines Tumor Necrosis Factor (TNF)-α, interleukin 
(IL)-1β, IL-6 and IL-10 (Figure 1) and chemokines (C-X-C-motif ) ligand (CXCL)8 (also known 
as IL-8), Monocyte Chemoattractant Protein (MCP)-1, Macrophage Inflammatory Protein 
(MIP)-1α and MIP-1β, blood was frequently sampled throughout the experiment. All plasma 
cytokine concentrations were below detection limits in all subjects prior to endotoxin 
administration and significantly increased afterwards (Figure 2). In the placebo group, no 
increases in any of the cytokines and chemokines were observed.
Figure 1. Kinetics and total production of cytokines 
In the left panels, plasma concentrations of Tumor Necrosis Factor (TNF)-α, Interleukin(IL)-1β, IL-6 and IL-10 over time 
are depicted. The arrow represents the time of bolus endotoxin administration, the grey bar represents the period of 
endotoxin infusion in the continuous endotoxin group. Data are expressed as mean ± SEM pg/mL. Differences between 
groups were evaluated using 2-way ANOVAs (of time x group), and interaction term p-values are displayed. In the right 
panels, dot plots of the area under the time-concentration curve (AUC) with mean ± SEM are shown. Differences between 
groups were evaluated using Students t-tests. * p<0.05, ** p<0.01, * p<0.0001, # p=0.05-0.10. 
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Figure 2. Kinetics and total production of chemokines 
In the left panels, plasma concentration of CXC motif ligand (CXCL) 8, Monocyte Chemoattractant Protein (MCP) and 
Macrophage Inflammatory Protein (MIP)-1α and 1β over time are depicted. The arrow represents the time of bolus 
endotoxin administration, the grey bar represents the period of endotoxin infusion in the continuous endotoxin group. 
Data are expressed as mean ± SEM pg/mL. Differences between groups were evaluated using 2-way ANOVAs (of 
time x group), and interaction term p-values are displayed. In the right panels, dot plots of the area under the time-
concentration curve (AUC) with mean ± SEM are shown. Differences between groups were evaluated using with Students 
t-tests. * p<0.05, ** p<0.01, * p<0.0001. 
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Kinetics of plasma cytokines and chemokines
In the continuous infusion group, the kinetics of all cytokines and chemokines were 
markedly different compared with bolus administration of 2 ng/kg (Figure 1 and 2). Of note, 
in the continuous infusion group plasma levels of TNF-α and MIP-1α already decreased 
before endotoxin infusion was stopped. The differences between 1 and 2 ng/kg bolus 
administration groups were less pronounced, and only reached statistical significance for 
TNF-α, IL-1β, IL-10 and MIP-1α. 
Total cytokine and chemokines production
The total cytokine response, expressed as the area under the time-concentration curve 
(AUC), was higher for IL-1β, IL-6, IL-10, MCP-1 and MIP-1α in the continuous infusion group 
compared with the 2 ng/kg bolus group, but similar for TNF-α and CXCL8. There was a 
trend towards higher total production of MIP-1β in the continuous infusion group. Except 
for higher production of IL-10 in the 2 ng/kg bolus administration group, there were no 
differences in total cytokine production between the 1 and 2 ng/kg bolus groups. 
Clinical parameters
Endotoxin-induced flu-like symptoms (headache, nausea, shivering, muscle and back 
pain) reported by the subjects were scored every 30 minutes at 0-5 points. These 
symptoms remained at baseline in placebo-treated subjects, whereas the onset of flu-like 
symptoms was observed one hour after initiating endotoxin administration (Figure 3). 
Continuous endotoxin infusion resulted in prolonged, but equally severe, flu-like 
symptoms in comparison to 2 ng/kg bolus administration. Small differences in the kinetics 
of the symptom scores were identified between the 1 and 2 ng/kg bolus administration 
groups. However, the total burden of symptoms, represented by the area under the time-
symptom curve, was identical in these groups. The rise in temperature was markedly more 
pronounced in the continuous administration group compared with the 2 ng/kg bolus 
group, whereas there were no differences in the temperature response between the 1 and 
2 ng/kg bolus administration groups (Figure 3). Although an endotoxin-dose-dependent 
increase in heart rate was observed, mean arterial pressure decreased to a similar extent in 
all subjects, also in those who received placebo (Figure 3).
Hematological parameters
Endotoxemia resulted in neutrophilia, and a mono- and lymphocytopenia, with the nadir 
at two and four hours, respectively (Figure 4). These hematologic changes were more 
pronounced in the continuous infusion group compared with bolus administration of 2 ng/
kg endotoxin. Neutrophilia was similar after a endotoxin bolus of 1 and 2 ng/kg, while the 
kinetics of circulating monocyte and lymphocyte numbers differed slightly, yet significantly.
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Figure 3. Kinetics and area under the curve of clinical parameters 
In the left panel, change over time of symptoms (arbitrary units), temperature (oC), heart rate (beats per minute (bpm)), 
and mean arterial pressure (MAP) (mmHg) over time are depicted. The arrow represents the time of bolus endotoxin 
administration, the grey bar represents the period of endotoxin infusion in the continuous endotoxin group. Data are 
expressed as mean ±SEM. Differences between groups were evaluated using 2-way ANOVAs (of time x group), and 
interaction term p-values are displayed. In the right panel, dot plots of the area under the time-concentration curve 
(AUC) with mean ± SEM are shown. The AUC of temperature, heart rate and MAP was corrected for baseline. Differences 
between groups were evaluated using with Students t-tests. * p<0.05, ** p<0.01, * p<0.0001. 
Hierarchical clustering and exploratory factor analysis
To identify relationships and similarities between cytokines and subjects, we performed 
hierarchical clustering analysis on cytokine responses and subjects. This analysis revealed a 
separate cluster for the anti-inflammatory cytokine IL-10, while three clusters were identified 
consisting of CXCL8, TNF-α and MCP-1, MIP-1α and MIP-1β, and IL-6 and IL-1β (Figure 5). 
Subjects clustered into three distinct groups; those who received continuous infusion 
(middle rows), those with low cytokine responses (upper rows) after bolus administration, 
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and those with high cytokine responses (lower rows) after bolus administration. To explore 
to what extent cytokines responses are related, we performed exploratory factor analyses. 
This is an unsupervised method that can identify latent constructs (factors) in a multi-
dimensional data set. The loading of a variable on a factor represents the relative weight of 
the variable in the factor. Exploratory factor analyses revealed similar grouping of cytokines 
(Table 2); with high loadings of CXCL8 and TNF-α in factor 1, a high loading of IL-10 in 
factor 2, a high negative loading of IL-1β and IL-6 in factor 3, and high loadings of MIP-1α 
and MIP-1β in factor 4. These factors explain 92% of the variance in the dataset. Factor 3, 
which has high negative loadings of IL-1β and IL-6, correlated with symptoms and change 
in temperature (Figure 6). As such, high values of IL-1β and IL-6 are associated with higher 
symptom severity and a larger increase in temperature. Change in heart rate correlated 
with factor 2, which has a high loading of IL-10. 
Figure 4. Time course of leukocytes
Bars represent mean ± SEM of circulating numbers of neutrophils, monocytes and lymphocytes. Differences between 
groups were evaluated using 2-way ANOVAs (time x group), and interaction term p-values are displayed. 
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Factor 1 Factor 2 Factor 3 Factor 4
% of variance 
explained
64.5% 10.9% 9.2% 7.5%
CXCL8 0.999
TNF-α 0.805 0.189
 MCP-1 0.472 0.213 -0.255 0.256
IL-10 1.010
IL-1β -1.008
IL-6 0.243 0.262 -0.688
MIP-1β 0.989
MIP-1β 0.302 0.730
Table 2. Exploratory factor analysis pattern matrix
Pattern matrix after oblimin rotation with Kaiser Normalisation as obtained from EFA on log-transformed normalized 
area’s under time-concentration curves of cytokines after endotoxin administration. Only loadings >0.1 are displayed. 
Figure 5. Hierarchical clustering of cytokines and chemokines and subjects
Each subjects occupies a row and each cytokine or chemokines occupies a column. The color code shows the normalized, 
log-transformed plasma concentration below (blue) or above (red) the mean, or at the median (black). The vertical 
axis on the left shows the color code of each subject classified as 1 ng/kg (light grey), 2 ng/kg (dark grey) or continuous 
infusion (black). 
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Figure 6. Correlations of factors with clinical parameters 
Correlations between individual score on Factor 3 and the area under the curve (AUC), Factor 3 and symptoms (Panel 
A) and the baseline-corrected AUC of temperature (Panel B) and Factor 2 and the baseline-corrected AUC of heart rate 
(Panel C). R and p-values were calculated using Pearson correlations. 
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Discussion
Herein, we characterize a novel human in vivo model of systemic inflammation elicited by 
continuous endotoxin infusion. Furthermore, we provide a framework for interpretation 
of this model by also describing two models of systemic inflammation elicited by bolus 
administration of endotoxin. This novel model of continuous infusion resulted in a higher 
production of IL-6, IL-10, MCP-1 and MIP-1α, and different kinetics of all cytokines as well 
as circulating leukocyte numbers. Furthermore, it resulted in a more pronounced rise in 
temperature and heart rate, and prolonged duration of flu-like symptoms. As such, this 
novel model induces a more pronounced and sustained systemic inflammatory response. 
There were no relevant differences in cytokine responses, clinical parameters, and leukocyte 
kinetics between bolus administrations of 1 or 2 ng/kg endotoxin. In addition, unsupervised 
clustering and exploratory factor analysis revealed identical clusters of cytokines, some of 
which are clearly associated with clinical symptoms and fever. 
We are the first to describe a model of continuous infusion of endotoxin at a relatively high 
dose of 1 ng/kg/h. Low dose endotoxin infusion of another E coli derived batch (G2 B274, 
0.075 ng/kg/h) has been described previously20. At this lower dose, endotoxin infusion 
increased body temperature with 0.5 oC, and cytokine levels peaked to 5-10 and 20-70 pg/
mL for TNF-α and IL-6, respectively20. These changes are far more discrete compared with 
the higher dose continuous infusion model reported here, in which body temperature rises 
with 2.5 oC and peak levels of TNFα and IL-6 are 340 pg/ml and 1000 pg/mL respectively. As 
such, low dose infusion mimics low-grade inflammation, as observed in chronic illnesses 
such as metabolic syndrome, atherosclerosis and type 2 diabetes20, whereas high dose 
infusion results in more profound systemic inflammation as observed in patients with 
sepsis. The cumulative dose of 4 ng/kg of endotoxin has been administered safely as a 
bolus in previous studies10–12. Therefore, no safety issues were expected, and indeed no 
serious adverse events occurred. 
Previous studies have evaluated the dose-effects of different batches of endotoxin, in bolus 
administrations ranging from 0.5 ng/kg to 4 ng/kg10–12. These studies have shown that the 
extent of inflammation elicited by endotoxin administration is dose-dependent, but the 
difference between successive dosages may be too small to be significant. Similarly, we did 
not observe a clear dose-dependent effect concerning the 1 and 2 ng/kg endotoxin bolus 
administrations, although this was not the primary goal of this study. For most cytokines, the 
total response in the continuous model was higher compared to the 2 ng/kg bolus model. 
Although our study design does not allow to differentiate whether this is due to dose or 
infusion mode, these data indicate a more profound systemic inflammatory response using 
the continuous infusion protocol. However, in this context it is noteworthy that the total 
production of TNF-α and CXCL8 remained similar to that observed after bolus administration 
of 2 ng/kg endotoxin. TNF-α is known as the primary mediator in the inflammatory response 
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and CXCL8 attracts and activates leukocytes to the site of infection21. Speculatively, both 
TNF-α and CXCL8 are under the control of a negative feedback mechanism that prevents 
unrestrained triggering of the inflammatory cascade, thereby prohibiting an uncontrolled 
pro-inflammatory response. This theory is supported by the observation that in the 
continuous endotoxin infusion group, plasma levels of TNF-α are already declining while 
endotoxin infusion continues. This phenomenon is also observed in patients with sepsis, 
in whom plasma levels of TNF-α decline rapidly and therefore do not represent disease 
severity22. In contrast to the restrained production of TNF-α and CXCL8, we observed a 
fourfold increase in IL-10 and IL-6 during continuous endotoxin infusion in comparison 
to bolus administration. IL-10 is the archetypal anti-inflammatory cytokine which inhibits 
the production of TNF-α and IL-1β. IL-6 exerts both pro- and anti-inflammatory effects, as 
it not only activates B- and T-lymphocytes and triggers the acute phase response and the 
coagulation cascade, but also can inhibit production of TNF-α21. Therefore, the distinct surge 
in IL-10 and IL-6 levels may be part of the negative feedback mechanism that controls TNF-α 
and CXCL8. Understanding the orchestration of the pro- and anti-inflammatory balance is 
of great interest, as a shift towards anti-inflammation is observed in patients with ongoing 
systemic inflammation23. This shift is presumed to prevent collateral damage of the pro-
inflammatory response, but can also result in loss of immunocompetence and subsequently 
increase susceptibility to secondary infections. In sepsis patients, this phenomenon 
is termed sepsis-induced immunoparalysis24, although it is also observed in patients 
following trauma25 and cardiac resuscitation26 within hours after the insult. Therefore, the 
disproportionate production of anti-inflammatory cytokines during continuous infusion 
may mirror inflammation-induced immunoparalysis observed in patients. 
Two independent, unsupervised clustering methods yielded similar groups of cytokines. 
Although these analyses uncover the relationships between cytokines, they do not provide 
a theoretical framework to explain these relationships and need to be interpreted with 
caution. Nevertheless, some notable relationships are observed. First, the primordial anti-
inflammatory cytokine IL-10 has its own cluster, which explains 10% of the variance of the 
data Second, the aforementioned pro-inflammatory cytokine TNF-α and the chemokine 
CXCL8 are closely linked. The third group consists of IL-1β and IL-6, which are both potent 
pyrogens. The last group consists of MIP-1α and MIP-1β, both chemokines produced by 
macrophages, which attract and activate granulocytes and stimulate the production 
of other cytokines. Perhaps not surprisingly, component 3, with pyrogens IL-6 and IL-1β 
correlates significantly with the development of fever and symptoms. A direct correlation 
between the level of cytokines and clinical outcomes was previously unidentified10. It 
appears plausible that, using exploratory factor analysis, we have increased the power to 
identify meaningful correlations by quantifying the response of each individual on factors, 
which are groups of cytokines that act alike, instead of the cytokines by themselves. 
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Endotoxemia models have limitations. First, endotoxemia is an experimental model of 
inflammation, which only embodies certain aspects of the pathophysiology of sepsis, 
trauma, burns, and major surgery. However, as these conditions are heterogeneous by 
themselves, their pathogenesis is difficult to study in patients. Therefore, endotoxemia 
models should be envisioned as a complementary method to study the pathophysiology 
of systemic inflammation, in addition to in vitro, ex vivo and animal studies, and clinical 
studies in patients. Second, we did not identify relevant changes in mean arterial blood 
pressure in comparison to the placebo group. This is in contrast to the findings of a 
previous study in which a bolus administration of 4 ng/kg EC-5 endotoxin resulted in a 
profound hyperdynamic state with depressed left ventricular ejection fraction and reduced 
myocardial contractility27. Perhaps a bolus administration of 4 ng/kg, instead of a gradual 
infusion is required to produce such effects. The herein described models should therefore 
be used with apprehension to study hemodynamic changes in patients with systemic 
inflammation, and other models of sepsis may be more suitable for this purpose. We have 
not included a group in which a bolus injection of 4 ng/kg was administered to identify if 
differences between bolus and continuous infusion are the resultant of differences in dose 
or infusion rate. This limits the interpretation as to what extent the differences between the 
models are caused by dose or infusion mode.
The human model of systemic inflammation evoked by continuous infusion of endotoxin 
as described in the present study provides several new research opportunities. In bolus 
models, the inflammatory response comes and goes rapidly, limiting the possibility to 
demonstrate an effect of an intervention initiated following endotoxin administration. 
With continuous infusion, inflammation develops more gradually and is sustained for 
several hours, which extends the time window to demonstrate an effect of a therapeutic 
intervention, probably to a time point after initiation of endotoxin infusion. This is highly 
relevant, as in most patients with systemic inflammation, such as those suffering from 
sepsis, trauma or burns, there will be no opportunity for treatment before the inflammatory 
insult. Being able to demonstrate efficacy of an intervention administrated during in-
flamma tion would improve the clinical applicability. In addition, although still relatively 
short-lived, continuous endotoxin infusion may better represents the physiologic response 
of sustained immune triggering as observed in patients, including the emerging negative 
feedback mechanisms and development of endotoxin tolerance.
In conclusion, continuous infusion of endotoxin elicits a safe, reproducible, controlled, 
systemic inflammatory response in humans in vivo, which lasts for several hours. This 
model provides new options to study the innate immune response during continuous 
exposure to inflammatory stimuli. Furthermore, it offers a larger time window to evaluate 
immunomodulatory interventions following the onset of inflammation.
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Methods
Study design
Data were obtained from the control arms of three randomized controlled studies, using 
placebo or endotoxin bolus administrations of 1 or 2ng/kg, or a bolus administration of 
1ng/kg followed by continuous infusion of endotoxin at a dose of 1ng/kg/h. Studies were 
performed after approval of the local ethics committee CMO Regio Arnhem-Nijmegen 
and are registered at ClinicalTrials.gov (NCT02642237 (December 2015); NCT02085590 
(March 2014); NCT02612480 (November 2015), respectively). All study procedures were in 
accordance with the declaration of Helsinki, including the latest revisions.
The purpose of this report is to characterize a novel human endotoxemia model aimed 
at eliciting systemic inflammation in a more clinically relevant manner and potentially 
providing more opportunities for pharmacologic modulation. To provide an interpretational 
context, data of bolus injections of 1 and 2 ng/kg of the same endotoxin are also described. 
Because we did not include a group that received a bolus administration of 4 ng/kg (the 
same cumulative dose as used in the continuous infusion group), it needs to be stressed 
that differences between the continuous infusion group and the bolus groups may either 
originate from a difference in infusion rate or a difference in cumulative dose. 
Study protocols
Eligible subjects were healthy, non-smoking male subjects aged 18-35 years, with a normal 
physical examination, electrocardiography, and routine laboratory values at the screening 
visit. Exclusion criteria were pre-existent disease, febrile illness in the past four weeks and 
drug use. All subjects gave written informed consent to participate in the study. Before the 
experiment, subjects refrained from caffeine and alcohol for 24 h and from food and drinks 
for 12 h. Radial artery cannulation (Angiocath; Becton Dickinson, USA) facilitated blood 
pressure monitoring (Edward Lifesciences, Irvine, CA, USA) and blood withdrawal. A venous 
cannula was placed in an antebrachial vene for intravenous (i.v.) hydration and endotoxin 
administration. A three-lead electrocardiogram registered heart rate. All haemodynamic 
data was recorded with an interval of 30 seconds using an in-house developed system from 
a Philips M50 monitor (Eindhoven, The Netherlands).
To prevent vasovagal responses subjects were prehydrated by infusion of 1.5L glucose 
2.5%/ NaCl 0.45% in one hour28. Purified lipopolysaccharide (LPS, US Standard Escherichia 
coli O:113 endotoxin) was obtained from the Pharmaceutical Development Section 
of the National Institutes of Health (Bethesda, MD, USA). The lyophilized powder was 
reconstituted in 5 mL NaCl 0.9% for injection and vortex mixed for 20 min. An i.v. bolus of 
endotoxin was administered at a dose of 1 ng/kg or 2 ng/kg at 0h. Continuous infusion was 
initiated after a bolus of 1 ng/kg at 0h, followed by a continuous infusion at 1 ng/kg/h for 
3 h, resulting in a cumulative dose of 4 ng/kg shown to be safe in previous studies10–12. The 
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placebo group received matched bolus volumes of vehicle (NaCl 0.9%) at 0h. Hydration 
was continued with 150 ml/h for 6 h, and 75 ml/h during the rest of the experiment. Every 
30 min, temperature was measured using a tympanic thermometer (FirstTemp Genius 2; 
Covidien, Dublin, Ireland) and flu-like symptoms (headache, nausea, shivering, muscle and 
back pain) were scored on a six-point scale (0 = no symptoms, 5 = worst ever experienced), 
resulting in a total symptom score range of 0–25.
Cytokine analysis 
Ethylenediaminetetraacetic-(EDTA) anticoagulated blood was collected at various time 
points, centrifuged (2000g, 4˚C, 10 min) and plasma was stored at -80°C until analysis. 
As plasma concentrations may differ between assay manufacturers and batches, we re-
analyzed concentrations of TNF-α, IL-6, CXCL8, IL-10, IL-1β, MIP-1α, MIP-1β and MCP-1 in all 
samplesbatchwise in one run using a simultaneous Luminex assay (R&D systems; Abingdon 
Science Park, UK). The lower detection limits were as follows; TNFα 1,46 pg/mL, IL-1B 0,76 
pg/mL, IL-6 1,76 pg/mL, CXCL8 1,41 pg/mL, IL-10 1.22 pg/mL, IFNy 0,66 pg/mL, MIP1a 74,4 
pg/mL, MIP1B 34 pg/mL, IL-1RA 26 pg/mL and MCP-1 13,2 pg/mL. Cross-reactivity was 
below 0.5% for all the cytokines, and the interassay variation was below 17%.
Leukocyte counts 
Analysis of leukocyte counts were measured using routine methods also used for patient 
samples (flow cytometric analysis on a Sysmex XE-5000). 
Statistical analysis 
Distribution of data was tested for normality using Shapiro-Wilk test. As all data were 
normally distributed, they are presented as mean ± SEM. Total cytokine production is 
expressed as the area under the time curve (AUC) and group differences were analyzed 
using unpaired Students t-tests. Differences between groups in kinetics were analyzed 
using two-way analysis of variance (ANOVA) (group x time). Within group comparisons 
were made using one-way ANOVA followed by Bonferroni post-hoc tests. Hierarchical 
clustering analysis (HCA) was used to analyze coherence between cytokines. HCA is an 
unsupervised method to represent the relationships among variables with the length of the 
branch reflecting the degree of similarity. AUCs of cytokines from the endotoxemia groups 
were log-transformed and normalized, after which HCA was performed using Euclidean 
distances and an average clustering algorithm (CIMminer, Genomics and Bioinformatics 
group, National Cancer Institute, Bethesda, MD, USA). This analysis identified clusters of 
the cytokines (AUCs) and subjects . Exploratory factor analysis (EFA) was performed to 
identify groups of cytokine responses that correlate to such an extent that they could be 
summarized into one new variable (a factor). Thereby EFA is an unsupervised method that 
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identifies latent constructs (or factors) which can summarize data in factors that cannot be 
measured directly.. These factors can be used to assess the coherence between cytokines 
and to assess the relation between clusters of cytokines with clinical parameters. EFA was 
performed on log-transformed cytokine AUCs using Oblimin rotation, as we assume that 
latent constructs of cytokine data may correlate and not be entirely independent. The 
scores of the subjects on the newly derived factors, which summarize all the cytokine data, 
were correlated with the AUC of symptoms, change in temperature, and change in heart 
rate using Pearson correlation analysis. Unless specified otherwise, statistical analyses were 
performed using Graphpad Prism version 5.0 (Graphpad Software, San Diego, CA, USA) 
and SPSS for Windows 22.0 (SPSS Inc, Chicago, IL, USA). P-values <0.05 were considered 
statistically significant. 
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Abstract
The experimental human endotoxemia model is used to study the systemic 
inflamma tory response in vivo. The previously used lot of endotoxin, which was 
used for over a decade, is no longer approved for human use and a new GMP-
grade batch has become available. We compared the inflammatory response 
induced by either bolus or continuous administration of either the previously 
used lot #1188844 or new lots of endotoxin (#94332B1 and #94332B4, n=8-20 per 
group). Compared to lot #1188844, bolus administration of lot #94332B1 induced 
a more pronounced systemic inflammatory response including higher plasma 
levels of pro-inflammatory cytokines and more pronounced clinical signs of 
inflammation. In contrast, continuous infusion of lot #94332B4 resulted in a slightly 
less pronounced inflammatory response compared to lot #1188844. Furthermore, 
we evaluated whether lot #1188844 displayed in vivo potency loss by reviewing 
inflammatory parameters obtained from 17 endotoxemia studies performed in 
our center between 2007 and 2016. Despite interstudy variability in endotoxemia-
induced effects on temperature, heart rate, symptoms and leukocyte counts, the 
magnitude of these effects did not decrease over time. In conclusion, although all 
lots of endotoxin induce a pronounced inflammatory response, the magnitude 
differs between lots. We observed no potency loss of endotoxin over time. 
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Introduction
A dysregulated systemic inflammatory response plays a role in a plethora of pathological 
conditions, such as sepsis1, trauma2, burns3, and major surgery4. An overzealous response 
may harm the patient by inducing tissue damage. However, a suppressed inflammatory 
response can be equally detrimental, as it compromises the host’s ability to combat 
infections. The experimental human endotoxemia model has contributed considerably 
to our understanding of the systemic inflammatory response. In this model, intravenous 
administration of bacterial endotoxin, mostly E. coli-derived, to healthy volunteers results 
in a transient systemic inflammatory response5,6. Compared to the uncertainties regarding 
the cause, time of onset and extent of inflammation7, and large interindividual differences 
in age, comorbidities, and medication use e.g. in patients with sepsis, the experimental 
human endotoxemia is considered a standardized, controlled and safe model of systemic 
inflammation5. Over time, different lots of E. coli endotoxin have been in use. The EC-5 lot, 
derived from non-GMP bulk material, was vialed in 1976 and distributed by the FDA, but 
use of this lot was ceased in the late nineties, as it did not meet regulatory standards. In 
1997 and 2006, two new lots (#67801 and #1188844, respectively) derived from the same 
non-GMP bulk material used for EC-5, were vialed under GMP-conditions by the NIH. These 
lots were named Clinical Center Reference Endotoxin (CCRE). Back then, researchers were 
under the impression that the EC-5 lot had lost its potency to elicit a systemic inflammatory 
response8, which was confirmed in a head-to-head comparison of EC-5 with CCRE9. From 
1997 to 2016, the CCRE lots were provided to researchers by the Clinical Center Endotoxin 
Repository of the National Institute of Health (NIH), who also coordinated potency and 
sterility testing. Recently, regulatory authorities required the use of full GMP pharmaceutical 
grade endotoxin. Therefore, use of the CCRE lot was no longer permitted and production 
of a novel GMP-grade CCRE batch was commissioned by the NIH, and produced by List 
Biologicals Laboratories Inc. (Campbell CA, USA). 
For the comparison of data obtained in different experimental human endotoxemia 
studies, it is important to know whether the systemic inflammatory response induced 
by lot #1188844 and the new GMP-grade lots are comparable. In addition, although it 
was previously concluded that the EC-5 lot lost potency over time, the question remains 
whether this also applies to the #1188844 lot, which may be relevant for new batches and 
lots. 
Herein, we performed a head-to-head comparison of the systemic inflammatory response 
induced by different lots of endotoxin using bolus as well as continuous administration. 
First, we compared the response to bolus administration of the #1188844 lot and the novel 
#94332B1 lot. Second, we compared the response to continuous infusion of the #1188844 
lot and another new lot, named #94332B4. We assessed plasma cytokine/chemokine levels, 
hemodynamic alterations, symptoms, and changes in leukocyte counts. Furthermore, 
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to assess potential potency loss of the #1188844 lot over time, we reviewed clinical 
parameters of systemic inflammation obtained in 17 endotoxemia studies performed at 
our department between 2007 and 2016. 
Methods
Study design
For head-to-head comparison of different lots of endotoxin, we compared clinical para-
meters of systemic inflammation and cytokine/chemokine data obtained from two studies 
in which subjects received a bolus administration of 2 ng/kg endotoxin from either the lot 
#1188844 (vialed in 2006) or lot #94332B1 (new GMP-grade lot), and from two studies in 
which bolus administration of 1 ng/kg of endotoxin was followed by continuous infusion 
of endotoxin at a dose of 1 ng/kg/h for 3 hours using either lot #1188844 or lot #94332B4 
(another new GMP-grade lot). To assess potential potency loss of lot #1188844 over 
time, we compared clinical parameters of systemic inflammation obtained from subjects 
randomized to the control groups (no intervention besides administration of endotoxin) of 
17 human endotoxemia studies performed at the department of Intensive Care Medicine 
of the Radboud university medical center using the bolus model (administration of 2 ng/
kg endotoxin, lot #1188844) from 2007 to 2016. A list of included studies is provided in 
Table 1. To compare these responses to those observed after bolus administration of a new 
GMP-grade batch, we used data obtained in the above described study employing bolus 
administration of 2 ng/kg #94332B1. 
Apart from the use of different batches of endotoxin, the study procedures were identical 
and in accordance with the declaration of Helsinki, including the latest revisions. All studies 
were approved by the local ethics committee (CMO Arnhem-Nijmegen), and registration 
numbers are listed in Table 1. Data of most studies described in this work have been 
published previously (references provided in Table 1).
In all studies, eligible subjects were healthy, non-smoking male subjects aged 18-35 years. 
Subjects were included after providing written informed consent and when declared 
eligible based on a full medical history, a normal physical examination, electrocardiography, 
and routine laboratory values. Exclusion criteria were pre-existent disease, drug use and 
febrile illness in the past four weeks. The experiments were performed in accordance to 
our standardized protocol described in detail elsewhere5. In short, subjects refrained from 
caffeine and alcohol for 24 h and from food and drinks for 12 h before the experiment. 
Continuous blood pressure monitoring and blood withdrawal were facilitated by 
placement of an arterial cannula. Endotoxin and intravenous hydration were administered 
through a venous cannula. Heart rate was registered with a three-lead electrocardiogram, 
and all hemodynamic data were recorded. Every 30 min, temperature was measured using 
a tympanic thermometer and flu-like symptoms (headache, nausea, shivering, muscle 
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and back pain) were scored on a six-point Likert scale (0 = no symptoms, 5 = worst ever 
experienced) with addition of 3 points for vomiting, resulting in a total symptom score 
ranging from 0–28. Furthermore, subjects were prehydrated by infusion of 1.5 L glucose 
2.5%/NaCl 0.45% during the one-hour-period prior to start of endotoxin administration. 
Hereafter, hydration was continued with 150 ml/h for 8 hours. 
year n Registration number Mode of administration Lot
10 2007 10 NL17473.091.07 bolus  #1188844 
11 2007 7 NL20388.091.07 bolus  #1188844 
12 2008 10 NL24017.091.08 bolus  #1188844 
submitted 2009 10 NL27052.091.09 bolus  #1188844 
13 2009 10 NL29171.091.09 bolus  #1188844 
14 2009 6 NL27963.091.09 bolus  #1188844 
15 2009 10 NL30625.091.09 bolus  #1188844 
16 2011 6 NL36068.091.11 bolus  #1188844 
17 2011 12 NL38438.091.11 bolus  #1188844 
18 2012 12 NL42337.091.12 bolus  #1188844 
19 2013 10 NL43020.091.12 bolus  #1188844 
20 2013 10 NL44630.091.13 bolus  #1188844 
submitted 2015 12 NL49674.091.14 bolus  #1188844 
21 2016 15 NL54870.091.15 bolus  #1188844 
in preparation 2016 10 NL53411.091.15 bolus  #1188844 
submitted 2016 12 NL56686.091.16 bolus  #1188844 
submitted 2015 10 NL53584.091.15 bolus  #1188844 
in preparation 2017 8 NL61136.091.17 bolus #94332B1
22 2015 10 NL51923.091.14 continuous  #1188844 
submitted 2016 20 NL57410.091.16 continuous #94332B4
Table 1. Experimental human endotoxemia studies included for analyses 
Registration number represents registration at the Dutch national registry (toetsingonline.nl) for medical research 
involving human subjects. Bolus administration was performed at a dose of 2 ng/kg, continuous administration was 
performed by infusion of 1 ng/kg, followed by 1 ng/kg/h for 3 hours
 
Endotoxin 
All endotoxin lots were derived from an E. coli Type O:113 H10:K negative strain of bacteria. 
Lot #1188844 was derived from bulk material produced by the NIAID and FDA in 1967, and 
vialed in 2006 under GMP-conditions by the Pharmaceutical Development Section of the 
NIH (Bethesda, MD, USA). The lots #94332B1 and #94332B4 were both derived from the 
same new GMP-grade bulk material and vialed under GMP-conditions by List Biological 
Laboratories, Inc (Campbell, California, USA). This GMP-grade endotoxin has previously 
shown to be safe for administration in humans23.
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Cytokine and chemokine analysis 
Ethylenediaminetetraacetic-anticoagulated blood was collected at various time points 
up to 8 hours after start of endotoxin administration. After centrifugation (2000g, 4˚C, 10 
min), plasma was stored at -80°C until further analysis. Concentrations of Tumor Necrosis 
Factor (TNF)α, Interleukin (IL)-6, IL-8, IL-10, Monocyte Chemoattractant Protein (MCP)-1 and 
Monocyte Inflammatory Protein (MIP)-1β were measured using a simultaneous Luminex 
assay (Milliplex, Merck Millipore, Billerica, MA, USA). To enable head-to-head comparison 
of studies using different endotoxin lots, cytokine/chemokine analysis was performed 
batchwise (in one run). For all measured mediators, the lower detection limit was 3.2 pg/ml.
Leukocyte counts 
Analysis of leukocyte (subset) counts were measured using standardized routine methods 
at the Laboratory of Clinical Chemistry of the Radboud university medical center.
In vitro endotoxin potency 
All endotoxin vials described in this study contained 1 microgram of endotoxin, which is 
claimed to correspond to a potency of 10.000 endotoxin units (EU) per vial. In vitro potency 
measurements of lot #1188844 were commissioned by the NIH to determine the actual 
potency, and were performed on randomly selected vials, by commercial entities with 
extensive experience in the conduct of endotoxin assays. List Biologicals performed in vitro 
potency measurements for the #94332 batch. In vitro potency was quantified as EU/vial 
using the Limulus amebocyte lysate (LAL) test. This test is based upon a clotting reaction of 
amoebocytes form the Limulus polyphemus with endotoxin, and estimates the endotoxin 
content with an uncertainty range of 50-200%24. 
Statistical analysis 
Distribution of data was tested for normality using Shapiro-Wilk test. Data are presented as 
mean with standard error of the mean (SEM). Between–group differences over time were 
analyzed using repeated measures two-way analysis of variance (ANOVA) (group * time 
interaction term). Linear regression analysis was performed to assess changes over time in 
the studies performed between 2007 and 2016 and coefficients of variation were calculated 
to asses interstudy variation. Clinical parameters of systemic inflammation obtained from 
the study using bolus administration of lot #94332B1 were compared to values obtained 
from all studies with lot #1188844 using unpaired Student’s t-tests. Statistical analyses were 
performed using Graphpad Prism version 5.03 (Graphpad Software, San Diego, CA, USA). 
P-values <0.05 were considered statistically significant. 
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Results
Head-to-head comparison of the systemic inflammatory response 
 induced by different lots of endotoxin
Demographic characteristics and safety
Demographic characteristics of the subjects participating in the studies employing bolus 
and continuous endotoxin administration are listed in Tables 2A and 2B, respectively. Apart 
from a higher body mass index (BMI), subjects that received a bolus administration of lot 
#94332B1 were comparable to those that received the #1188844 lot. All subjects were well 
at time of discharge and no serious adverse events occurred in any of the studies. 
A
Bolus
Lot #1188844 
n=10
Lot #94332B1
n=8 p-value
Age [yrs] 22.1 ± 1.0 24.1 ± 1.4 0.24
Height [cm] 183 ± 4 184 ± 1 0.96
Weight [kg] 73 ± 2 86 ± 1 <0.001
BMI [kg/m²] 21.8 ± 0.6 25.5 ± 0.4 <0.001
B
Continuous
Lot #1188844 
n=10
Lot #94332B4
n=20 p-value
Age [yrs] 23.6 ± 1.6 22.4 ± 0.5 0.36
Height [cm] 182 ± 2 182 ± 1 0.77
Weight [kg] 77 ± 4 82 ± 2 0.23
BMI [kg/m²] 23.2 ± 0.7 24.5 ± 0.9 0.16
Table 2. Demographic characteristics of subjects receiving (A) bolus and (B) continuous 
administration of different lots of endotoxin 
Data were obtained during screening visit and are presented as mean±SEM. P-values were calculated with unpaired 
Student's t-tests. yrs: years, cm: centimeter, BMI: body mass index, kg: kilogram, m: meter
 
Plasma cytokine and chemokine levels
Bolus as well as continuous administration of endotoxin resulted in a profound increase 
in plasma levels of TNFα, IL-6, IL-8, IL-10, MCP-1, MIP-1α and MIP-1β (Figures 1 and 2). In 
the bolus model, concentrations of the pro-inflammatory mediators TNFα, IL-6, IL-8, MCP-
1, MIP-1α, MIP-1β were significantly higher in response to administration of #94332B1 
compared to administration of lot #1188844 (Figure 1). There were no differences in levels 
of the anti-inflammatory cytokine IL-10. The cytokine/chemokine responses induced by 
continuous infusion with either lot #1188844 or #94332B4 were highly comparable for IL-6, 
IL-8, MCP-1, MIP-1α and MIP-1β, whereas plasma concentrations of TNFα and IL-10 were 
significantly higher in subjects who received lot #1188844 (Figure 2).
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Figure 1. Plasma cytokine/chemokine levels upon bolus administration of endotoxin of lot 
#1188844 (n=10) and lot #94332B1 (n=8) 
Plasma concentrations (pg/mL) of Tumor Necrosis Factor (TNF)α, Interleukin(IL)-6, IL-8, IL-10, MCP-1, MIP-1α, and MIP-
1β are depicted over time. At t=0 endotoxin was administered at a dose of 2 ng/kg. Data are expressed as mean±SEM. 
Differences between groups were evaluated using two-way ANOVA on log transformed data and interaction term (time 
* group) p-values are displayed. 
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Figure 2. Plasma cytokine/chemokine levels upon continuous administration of endotoxin of lot 
#1188844 (n=10) and lot #94332B4 (n=20) 
Plasma concentrations (pg/mL) of Tumor Necrosis Factor (TNF)α, Interleukin(IL)-6 , IL-8, IL-10, MCP-1, MIP-1α, and MIP-1β 
are depicted over time. At t=0 endotoxin was administered at a dose of 1ng/kg, followed by a continuous infusion of 1 
ng/kg/h for 3 hours, as indicated by the grey bar. Data are expressed as mean±SEM. Differences between groups were 
evaluated using two-way ANOVA on log transformed data and interaction term (time * group) p-values are displayed.
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Flu-like symptoms, temperature and hemodynamic changes
Administration of endotoxin resulted in flu-like symptoms in all subjects, mainly consisting 
of headache, shivering, muscle-, and back pain, occasionally nausea and, incidentally, 
vomiting (Figures 3A and 4A). As expected, systemic inflammation was characterized by 
an increase in body temperature and heart rate, and a decrease in mean arterial pressure 
(Figure 3B-D and 4B-D). Bolus administration of lot #94332B1 resulted in an earlier onset of 
symptoms (Figure 3A), with distinctly higher temperature and heart rate, and a lower mean 
arterial pressure compared to administration of lot #1188844 (Figure 3B-D). Continuous 
infusion of lot #94332B4 resulted in a more gradual development of symptoms compared 
with infusion of the #1188844 lot, with lower symptom scores at 1.5 and 2 hours after 
start of endotoxin infusion (Figure 4A). Correspondingly, the increase in heart rate was 
more pronounced in subjects that received lot #1188844, accompanied by a slightly, but 
significantly, more pronounced decrease in mean arterial pressure (Figure 4C-D). There was 
no significant difference in the course of temperature between the groups (Figure 4B). 
Figure 3. Clinical parameters of systemic inflammation upon bolus administration endotoxin of lot 
#1188844 (n=10) and lot #94332B1 (n=8) 
Changes over time of (A) symptoms (arbitrary units), (B) temperature (°C), (C) heart rate (beats per minute [bpm]), and 
(D) mean arterial pressure (mmHg) are depicted. At t=0 endotoxin was administered at a bolus dose of 2 ng/kg. Data are 
expressed as mean±SEM. Differences between groups were evaluated using two-way ANOVA and interaction term (time 
* group) p-values are displayed. 
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Figure 4. Clinical parameters of systemic inflammation upon continuous administration of 
endotoxin of lot #1188844 (n=10) and lot #94332B4 (n=20) 
Changes over time of (A) symptoms (arbitrary units), (B) temperature (°C), (C) heart rate (beats per minute [bpm]), and 
(D) mean arterial pressure (mmHg) are depicted. At t=0 endotoxin was administered at a dose of 1ng/kg, followed by a 
continuous infusion of 1 ng/kg/h for 3 hours, as indicated by the grey bar. Data are expressed as mean±SEM. Differences 
between groups were evaluated using two-way ANOVA and interaction term (time * group) p-values are displayed. 
 
Hematological parameters
Bolus administration resulted in a transient decrease in neutrophils, lymphocytes and 
monocytes, followed by a distinct neutrocytosis (Figure 5A-C). Compared with lot #1188844, 
neutrocytosis was more pronounced (Figure 5A), there was a trend towards prolonged 
monocytopenia (Figure 5B), and the initial decrease in lymphocyte numbers (Figure 5C) 
was more marked after administration of lot #94332B1. . Continuous infusion of both lots 
of endotoxin caused a transient mono- and lymphocytopenia, followed by a neutrocytosis 
and monocytosis, without any differences between lots (Figure 6A-C). 
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Figure 5. Circulating neutrophil (A), monocyte (B), and lymphocyte (C) numbers upon bolus 
administration of endotoxin of lot #1188844 (n=10) and #94332B1 (n=8) 
At t=0 endotoxin was administered at a bolus dose of 2 ng/kg. Data are expressed as mean±SEM. Differences between 
groups were evaluated using two-way ANOVA and interaction term (time * group) p-values are displayed. 
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Figure 6. Circulating neutrophil (A), monocyte (B), and lymphocyte (C) numbers upon continuous 
administration of endotoxin of lot #1188844 (n=10) and #94332B4 (n=20) 
At t=0 endotoxin was administered at a dose of 1ng/kg, followed by a continuous infusion of 1 ng/kg/h for 3 hours, as 
indicated by the grey bar. Data are expressed as mean±SEM. Differences between groups were evaluated using two-way 
ANOVA and interaction term (time * group) p-values are displayed.
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Assessment of potential potency loss of lot #1188844 over time
Between 2007 and 2016, 17 experimental human endotoxemia studies were performed at 
our center using bolus administration of 2 ng/kg of lot #1188844 (Table 1). Linear regression 
revealed no significant changes over time in temperature, leukocyte count, and symptom 
score, (Figure 7A, 7C, and 7D, respectively). There was a slight, but significant, increase in 
peak heart rate over the years (Figure 7B). Interstudy variability for the endotoxin-induced 
effects on heart rate and leukocyte counts was relatively small (variation coefficients of 4.9% 
and 10.2%, respectively), whereas interstudy variation in temperature changes (15.3%) and 
peak symptom scores (24.7%) was more substantial. Furthermore, the in vitro endotoxin 
potency was highly variable over the years (30.4%), but did not significantly decrease over 
time (Figure 7E). 
Figure 7. In vivo potency of endotoxin administration of lot #1188844 over time 
Clinical parameters of systemic inflammation induced by bolus administration of 2 ng/kg lot #1188844 in studies 
performed in our center from 2007 to 2016 (in black) and novel lot #94332B1 in 2017 (in red) are depicted. Maximum 
temperature increase (Δ temperature) (A), peak heart rate (B), peak leukocytes (C), and peak symptoms (D). In vitro 
potency as determined by LAL tests between 2007 and 2015 for lot #1188844, and for the #94332B1 lot in 2017 (E). 
Data are expressed as mean±SEM. Linear regression analysis was performed, and the slopes (R) with 95% confidential 
intervals and p-values are reported.
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To provide an additional assessment of the in vivo potency of the new lot #94332B1 versus the 
previously used #1188844 lot, we compared clinical parameters of systemic inflammation 
induced by bolus administration of #94332B1 (n=8) with the aggregate mean of these 
parameters obtained from the previous 17 studies using bolus administration of #1188844 
(n=172). The maximum temperature increase was significantly higher after administration 
of #94332B1 compared with lot #1188844 (2.7±0.1 vs. 1.6±0.1oC, respectively, p=0.0001, 
Figure 7A), as was the maximum heart rate (104±3 vs. 94±1 beats per minute, p<0.0001, 
Figure 7B). Peak leukocyte numbers (15.0±1.7 vs. 11.±0.3 *109/mL, p=0.10, Figure 7C) 
and maximum symptom scores (7.0±1 vs. 5.9±0.3, respectively, p=0.31, Figure 7D) were 
comparable between lots. 
Discussion
In the present work, we compare the systemic inflammatory response induced by two 
lots derived from a new GMP-grade batch of endotoxin with the response induced by 
the previously used lot #1188844 in humans in vivo. Compared with lot #1188844, bolus 
administration of the new #94332B1 lot resulted in a more pronounced inflammatory 
response, with higher levels of pro-inflammatory cytokines and chemokines, an earlier 
onset of symptoms, higher temperatures and heart rate, and more profound neutrocytosis. 
In contrast, continuous infusion of another new lot (#94332B4) resulted in a slightly less 
pronounced inflammatory response compared to continuous infusion of #1188844, with 
lower levels of TNFα and IL-10 and a more gradual onset of symptoms and increase in heart 
rate, but no differences in other cytokines/chemokines, temperature, or leukocyte numbers. 
In addition, despite considerable interstudy variability in especially flu-like symptoms and 
fever, no decline in endotoxin-induced clinical parameters of systemic inflammation were 
observed over a period of 10 years in our center, indicating that the #1188844 lot did not 
lose potency. 
A previous study compared the in vivo potency of the EC-5 lot (which was used until 1999) 
with that of the CCRE lot vialed in 1997 (#67801). Both of these lots were derived from 
the same bulk material. This head-to-head comparison, using bolus administration (4 ng/
kg) in 4 subjects per group9, showed that administration of the older EC-5 lot resulted in 
lower peak temperatures, leukocyte counts, cytokine responses, cortisol production, and 
C-reactive protein levels. Based on this, the authors concluded that endotoxin may lose its 
potency over the years. In the current work, we have not only evaluated cytokine responses 
and inflammatory parameters of lot #1188844 versus two lots derived from novel GMP-
grade bulk material, but we also performed an over-time analysis of clinical parameters of 
systemic inflammation induced by lot #1188844 in a large group of subjects. These in vivo 
data did not show a time-dependent decrease in effect size. Although we observed a slight 
increase in peak heart rate over the years, these changes were not related to differences 
228 | Chapter twelve
in body temperature, and despite being statistically significant, the rather small increase 
likely has limited relevance. 
The in vitro quantification of endotoxin potency is notoriously difficult, and various 
methods have been described over the years25. The Limulus amebocyte lysate (LAL) assay 
is the most well-known method, and this was also employed for the in vitro potency data 
reported in the current work24. In this assay, specimens and controls are diluted serially and 
these dilutions are added to the hemolymph of the horseshoe crab. A coagulation reaction 
takes place for as long as the endotoxin concentration is sufficient. Due to the 1:1 dilution 
metho dology used in the assay, the true endotoxin concentration lies between 50% and 
200% of the reported concentration. This is a plausible explanation for the highly variable 
in vitro potency results of the #1188844 lot described in the present study. An alternative 
endotoxin measurement method is the endotoxin activity assay (EAA). This assay involves 
chemiluminescent measurement on the oxidative burst reaction of activated neutrophils 
to complement-coated LPS-IgM immune complexes26. As such, this assay does not measure 
endotoxin content directly. The use of endogenous neutrophils in the assay represents 
a potential limitation, as there may exist large interindividual differences in neutrophils, 
especially under pathological conditions, which might not be fully corrected by the use 
of positive and negative controls in the assay26. Furthermore, the EAA assay can only be 
performed in real time using whole blood, not on stored material, and the results are semi-
quantitative (i.e. the assay reports low, intermediate, or high endotoxin levels). Recently, a 
reversed high-performance liquid chromatography/mass spectrometry (HPLC/MS) method 
to detect endotoxin in biological samples was developed, which is based on quantifying 
3HM, the most abundant hydorylated fatty acid of the lipid A moiety27. Plasma endotoxin 
levels measured using this new method were shown to correlate with disease severity in 
patients suffering from systemic inflammatory response syndrome27. This method appears 
to be promising, but requires additional validation.
Our results show that there exists considerable variation in inflammation parameters 
between individual studies, which for example can be attributed to differences in diet, 
genetic background, and previous illnesses. Especially the variation in symptoms was 
substantial, but it has to be emphasized that symptom scores are notoriously subjective28. 
Endotoxin experiments in our department were carried out with one, two or three subjects 
simultaneously in the same room. Therefore, it is possible that symptoms reported are 
affected by the presence of symptoms in the other subjects. 
Lot #1188844 was large and was used in over 17 studies over a period of 10 years in our 
center alone. New lots from the new GMP-grade batch are produced in smaller quantities. 
Herein, we report results obtained using the new lots #94332B1 and #94332B4, and 
these lots already have several successors. Although lot #94332B1 was more potent than 
#1188844 using the bolus administration model, the other new lot (#94332B4) showed 
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to be less potent than lot #1188844 in the continuous infusion model. These findings 
suggest that there are potency differences between these two new lots, despite the fact 
that they are derived from the same bulk material. However, because we used different 
modes of endotoxin administration and did not compare these two new lots head-to-
head, no definite conclusions can be drawn pertaining to this issue. For now, it is only safe 
to conclude that directly comparing responses induced by different lots of endotoxin is not 
recommended, and that a control group (e.g. a group that only receives endotoxin) should 
always be included in intervention studies using the experimental human endotoxemia 
model. 
This work has several limitations. First, subjects who received a bolus of lot #94332B1 had 
a 14% higher body weight, but similar length compared to subjects that received a bolus 
of the #1188844 lot. Therefore, they received 14% more endotoxin as it is dosed per kg 
body weight, which theoretically could partially explain the increased cytokine production 
and symptoms. However, we have previously shown that BMI does not correlate with 
the endotoxin-induced increase in plasma cytokine levels, nor with the increase in body 
temperature29. Furthermore, taking into account that previous work did not reveal a 
proportional increase in the cytokine response with higher dosages of endotoxin6, the 200-
300% increase in cytokine levels observed in the #94332B1 group is unlikely to be explained 
by the 14% higher endotoxin dose. Another drawback is that we only present a limited 
set of inflammatory parameters for the in vivo potency analysis over time. It would have 
been valuable to include cytokine responses as well. Unfortunately, this is not possible, 
as original cytokine data were obtained using various assays which are not sufficiently 
comparable due to interassay variability, and plasma samples are no longer available for 
batchwise reanalysis. Furthermore, cytokines show substantial degradation after 5 years, 
even when stored at -80 °C30. A final limitation is that the LAL tests were performed by 
several commercial parties, which adds an extra source of variation. 
In conclusion, similar to the previous lots, administration of lots derived from the novel 
GMP-grade endotoxin batch elicit a transient, controlled, and safe systemic inflammatory 
response in humans in vivo. However, newer lots of endotoxin are neither necessarily 
equipotent to previous lots, nor to other new lots. Although we found no evidence for 
loss of potency of the #1188844 lot over time, there is considerable interstudy variability 
in inflammatory parameters, despite using the same lot of endotoxin and experimental 
protocol. As such, we propose that for interventional studies with e.g. immunomodulatory 
compounds, direct comparison of cytokine responses or clinical parameters of systemic 
inflammation is only valid using a control group within the same study, using the same lot 
of endotoxin. 
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This thesis describes animal and translational studies into the effects of oxygenation and 
anti-platelet therapy on the inflammatory response. This work aimed to identify potential 
immunomodulatory interventions that are readily available for critically ill patients 
suffering from a dysregulated immune response. 
Chapter 1 provides an introduction on the innate immune system and the pathophysiology 
of sepsis. A dysregulated immune response to infection plays a pivotal role in sepsis-
induced tissue damage, organ injury and death. Depending on the immunologic state of 
a patient, interventions that suppress or potentiate the immune response may improve 
outcome. However, until now biomarkers that can accurately identify the immune status 
of patients are lacking, and immunomodulatory interventions applied to heterogeneous 
groups of sepsis patients without immunologic stratification have resulted in negative 
trials. New promising candidate therapies for immunomodulation in patients suffering 
from a dysregulated immune response may be identified by combining experimental and 
epidemiologic data. Oxygenation and anti-platelet therapy represent such candidates, as 
they have both been identified as amenable factors that have shown immunomodulatory 
potential in vitro, and are associated with outcome in epidemiologic studies. Oxygen and 
the anti-platelet agent acetylsalicylic acid are both widely available at a low cost, and both 
have a well-known low risk profile. However, results from in vitro and animal studies on 
immunomodulation need to be translated to the human in vivo situation to assess their true 
potential. The experimental human endotoxemia model facilitates translational studies into 
the effects of therapeutic interventions on systemic inflammation in humans in vivo. This 
standardized, controlled and reproducible model consists of the intravenous administration 
of E. coli-derived endotoxin (lipopolysaccharide [LPS]) to healthy volunteers, resulting in 
a systemic inflammatory response characterized by flu-like symptoms, fever, changes in 
circulating leukocytes and an increase in plasma cytokines. Participating subjects can be 
treated in advance or during systemic inflammation with putative immunomodulatory 
therapies to evaluate the efficacy of these therapies. 
Part I The effects of oxygenation and oxygen-dependent 
pathways on the inflammatory response
Chapter 2 reviews the effects of hypoxia on the inflammatory response, and these effects 
are interpreted in the context of a dysregulated immune response in critically ill patients. 
An overview of the interactions between hypoxia and immunity at a molecular, cellular and 
clinical level is provided. Hypoxia results in stabilization of the transcription factor Hypoxia 
Inducible Factor (HIF)-1α and enhances adenosine metabolism. These cellular mechanisms 
may exert both pro- and anti-inflammatory effects, which depend on the cell- and tissue 
type and duration of hypoxia. In addition, it is hypothesized how tailoring oxygenation 
may modulate the immunologic response in critically ill patients towards a more favorable 
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phenotype, and potential oxygen-dependent pharmacological targets to modulate the 
inflammatory response, including HIFs and adenosine metabolism, are discussed. 
In chapter 3, the effects of short-term hypoxia on the endotoxin-induced systemic 
inflamma tory response in vivo were investigated in mice and men. The effects of hypoxia 
were studied by exposing mice to hypoxia or normoxia during endotoxemia. Hypoxic mice 
exhibited higher levels of the key anti-inflammatory cytokine interleukin(IL)-10, and lower 
levels of pro-inflammatory cytokines. These hypoxia-induced anti-inflammatory effects 
were shown to be very rapid, and regulated at a post-transcriptional level. Furthermore, 
the augmentation of IL-10 was found to be dependent on increased levels of adenosine 
and adenosine 2B receptor signaling, and not on HIFs. We translated these findings to the 
human situation and demonstrated identical effects: hypoxia during experimental human 
endotoxemia resulted in a two-fold increase of circulating levels of the anti-inflammatory 
cytokine IL-10 and a concurrent 30-50% attenuation of pro-inflammatory cytokines TNF-alpha, 
IL-6, and IL-8. Furthermore, hypoxia also increased blood adenosine concentrations. Ex vivo 
experiments using human whole blood corroborate the involvement of the adenosine 2B 
receptor in the hypoxia-induced anti-inflammatory phenotype. In chapter 4, the effects of 
hypoxia and inflammation on iron homeostasis were explored in humans in vivo using the 
same experimental setup described in chapter 3. Iron homeostasis is tightly regulated by 
the hormone hepcidin, which prevents iron uptake from the gut. Inflammation is known 
to strongly induce hepcidin, whereas hypoxia putatively suppresses hepcidin, although 
the interplay between both conditions had not been studied in humans before. Systemic 
inflammation indeed resulted in augmentation of plasma hepcidin, and this effect was 
attenuated by hypoxia. Correspondingly, serum iron and transferring saturation were 
augmented by hypoxia. We concluded that hypoxia partially attenuates the endotoxin-
induced increase in hepcidin levels, and thereby increases serum iron levels, findings which 
may be of special relevance to critically ill patients in whom inflammation and hypoxia often 
coincide.
Systemic inflammation is known to affect coagulation, and hypoxia is presumed to have 
procoagulant effects promoting the development of thrombosis, although this is based 
on controversial evidence. In chapter 5, we described how hypoxia and inflammation 
affect platelet function and coagulation during systemic inflammation in humans in vivo, 
again using the same experimental setup described in chapter 3. Systemic inflammation 
resulted in an increase in platelet-monocyte complexes and increased platelet reactivity, 
but these effects were found to be attenuated rather than augmented by hypoxia. Hypoxia 
did not affect the inflammation-induced changes in plasmatic coagulation and endothelial 
activation. Therefore, these data do not support the widely suspected procoagulant effects 
of hypoxia in vivo. 
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Adaptation to hypoxia at a molecular and cellular level has been described to depend on 
HIFs to a large extent. HIFs are involved in adaptation to hypoxia, including angiogenesis, 
glycolysis and regulation of immune responses. The degradation of HIFs is oxygen 
dependent, and the Von Hippel Lindau protein (pVHL) is one of the critical proteins 
involved. Patients with Von Hippel-Lindau disease have an inborn genetic defect in the 
gene that encodes for pVHL and thereby represent a human knock-out model to study 
the relevance of this pathway. Of interest, patients with Von Hippel-Lindau disease are at a 
high risk to develop malignancies and a HIF-mediated augmented immune response may 
contribute to a tumor-promoting environment in these patients. In chapter 6, the cytokine 
production capacity of leukocytes obtained from patients with Von Hippel-Lindau disease 
was studied and compared with that of matched healthy controls. It was demonstrated 
that pro- and anti-inflammatory cytokine production in response to ex vivo stimulation 
with LPS was not augmented in patients with Von Hippel Lindau disease. In contrast, the 
production of interleukin-6 was attenuated in patients compared with controls. These data 
indicate that the genetic defect in the leukocytes of these patients is unlikely to contribute 
to a pro-inflammatory tumor-promoting environment. 
Next to hypoxia, hyperoxia also has been implicated to affect systemic inflammation and 
outcome in patients with critical illness. However, in vivo evidence of immunomodulatory 
effects of hyperoxia is very limited. In the study described in chapter 7, it is demonstrated 
that short-term hyperoxia (exposure to 100% oxygen) neither induces an inflammatory 
response itself, nor affects the inflammatory response during endotoxemia in mice and 
men. In addition, no effects on neutrophil phagocytosis and generation of reactive oxygen 
species were observed. These data do not support the use of short-term hyperoxia as an 
immunomodulatory treatment strategy. 
Part II The effects of platelet inhibitory therapy  
on the inflammatory response
Anti-platelet therapy is a cornerstone in the secondary prevention of cardiovascular 
disease. This treatment usually consists of daily low dose acetylsalicylic acid (ASA) and a 
second platelet inhibitor in the first year following a cardiovascular event. Intriguingly, the 
use of ASA has been associated with improved outcome in patients with sepsis, and a class 
of antiplatelet agents known as P2Y12 inhibitors have been linked to immunomodulatory 
effects. In chapter 8, the effects of clinically relevant combinations of antiplatelet therapy on 
the immune response during experimental human endotoxemia were studied. Following 
seven days of treatment with either double placebo, ASA with placebo, ASA with ticagrelor 
or ASA with clopidogrel, systemic inflammation was elicited by endotoxin administration. 
Using a novel method of continuous, instead of bolus, infusion of endotoxin we provoked 
a prolonged systemic inflammatory response in all subjects. Compared with the double 
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placebo group, treatment with ASA enhanced the pro-inflammatory cytokine response, 
exemplified by higher plasma levels of TNF, IL-6, IL-8, MCP-1 and MIP-1α. Addition of 
the P2Y12 inhibitors ticagrelor or clopidogrel did not relevantly alter this response. Ex 
vivo experiments revealed that pro-inflammatory effects of ASA are mediated through 
inhibition of prostaglandin E2 production by platelets. These results suggest that the 
observed beneficial outcomes in septic patients who use ASA may be related to immune-
enhancing effects. In chapter 9, we respond to a study demonstrating an independent 
association between chronic treatment with low dose ASA and macrolides and survival of 
septic shock. Although the authors hypothesize that the anti-inflammatory effects exerted 
by these drugs may explain the decreased mortality, we put forward that the inhibition 
of prostaglandin production by ASA might result in interruption of a negative feedback 
mechanism of prostaglandins on cytokine production. In turn, this results in an enhanced 
immune response (as demonstrated in chapter 9), which subsequently enhances bacterial 
clearance in case of infection. Speculatively, these effects of ASA could be used to treat or 
prevent sepsis-induced immunoparalysis. The latter hypothesis was tested in chapter 10. 
In this study, we assessed the effects of ASA on the development of endotoxin tolerance, 
a model for sepsis-induced immunoparalysis. To this end, healthy volunteers were 
challenged with endotoxin twice with an interval of seven days. The first endotoxin 
challenge resulted in the development of endotoxin tolerance, which was exemplified by 
a profoundly attenuated inflammatory response upon the second endotoxin challenge. To 
evaluate whether ASA could prevent the development of endotoxin tolerance, subjects 
were treated with ASA starting seven days prior to the first endotoxin administration and 
ASA was continued until the second endotoxin administration. This prophylactic use of ASA 
did not prevent the development of endotoxin tolerance compared to the placebo-treated 
control group. To assess whether ASA could reverse endotoxin tolerance, subjects were 
treated with ASA following the first endotoxin challenge. Using this approach, ASA partially 
reversed endotoxin tolerance, illustrated by enhanced plasma levels of TNF, IL-6, IL-8 upon 
the second endotoxin challenge compared with the placebo group, whereas plasma levels 
of IL-10 were attenuated. Furthermore, ASA treatment decreased urinary prostaglandin E 
metabolite levels, substantiating the involvement of prostaglandin E2 inhibition in the ASA-
induced pro-inflammatory effects observed. These data suggest that patients with sepsis-
induced immunoparalysis may benefit from initiating ASA treatment. 
Part III Comparisons of human endotoxemia models
In chapter 11, responses to bolus administration of endotoxin (in two dosages) and 
con ti nuous administration of endotoxin were compared in healthy volunteers. Bolus 
admini stration of 1 ng/kg/h followed by continuous infusion of 1 ng/kg/h for 3 hours 
resulted in a more pronounced increase in plasma cytokine levels and more prolonged 
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symptoms and fever compared with bolus administrations of 1 or 2 ng/kg endotoxin. 
Therefore, this novel continuous endotoxin model likely bears more similarities to immune 
responses observed in patients and accommodates a larger time window to evaluate 
immuno modulatory therapies. 
In chapter 12, the in vivo cytokine response towards different batches of endotoxin were 
compared, both using bolus administration and continuous infusion models. Furthermore, 
the in vivo potency of endotoxin, expressed as endotoxemia-induced changes in clinical 
parameters (temperature, symptoms and hemodynamics) over the last 12 years was 
explored. Cytokine responses upon administration of different batches of endotoxin 
differed significantly from each other. Although there is no loss of in vivo potency after 
several years, clinical responses vary substantially between studies. Therefore, we conclude 
that caution is warranted when comparing different endotoxemia studies and trials 
evaluating the immunomodulating properties of new compounds should always be 
conducted with contemporaneous control groups. 

CHAPTER 14 
Discussion and future perspectives

 Discussion  | 243
14
Previous in vitro and observational studies have suggested that oxygenation and anti-
platelet therapy may exert the potential to modulate systemic inflammation. Both these 
interventions have been used in medicine for over centuries, and therefore have a well-
known risk profile, low costs and are widely available. This thesis comprises animal and 
translational studies into the immunomodulatory effects of these interventions in vivo, 
in order to identify possible effective strategies for patients suffering from dysregulated 
systemic inflammation.
In this chapter, the results presented in this thesis will be discussed in the perspective 
of current insights in the syndrome of sepsis and critical illness, oxygenation and the 
adenosine pathway, and platelet activity and anti-platelet therapy. First, the historical and 
current definitions of sepsis and challenges in this research field will be discussed, followed 
by a reflection on the potential to successfully modulate the immune response in critically 
ill patients and improve outcome by intervening in oxygenation, the adenosine pathway, 
and platelets. Lastly, the use of experimental human endotoxemia models to study sepsis 
and immunomodulatory interventions will be discussed.
Sepsis research then and now
Clinical research to improve the outcome in sepsis has been hampered by a problematic 
definition of sepsis, incomplete understanding of the underlying pathophysiology, and the 
inability to select patients that are likely to benefit from specific interventions. 
Defining and diagnosing sepsis
One of the major problems in sepsis research is that sepsis is not a homogenous, clearly 
defined pathological condition. Sepsis is a clinical syndrome, of which the diagnostic 
criteria were formulated at a conference in 19911. This consensus-based definition of sepsis 
focused on the host response as defined by the Systemic Inflammatory Response Syndrome 
(SIRS) criteria (i.e. fever or hypothermia, leukocytosis or leukopenia, tachycardia and 
tachypnea). Patients with at least two of these criteria and a proven (or suspected) infection 
met the diagnostic criteria of sepsis. These criteria are neither sensitive, nor specific, and 
do not differentiate between uncomplicated infections and sepsis complicated by organ 
dysfunction. Sepsis was redefined in 2016, and the updated definition describes three 
major characteristics of sepsis: provocation by a pathogen, a dysregulated host response 
and a focus on subsequent organ dysfunction2. 
Unfortunately, the clinical applicability may be limited. One of the reasons for this is the 
lack of a validated method to determine ‘a dysregulated host response’. So, although it is 
agreed upon what sepsis ‘is’, there is no gold standard to identify ‘who’ has sepsis. Therefore, 
the authors of the guideline advise to evaluate patients for sepsis in a stepwise manner. All 
patients with a suspected infection can be screened for sepsis using the quick Sequential 
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Organ Failure Assesment (qSOFA), which comprises an increased respiratory rate, altered 
mental status and lowered systolic blood pressure. In case of a positive qSOFA, a full 
evaluation of organ failure using all SOFA score items should be performed. This evaluation 
consists of an assessment of PaO2 /FiO2 ratio, Glasgow Coma Scale, mean arterial pressure, 
vasopressor requirement, serum creatinine or urine output, bilirubin and platelet count to 
assess pulmonary function, mental status, hemodynamic status, renal and liver dysfunction 
and hematologic abnormalities, respectively. Patients are diagnosed with sepsis if the SOFA 
score is 2 or more. Septic shock is present if patients require vasopressor therapy and have 
a serum lactate >2 mmol/L in spite of adequate fluid resuscitation2. Using these criteria, 
the definition characteristics of suspected or confirmed infection and organ dysfunction 
are incorporated into the clinical criteria of sepsis. It remains problematic to define and 
operationalize the dysregulated host response component of the definition, as sepsis 
comprises a broad spectrum of clinical pathologies which are incompletely understood, as 
further detailed below.
Characterizing the dysregulated host response in sepsis to improve patient selection
As detailed in the introduction of this thesis, patients may have an overriding pro-
inflammatory or anti-inflammatory response. This response may result either in organ 
damage, as collateral damage of the overzealous immune response, or susceptibility 
for opportunistic infections as a consequence of a too pronounced or persistent anti-
inflammatory immune response. The latter phenomenon is known as sepsis-induced 
immunoparalysis. Consequently, they may either experience benefit or harm from 
immunomodulatory interventions aimed at dampening inflammation or enhancing 
immunocompetence. Unfortunately, up to now we are unable to properly characterize 
which patients may benefit from a certain intervention, and this represents one of the root 
causes of the plethora of negative trials on anti-inflammatory agents3. Anti-inflammatory 
agents may be beneficial in patients with overriding pro-inflammatory responses and 
organ injury, but can be harmful in patients with immunoparalysis. Combining these 
effects in a clinical trial in unselected sepsis patients may nullify the clinical response in the 
studied population as a whole, leading to the discardment of the studied anti-inflammatory 
intervention as a successful therapy. The above stated is supported by a meta-regression 
study showing that anti-inflammatory therapy is beneficial in animal models with a very 
high mortality, but not in moderately lethal models (i.e. 30-40% mortality)4. In addition, 
post-hoc analyses of negative trials have also shown that a proportion of patients indeed 
may benefit from anti-inflammatory therapy. A striking example is the interleukin-1 
receptor antagonist Anakinra. The initial trial published in 1997 did not show any effect on 
survival in an unselected group of sepsis patients5. However, a recent post-hoc subgroup 
analysis did reveal a beneficial effect in patients with features of the macrophage activation 
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syndrome, a profound pro-inflammatory phenotype6. Importantly, post-hoc analyses 
hamper strong conclusions, but this finding is of interest and warrants further, prospective, 
research. As such, it is clear that, in order to identify patients that may benefit from either 
an anti- or pro-inflammatory intervention, the immunologic status of a specific patient 
needs to be properly characterized. Various attempts to identify a single biomarker that 
reflects the immunologic phenotype of a patient have been made. Examples include 
monocytic expression of the human leukocyte antigen-D Related (HLA-DR) surface 
receptor and cytokine production by ex vivo-stimulated leukocytes3. However, it is highly 
unlikely that a single marker can accurately reflect the immunologic phenotype of a 
patient7. Recently, focus has shifted to big data approaches, for instance comprehensive 
analyses of the leukocyte transcriptome. Such an approach has been shown to distinguish 
between patients with sterile inflammation and patients with proven or suspected 
infection8,9. Nevertheless, it needs to be recognized that these transcriptional changes also 
change over time10. It was recently shown that the leukocyte transcriptome can be used 
to differentiate between subtypes of sepsis. Two distinct sepsis response signatures, or so-
called endotypes, were identified in a group of patients with sepsis11. The signature that 
was characterized by an immunosuppressed phenotype included transcriptomic changes 
associated with endotoxin tolerance, T-cell exhaustion and a downregulation of HLA-DR 
expression. Patients with this immune-suppressed phenotype had a higher disease severity 
and 14-day mortality. Of note, the two identified endotypes were similar in terms of age, 
sex and cultered micro-organisms, and could neither be identified by regularly used clinical 
criteria such as vasopressors requirement, activated protein C levels, and renal failure. In a 
Dutch cohort of patients admitted to the ICU with sepsis, 4 endotypes were differentiated 
based on genome-wide leukocyte gene expression profiles, and patients with one of these 
endotypes had a significantly higher risk of death12. Of note, similar to the aforementioned 
paper11, classification in these endotypes was also not possible using clinical parameters. 
The high mortality risk endotype was characterized by decreased expression of genes 
related to innate and adaptive immune cell functions, whereas the other endotypes 
displayed either increased expression of genes involved in innate immune functions (e.g. 
PAMP recognition and cytokine production) or in adaptive immune functions (e.g. T-helper 
cells, IL-4 signaling and B-cell development). 
Although classifying immunological phenotypes of septic patients according to their 
transcriptomic signature is still in its infancy, future sepsis trials may apply this approach to 
select patients for immune suppressing or enhancing treatment. The selection of a study 
population that is more likely to benefit from experimental therapy than an unselected 
population is known as enrichment. Study populations can be enriched by including 
patients with a greater likelihood of having a disease-related event, for example a secondary 
infection or death, which is prognostic enrichment. Predictive enrichment is selecting 
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patients who are more likely to respond to the intervention based on pathophysiological 
mechanisms13. In other fields of medical research, for example oncology, these kind of 
strategies have successfully been in use for considerable time14. Currently, patient and 
tumor characteristics are important factors used in the selection of patients for cancer 
therapy trials. Logically, in trials studying therapy targeted to certain biological markers, 
only patients with diseases that express these markers are included. Interestingly, the 
potential of such enrichment strategies in sepsis was illustrated by a recent retrospective 
analysis of data obtained from children with septic shock. These pediatric sepsis patients 
could be categorized into two endotypes based on a 100-gene signature response. The 
use of corticosteroids in children with one of these subtypes of septic shock was associated 
with a 10-fold reduction of a complicated course, which was defined as persistence of 
organ failure at day 7 or death at day 2813. 
Besides leukocyte transcriptomics, the immune status of septic patients may also be 
assessed using the patient as its own test tube. An immune-suppressed state, for example 
induced by immunosuppressive drugs in organ transplant patients, results in reactivation 
of latent viruses15,16. It has even been argued that dosing of immunosuppressive medication 
should be guided by viral reactivation. Similarly, viral reactivation has been observed in 
critically ill patients. Over 40% of sepsis patients demonstrate viral reactivation and this is 
associated with secondary fungal infections and survival17,18. This observation illustrates 
the consequences of immunoparalysis and viral reactivation might be used to select sepsis 
patients for immunostimulatory therapy in future immunotherapy trials.
Looking beyond sepsis
Most studies on immune dysregulation and immunomodulatory interventions have been 
performed in patients with sepsis, as it represents the archetypal syndrome of systemic 
inflammation. However, highly similar inflammatory responses and their sequelae have 
been observed following trauma, burns and major surgery. As described in the introduction 
of this thesis, endogenously released danger associated molecular patterns (DAMPs) can 
also activate the immune system, which may also cause activation of common pathways 
culminating in a dysregulated host response19,20. This is supported by the observation 
that the transcriptional changes in circulating leukocytes following severe trauma show 
great overlap (approximately 80%) with changes observed during experimental human 
endotoxemia19. Even more so, secondary infections due to immunoparalysis are observed 
in patients with sterile inflammatory conditions to the same extent compared to patients 
with sepsis21. Therefore, one could argue that the focus of research should not be on the 
difficult to diagnose syndrome of sepsis, but should rather shift to all patients with a 
critical-illness associated dysregulated inflammatory response, regardless of the inciting 
event. This could benefit the inclusion rate of trials, as more patients will be eligible for 
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participation, and of even greater importance, novel therapies may also benefit patients 
with dysregulated inflammation who do not have sepsis. 
In summary, although sepsis is now defined as a pathological process instead of a cluster 
of symptoms, much progress is still to be made in identifying and characterizing the 
pathophysiological mechanisms that cause dysregulation of the immune response. Future 
studies will need to focus on exploring the immunologic changes in patients with sepsis 
and the identification of patients that may benefit from immunomodulatory therapy, 
whether it be immunosuppressive or immune system-enhancing.
Immunomodulatory effects of oxygen and adenosine
In part I of this thesis, the role of oxygen, oxygenation and oxygen-dependent cellular 
mechanisms in inflammation was investigated. Furthermore, the relevance of these results 
for critically ill patients was discussed. We identified that short-term hypoxia attenuates 
inflammation through a mechanism involving enhanced stimulation of the adenosine 2B 
receptor and increased interleukin-10 production, whereas short-term hyperoxia does not 
affect the innate immune response. 
Oxygen and oxygenation in critical illness
Hypoxia as an immunosuppressive intervention in critical illness
Because our results show that short-term hypoxia profoundly attenuates the immune 
response in vivo, applying hypoxia to critically ill patients may represent a strategy to limit 
excessive inflammation and associated tissue damage and organ failure. Nevertheless, 
before this is clinically applicable, several important questions need to be answered. 
First, it remains to be determined whether the anti-inflammatory effects of short-term 
exposure to hypoxia demonstrated in this thesis also apply to situations in which ongoing 
inflammation as a result of an actual infection is present, as opposed to the single sterile 
inflammatory insult we employed (i.e. administration of endotoxin). Furthermore, it needs 
to be established that these anti-inflammatory effects may truly protect tissues from pro-
inflammatory damage. Answering these questions requires animal studies, as models 
of prolonged live pathogenic infections that induce organ failure are not available in 
humans. Examples of suitable animal models include the well-known cecal ligation and 
puncture (CLP) model or injection of fecal slurry, both of which recapitulate abdominal 
polybacterial sepsis, or intratracheal Pneumococcus or Klebsiella instillation to model 
pneumonia. Concurrently, questions about dosing and timing of hypoxia need to be 
answered. These include depth of hypoxia, duration, frequency, and initiation time. It is to 
be expected that timing will be delicate, as we demonstrated in this thesis that initiation 
of hypoxia 30 minutes after endotoxin administration failed to exert anti-inflammatory 
effects. Nevertheless, it needs to be noted that these results were obtained in a model 
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of short-lived inflammation elicited by bolus administration of endotoxin. It could very 
well be that the timing may not be as crucial in situations of prolonged inflammation. In 
this respect, it would also be worthwhile to investigate the effects of different timings and 
durations of hypoxia on the inflammatory response in humans in vivo using the continuous 
infusion endotoxemia model, pioneered in this thesis. Furthermore, based on the murine 
data presented in chapter 3 of this thesis, it is to be expected that short periods of hypoxia, 
e.g. 60-180 minutes) will suffice to induce a robust augmentation in tissue adenosine levels. 
Longer periods of hypoxia (i.e. multiple hours or days) are likely to induce HIF activity, 
which can have a multitude of possibly opposing immunologic as well as other effects. For 
instance, hypoxia for >12 hours resulted in increased morbidity and mortality in murine 
models of skin and lung infections22. 
Before clinical studies in patients can be initiated, it is mandatory that the questions raised 
above are answered satisfactory. If selection of patients with an overriding pro-inflammatory 
phenotype will be possible in the future, for example using the strategies alluded earlier 
in this chapter, pilot studies aimed at safety and feasibility of permissive hypoxia are 
within reach. Such studies should focus on dose finding, again including time of initiation, 
duration, frequency, and depth of hypoxia. Besides safety and feasibility, primary efficacy 
endpoints should focus on hypoxia-induced mitigation of inflammation (e.g. plasma IL-6 
levels) and inflammation-related organ damage (e.g. using the sequential organ failure 
assessment score (SOFA-score), including P/F ratio, Glasgow coma scale, blood pressure 
and vasopressor need, bilirubin, coagulation and renal function). Secondary endpoints 
should include development of secondary infections, viral reactivation, and possibly other 
novel markers of immunoparalysis, as this phenomenon might theoretically be enhanced 
by hypoxia. 
Current clinical practice regarding oxygenation
The results of the studies described in this thesis may not only contribute to the possible 
future use of hypoxia as an immunomodulatory intervention, they may also aid our 
understanding of phenomena observed in clinical practice and in clinical trials. We know 
from observational studies and trials that oxygenation levels are related to outcome23–25. 
The current guidelines on what optimal oxygenation targets are in critical care are however 
ambiguous. Although the acute respiratory distress syndrome (ARDS) guidelines advise a 
target arterial oxygen saturation (SaO2) of 88-92%, the guidelines of the British Thoracic 
Society recommend a target SaO2 of 94-98% for acutely ill patients or 88-92% for patients at 
risk of hypercapnic respiratory failure26. Similarly, the guidelines of the Thoracic Society of 
Australian and New Zealand state that oxygen should be administered if SaO2 is <92% and 
should be titrated to a SaO2 of 92-96%
27. The recommendations from the ARDS guidelines 
are based on consensus of experts, and the recommendations of the Thoracic Societies 
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are supported by low to very low quality of evidence (grade C and D). So, there is no high 
level of evidence for any oxygenation target. As alluded to before, observational studies 
have investigated the association between oxygenation levels at ICU admittance and 
outcome. These studies yielded a clear association between more severe hypoxia and 
poor outcome. The adjusted odds of mortality were 1.2 (95% CI 1.1-1.6) for patients with 
an PaO2 <8.5 kPa at ICU admission
24 in a nationwide Australian database study, and 1.12 
(95%CI 1.03-1.21) in a nationwide Dutch database study (PaO2 <8.9 kPa)
23. Similarly, in a 
post-hoc analysis of two Scandinavian multicenter randomized controlled trials in patients 
with sepsis, a PaO2 < 8 kPa was associated with an increased risk of death in adults (OR 
1.43 95%CI 1.19-1.65)28. A single center retrospective cohort study also identified that 
hypoxia (PaO2<8 kPa) was independently associated with hospital mortality in children 
(modified standard in-hospital mortality rate of 1.34 for hypoxia vs. 0.83 for normoxia)29. In 
contrast, a recent study revealed that hypoxia (median PaO2 of 7.7 kPa) at the emergency 
department appeared to result in a lower mortality compared to normoxic patients (13.2% 
versus 19.4%)30. Interestingly, the inclusion criteria for this last study was normoxia during 
ICU admittance, therefore, patients were presumably only hypoxic for a short period of 
time. Based on the work described in this thesis, it could be speculated that they may have 
benefited from anti-inflammatory and tissue-protective effects of hypoxia. The patients in 
the aforementioned studies were probably hypoxic for a more prolonged period of time, 
and this likely caused obvious detrimental effects such as ischemia of vital organs as well 
as other (HIF-dependent) effects22. Furthermore, these patient likely had higher illness 
severities, as attempts to correct hypoxia during admittance were apparently unsuccessful, 
and this may provide another explanation for their worse outcome. 
Hyperoxia has also been associated with poor outcome in a meta-analysis on various 
subsets of critically ill patients31. This meta-analysis analyzed differences between patients 
admitted to the ICU with hyperoxia or normoxia and the authors note that the included 
studies were heterogeneous and more evidence is necessary to provide optimal treatment 
targets. In addition, it is becoming increasingly clear that not only prolonged exposure to 
hyperoxia may result in adverse outcome. For instance, an observational study reported 
that even brief bouts of hyperoxia at the emergency department, with subsequent 
normalized oxygen levels in the ICU, are associated with increased mortality as well30. 
However, as these observational studies do not allow differentiation between severity 
of disease or failure to provide optimal treatment, these results cannot be used to draw 
conclusions about optimal oxygenation targets. It is of importance to emphasize that, 
even when oxygen targets are defined, these are not necessarily met in everyday clinical 
practice. ICU physicians and nurses were questioned on what levels of oxygenation would 
be regarded acceptable, and they generally stated this is a SaO2 of 85-95%. However, over 
70% of measured SaO2 in their own patients was higher than 95%. Only in 58% of these high 
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SaO2 episodes the level of oxygen administration was adjusted
32, indicating that ‘guideline’ 
adherence to oxygenation targets is low, and the avoidance of hyperoxia may not have a 
high priority in clinical practice yet.
Investigation of the optimal oxygenation target
There is mounting evidence of potential harmful effects of hyperoxia. As such, several 
efforts have been made to implement more conservative oxygen targets in daily practice. 
In a monocenter before-and-after feasibility study, a strategy with a conservative oxy-
genation target (SpO2 of 90-92%) in ICU patients was implemented. This target was found 
to be feasible and did not results in adverse biochemical, physiological or clinical out comes. 
Therefore, the authors concluded that a SpO2 of 90-92% is safe for use in a rando mized 
trial33. Similarly, a two-phased implementation of a conservative oxygen strategy (target 
SpO2 of 92-95% or PaO2 of 55-86 mmHg) in ICU patients resulted in fewer episodes 
of hyperoxia (9.0 and 7.6% in each phase) in comparison to the control period (15.3%), 
without an increase of hypoxic periods. Although not designed to show a survival benefit, 
adjusted hospital mortality was lower after implementation (odds ratio 0.84 and 0.82 in 
each phase)34. Besides these implementation studies, two controlled trials were performed 
to assess if there is a survival benefit with the use of certain oxygen targets. The first was a 
small (n=103) single-center study in which the effects on organ dysfunction and mortality 
of a conservative oxygen target (SpO2 of 88-92%) were evaluated and compared to a 
liberal oxygenation strategy (SpO2 of >96%). There were no differences between groups 
in new organ dysfunctions, nor ICU or 90-day mortality. Hence, the authors concluded 
that a conservative oxygenation strategy is safe and feasible35. A second single-center 
trial compared a conservative oxygen target of (PaO2 of 70-100 mmHg or SpO2 of 94-98% 
with a conventional oxygenation strategy (allowing PaO2 up to 150 mmHg or SpO2 97-
100%). Although this trial was stopped early due to enrollment issues after 480 patients, 
mortality was significantly lower in the conservative oxygen group, with shorter duration 
of shock, less liver failure and bacteriema36. Nevertheless, the interpretation of this studies 
is complicated, as the oxygen targets in the ‘conventional’ arm were relatively high 
(i.e. a PaO2 up to 150 mmHg). As ICU staff agreed unanimously that a PaO2 >98 mmHg 
is an unacceptable level of hyperoxia32, the ‘conventional’ arm should be interpreted as 
‘unacceptable hyperoxia’ and not as a clinically accepted control condition. In addition, the 
oxygenation target of 94-98% in the conservative group was not that extreme, compared 
to SpO2 88-92% and 92-95% targets in the aforementioned implementation studies
35. 
Therefore, the comparison in this study should be interpreted as a study investigating the 
effects of normoxia versus hyperoxia, and the conclusion is that hyperoxia is harmful. 
This conclusion was also drawn from the HYPER2S study, in which patients were randomized 
in a 2x2 factorial design to either hyperoxia (FiO2 of 100% in the first 24h) or normoxia 
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(FiO2 titrated to a SpO2 88-95%) and fluid resuscitation with either hypertonic or normal 
saline. The study was terminated prematurely for safety reasons, as patients with hyperoxia 
had a higher incidence of serious adverse events (85% versus 76%, p=0.02)37. The results 
of the HO2T or NO2T study (Clinicaltrials.gov NCT02378545), in which the resuscitation 
of patients with sepsis in the Emergency Department with hyperoxia (100% oxygen by 
non-rebreathing mask at 15L/min) or normoxia (titration of oxygen administration to SpO2 
of >94% and hourly evaluation) for the duration of the Emergency Department stay are 
compared, are highly anticipated. 
A possible explanation for the putative harmful effects of hyperoxia cannot be deduced 
from the results described in this thesis. However, we investigated short-term hypoxia, 
whereas in many other studies, including the abovementioned work in which hyperoxia 
was applied for 24 hours37, exposure is much longer. As such, harmful effects, e.g. related 
to augmented ROS production, may be the result of sustained hyperoxic exposure. 
Alternatively, it could be speculated that, by exposing patients to supranormal oxygen 
levels, the oxygen levels in inflamed and poorly perfused tissue may remain above the 
threshold that activates the hypoxia-induced anti-inflammatory and putative tissue-pro-
tective mechanism described in this thesis. This may play also a role in the worse outcomes 
observed in hyperoxic patients. 
Taken together, there is a paradigm shift from providing a surplus of oxygen to critically ill 
patients as a first line of treatment towards implementing conservative oxygen strate gies and 
avoidance of hyperoxia. The first reports on these implementations show that lower oxygen 
targets are safe and feasible. On the other hand, studies that compare liberal oxygenation, 
or hyperoxia, with conservative to normal levels of oxygen show either no therapeutic 
effect or a harmful effect of hyperoxia. All in all, from observational, implementation and 
randomized controlled studies there is evidence that hyperoxia should be avoided, and that 
targets SaO2 of 92-94% are safe and help to avoid hyperoxia. Whether or not even lower 
oxygen targets may be beneficial remains to be determined. Of importance, the possible 
therapeutic benefit of “permissive hypoxia” may be dependent on the immune status of the 
patient, as extensively discussed earlier in this chapter, once again stressing the need for 
novel biomarkers that can gauge a patient’s immunological phenotype.
The adenosine pathway in inflammation and critical illness
In this thesis, we reveal that the anti-inflammatory effects of short-term hypoxia involve 
enhanced adenosine signaling. Hence, also independent of hypoxia, the adenosine path-
way represents an interesting pharmacological target to modulate a dysregulated host 
response in patients with critical illness. 
Previous work has shown that extracellular adenosine levels increase as a result of tissue 
injury due to inflammation or hypoxia38. This increase in adenosine exerts various effects 
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on multiple (patho)physiological processes by activation of four adenosine receptors (A1, 
A2A, A2B and A3). These receptors are widely distributed, and downstream effects depend 
on adenosine affinity, tissue and receptor type38. Activation of adenosine receptors result 
in suppression of inflammation and/or enhanced resolution of inflammation. In this 
thesis, the involvement of the A2B receptor in the anti-inflammatory effects of short-
term hypoxia is revealed. This insight corroborates the hypothesis that stimulation of the 
adenosine receptors could propagate a shift towards an anti-inflammatory phenotype in 
critically ill patients. However, direct infusion of adenosine is complicated by its very short 
half-life (<10s) and adverse cardiovascular side effects. These cardiovascular effects are 
illustrated by the medical use of adenosine infusion for cardiac stress testing and blocking 
atrioventricular conduction to treat supraventricular tachycardia39. Similar to infusion 
of adenosine, direct stimulation of the adenosine receptor, also known as orthosteric 
agonism, carries risks of undesired hemodynamic side effects. An alternative strategy to 
take advantage of the anti-inflammatory effects of adenosine receptor stimulation is by 
modulating its binding affinity or functional efficacy, which is known as positive allosteric 
agonism. Hypothetically, positive allosteric agonism of adenosine receptors could result in 
the following scenario. Under physiologic circumstances, adenosine levels are too low to 
activate adenosine receptor signaling, even despite positive allosteric agonism. However, 
as the threshold for adenosine receptor signaling is lowered, even relatively minor cellular 
stress resulting from inflammation or hypoxia can lead to a sufficient increase in local 
adenosine levels to induce robust signaling at the site of inflammation or hypoxia. As a 
result, anti-inflammatory effects are sorted at the site of injury, and systemic side effects 
may be prevented40.The A2B receptor is especially suitable for positive allosteric agonism, 
as it has a relative low affinity for adenosine in comparison to the other adenosine receptors 
and is only activated when adenosine levels are substantially increased. 
It needs to be mentioned that the development of these kind of drugs is nevertheless 
in its infancy. Furthermore, the specific pharmacological A2B agonists PSB-1115, BAY 
60-6583 and the specific A2B antagonist CVT6883 have up till now only been used 
in animal models40. There is a limited amount of data of other adenosine receptor 
agonists/antagonists that have been used in humans. The A1 antisense oligonucleotide 
EPI-2010 was studied in asthma patients. Although it was well tolerated and exerted 
modest beneficial effects on asthma in steroid-naïve patients, the drug was ineffective 
in patients using inhalation steroids (standard treatment) and further development was 
discontinued41. The A1 allosteric enhancer T62 was in a phase I trial in patients with post-
herpetic pain, but the results remain unpublished until now, although it was reported that 
some patients experienced asymptomatic transient elevations in liver transaminases. The 
inhaled A2A agonist GW328267X42 and UK432097 (Clinicaltrials.gov NCT00430300, results 
unpublished) were assessed in patients with asthma and chronic obstructive pulmonary 
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disease, respectively, and showed no or very limited efficacy40. Only the A3 agonist CF101 
has been studied in a phase II/III trial for psoriasis, where it was shown to be safe, well 
tolerated and efficacious in patients with psoriasis43.
To conclude, although there are associations between oxygenation status and survival of 
critically ill patients, there are no evidence-based oxygenation targets. It is clear that much 
additional pre-clinical and clinical research is required pertaining targeted oxygenation 
strategies to treat the dysregulated immune response in critically ill patients. An alternative 
option to modulate the immune response using oxygen-dependent pathways is represented 
by adenosine receptor-modulating drugs. These agents are being developed for other 
indications, but based on their cellular effects, immunologic actions are likely, and it would 
be interesting to study these effects in the context of (dysregulated) systemic inflammation. 
Immunomodulatory effects of anti-platelet therapy
Similar to inflammation and hypoxia, inflammation and platelet activity are closely inter-
linked, and the studies in this thesis demonstrate that inflammation can be modulated 
using the anti-platelet therapy acetylsalicylic acid (ASA). 
Platelets in inflammation and critical illness
The interplay between platelets and systemic inflammatory conditions is supported by 
several clinical observations, for example the high incidence of thrombocytopenia in 
severe sepsis44 and the association of infections with the development of thrombocytosis45. 
Moreover, it is now becoming increasingly clear that thrombocytes are not just a reactive 
bystander in inflammation, but that they may modulate the inflammatory response 
in several ways46. First, platelet TLR expression can activate platelets in such a way that 
they can bind to bacteria, and platelets can directly kill these bacteria by production of 
thrombocidins or trap them for elimination by phagocytes. Second, platelets may interact 
with leukocytes, and promote leukocyte activation through expression of selectins, 
cytokines and chemokines. Third, activated platelets promote the activation of monocytes 
and dendritic cells to increase their antigen presentation to T-cells, which will lead to a 
subsequent enhanced adaptive immune response46. 
The fact that platelets do not only affect the immune response, but also may contribute to 
outcome is illustrated by an observational study that reported an association between the 
shelf-time of transfused platelets and complications in critically ill trauma patients. Of note, 
this association was particularly notable for the incidence of sepsis as a complication47. The 
reverse phenomenon, inflammation affecting platelet function, has also been reported. 
A prospective observational study showed that the percentage of platelet-monocyte 
complexes was higher in patients with influenza compared to patients admitted with a 
pneumonia or healthy controls48. 
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The exact mechanisms by which platelets may play a role in sepsis and other critical illnesses 
is not fully unraveled, but both platelet numbers and function have been implicated. 
For instance, the degree of thrombocytopenia at ICU admittance is associated with an 
increased 30-day mortality, apparently independent of disease severity44. In addition, 
platelets from patients with sepsis display increased surface P-selectin expression49,50, 
and increased plasma levels of soluble P-selectin51, indicating platelet activation. Besides 
platelet activation, well-functioning platelets, as measured by whole blood impedance 
aggregometry, are associated with a lower mortality (10%) compared to poor platelet 
function (40% mortality)52. 
These examples indicate that platelets and inflammation interact not only in vitro, but 
also in clinically relevant situations. In this thesis, it was demonstrated that anti-platelet 
therapy, in this case using acetylsalicylic acid (ASA), enhances the innate immune response 
during experimental human endotoxemia. The concept of using antiplatelet therapy as an 
immunomodulatory therapy is supported by a study that showed effects of antiplatelet 
therapy on infection-induced changes in the composition of immune cells. Normally, 
influenza vaccination increases the CD14highCD16+ monocyte count, which is also increased 
in patients with atherosclerosis and is predictive for cardiovascular events. An influenza-
vaccination induced increase in CD14highCD16+ cells could be counteracted by either high 
or low dosage ASA or clopidogrel treatment. In addition, vaccination-induced platelet 
P-selectin expression was also abolished by both of these antiplatelet drugs53. 
Studies described in this thesis repeatedly demonstrate that during experimental human 
endotoxemia, treatment with ASA augments the innate immune response and that 
addition of P2Y12 inhibitors does not relevantly alters this response. Furthermore, it is 
shown that ASA treatment partially reverses development of endotoxin tolerance, a model 
of sepsis-induced immunoparalysis. As such it represents an interesting therapy that may 
modulate the dysregulated immune response in critically ill patients. 
Acetylsalicylic acid as an immune system-enhancing intervention in critical illness
Several observational studies have identified a link between the use of ASA and a beneficial 
outcome in sepsis54–58, although this effect was not confirmed in all studies59. A recent 
meta-analysis found a 2-12% reduction in mortality risk in patients using ASA prior to onset 
of sepsis60. Similar beneficial associations with outcome were reported in patients with 
pneumonia61,62. In contrast, studies that evaluated the association between the use of anti-
platelet therapy and mortality in the general ICU population did not show such a consistent 
result. Although the use of antiplatelet therapy (predominantly ASA) was reported to be 
associated with a lower prevalence of ARDS63,64 and lower mortality65 in some studies, these 
results could not be reproduced by others66–68. Due to the observational nature of these 
studies, causative relationships cannot be ascertained. In addition, selection bias probably 
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confounds these studies considerably, as patients using ASA may be more motivated to live 
a healthy lifestyle, or are wealthy enough to visit a doctor and pay for medication. However, 
this “good patient” selection bias is contradicted by the discrepant observation that ASA use 
is related with better outcome in patients with sepsis, but not in the general ICU population. 
This suggests that ASA exerts effects that are specifically protective for sepsis, and do not affect 
outcome in other patients. Speculatively, the immune enhancing effect of ASA repeatedly 
reported in this thesis may result in more immunocompetence and improved bacterial 
clearance in patients with infections. This may explain the beneficial effects described above 
and is further supported by other work. For instance, a retrospective cohort study reported 
a lower rate of S. aureus bacteriema in dialysis patients who used ASA compared to patients 
not using ASA (0.17 vs. 0.34 events per catheter year). Intriguingly, this effect was specific 
for S. aureus and not observed for other species69. Furthermore, a retrospective cohort study 
compared episodes of S. aureus and E. coli blood stream infections and categorized them 
by ASA use (or not) prior to the infection. The propensity score-matched analysis revealed 
that prior ASA use was associated with a lower 30-day mortality in patients with S. aureus 
bacteriemia, but not in patients with E. coli bacteremia70. However, these potential beneficial 
effects were not confirmed in a nested-case control study in patients with vascular access 
for hemodialysis, where ASA use was not associated with a decreased risk of infection71. In 
this thesis, E. Coli-derived endotoxin was used to elicit a systemic inflammatory response. As 
Gram-positive and Gram-negative PAMPs, as well as endogenous DAMPS from sterile insults 
all result in a more or less common pathway of systemic inflammation, there are theoretical 
grounds that the endotoxin-induced systemic inflammatory response is generalizable to 
other pathogens or insults. Nevertheless, it is conceivable that Gram-positive and negative 
bacteria respond differently to the mounted inflammatory response, resulting in differences 
between susceptibility towards and clearance of infectious agents. 
Off-label use of ASA is still under investigation in a large number of randomized trials to 
evaluate its potential beneficial effects in a wide range of non-cardiovascular diseases. A 
very large primary prevention study is the ASPREE trial, in which 19000 healthy elderly 
patients in the USA and Australia are enrolled to receive either low dose ASA daily or 
placebo (Clinicaltrials.gov NCT01038583). This study will analyze the effect of primary 
prevention with ASA on a large number of age-dependent diseases such as cognitive 
impairment, vascular events, macular degeneration, cancer, osteoarthritis, fractures, sleep 
apnea, hearing loss and microvascular changes. Most relevant to the subject of this thesis 
will be the subgroup analysis in which the effect of ASA on the incidence of infections and 
sepsis will be studied. 
Our finding that treating healthy volunteers with ASA in between two endotoxin challenges 
partially reverses endotoxin tolerance suggests that initiating ASA treatment in septic 
patients admitted to the ICU could be beneficial by reversing immunoparalysis. Ideally, 
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as elaborated on previously in this chapter, only patients with immunoparalysis should 
be considered for this treatment. There are currently two trials ongoing that specifically 
evaluate the effects of ASA in critically ill patients. The first is a single-center study in Austria, 
in which consecutive ICU patients except for those with known allergies, planned surgery, 
bleeding, coagulation disorders, terminal illness, thrombocytopenia or pregnancy will 
be enrolled. These patients will be randomized to either ASA or placebo and the primary 
outcome is 28- and 90-day mortality (Clinicaltrials.gov NCT02285153). Another trial will 
randomize patients admitted with trauma in a 2x2 design to either ASA or placebo and 
rosuvastatin or placebo to reduce venous thrombosis. Although the primary outcome will 
be the incidence of venous thromboembolism, secondary endpoints will include acute 
lung injury, ventilator days, ICU length of stay, multiple organ failure and all-cause mortality 
(Clinicaltrials.gov NCT02901067). These trials may help to deduct whether initiation of ASA 
treatment on the ICU may contribute to improved immunocompetence against infections 
and sepsis. Unfortunately, beneficial effects of ASA in these general ICU patient groups 
may be difficult to detect, and it will probably remain to be determined whether treating 
patients with immunoparalysis on the ICU with ASA improves outcome. 
In conclusion, preclinical studies and observational studies in patients show that platelet 
reactivity and function and the immune response influence each other considerably. These 
effects likely play a role in critically ill patients on ASA, and initiating ASA in patients with 
immunoparalysis may be of benefit, but therapeutic efficacy needs to be determined in 
large clinical trials. 
Using endotoxin models to study systemic inflammation
As alluded to in the introduction of this thesis, studying the dysregulated immune 
response in patients is complicated by heterogeneity in terms of comorbidities, causative 
pathogens and time of onset and course of the disease. In addition, many effective 
immuno modulatory interventions in animal models of sepsis have not been effective in 
clinical studies7. These findings indicate that somehow, the gap between animal studies 
and clinical trials is too large. The experimental human endotoxemia model allows for 
the translational investigation of immunomodulatory therapies in humans in vivo in a 
standardized, controlled reproducible manner, thereby bridging this gap between animal 
studies and clinical trials. 
Experimental human endotoxemia entails a transient systemic inflammatory response 
elicited by intravenous injection of E. coli-derived endotoxin (lipopolysaccharide [LPS]), 
a cell wall component of this Gram-negative bacteria and a potent TLR4 agonist72. 
Experimental human endotoxemia has served as a valuable model for over decades73, and 
originated from fever-inducing therapies that were used more than 150 years ago for a 
range of diseases, including cancer73. Endotoxin was identified as the causative compound 
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inducing the fever (and this inflammatory) response, and the demand for a purified, 
standardized formulation grew. Such a formulation was developed by the FDA in 197674.
The experimental human endotoxemia model has been used in the Radboud university 
medical center since 2003. During this period, it has evolved into a well-tolerated, safe, 
and highly reproducible model of systemic inflammation. Examples of improvements 
of the safety of the model are the exclusion of subjects prone to vagal responses and a 
prehydration protocol75,76. To reduce heterogeneity, female volunteers are excluded, as 
they were shown to display a more potent immune response compared to men77, thereby 
increasing the variability of the measured endpoints and decreasing statistical power 
to detect differences between treatment groups. This exclusion of female subjects is 
however in conflict with the increasing awareness of the differences in prevalence, clinical 
manifestations and outcomes between women and men78,79. It was not until 1993 that 
the National Institute of Health has issued policies that required inclusion of women and 
minorities in clinical research and trial designs (The NIH Revitalization Act, 1993). Gender 
differences have been identified for widely used drugs such as analgesics80 and ASA81. 
The exclusion of women in the exploratory studies in this thesis may therefore result in 
an over- or underestimation of the immunomodulatory effects of the interventions in 
women. Although these studies are primarily designed to answer the question “has this 
intervention an effect on inflammation in humans?”, one may argue that both males and 
females need to be investigated. As a consequence, the number of subjects that needs to 
be included has to be higher to account for the larger intersubject variability. Of course, 
subsequent clinical studies in male and female patients need to verify if these interventions 
will result in improved outcome. 
With regard to clinical decision making, results from endotoxemia studies have to be 
interpreted with caution, as human experimental endotoxemia does not fully mimic the 
clinical syndrome of sepsis. No translational model of sepsis will ever fully reflect sepsis, 
if not only for the reason that there is no homologous course of the sepsis syndrome. 
Another issue that may limit the translation of experimental human endotoxemia studies 
to patients is the difference in pathogen burden. In the model, highly purified endotoxin is 
used to elicit inflammation. In patients, inflammation can be provoked by live pathogens, 
which can also be Gram-positive bacteria, fungi or yeasts, or a composition of several 
microbes. These concerns can be abated to some extent, as it was shown that the early 
transient physiochemical changes and biochemical pathway activation in the model are 
very similar to those observed in the early phase of injury and infection, and transcriptomics 
changes correspond well with those observed after trauma82. In addition, the changes in 
blood metabolites are also comparable to those observed in community-acquired sepsis83. 
So, although the initiating insult is not entirely comparable to the insult in patients, the 
experimental human endotoxemia model results in a common pathway of systemic 
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inflammation, which is also elicited by live pathogenic infections, trauma, surgery or burns. 
Another concern that may limit the applicability of the experimental human endotoxemia 
model is that the immune response is normally elicited with a bolus injection of endotoxin, 
instead of an ongoing inflammatory stimulus which is the case in patients with sepsis. 
Therefore, in this thesis the differences between the induction of systemic inflammation by 
bolus and continuous infusion of endotoxin was studied. The data showed that continuous 
infusion was well-tolerated, and resulted in a more pronounced and prolonged increase 
of most plasma cytokines. Of note, TNFα and MIP-1α plasma concentrations were already 
declining in most volunteers during endotoxin infusion. Hereby, this study also clarifies 
some aspects of the dynamics of cytokines during continuous inflammatory stimuli and 
further research into these cytokine kinetics is warranted. Possibly, subjects displaying 
a decline of cytokine levels during endotoxin infusion exhibit a more anti-inflammatory 
phenotype. This could be further explored by measuring other markers of immunoparalysis, 
e.g. HLA-DR, to better understand the kinetics of cytokine responses and its relationship 
with immunoparalysis. Such a continuous endotoxemia model also provides an extended 
time window to evaluate immunomodulatory interventions initiated after the initial 
insult. This is of paramount clinical relevance, as therapy can usually only be commenced 
following the insult (trauma/infection) in critically ill patients. This thesis also reports 
that the variation between experimental human endotoxemia trials is considerable. 
Furthermore, newer smaller batches may induce even more pronounced variance between 
different experimental human endotoxemia studies, making direct comparison between 
different studies even more cumbersome. 
In conclusion, over the years, the experimental human endotoxemia model has facilitated 
investigation of numerous immunomodulatory interventions and increased the insight 
in pathophsyiological mechanisms that occur during systemic inflammation. Despite its 
limitations, it is a valuable tool to translate findings from preclinical studies to the clinical 
patient situation. 
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Ernstig zieke patiënten die op de intensive care zijn opgenomen met een infectie of een 
ander ziektebeeld hebben veelal een ontregeld afweersysteem. Dit proefschrift beschrijft 
translationeel onderzoek naar mogelijke behandelingen om de afweerreactie te beïnvloeden. 
De effecten van zuurstof en trombocytenaggregatieremmers (bloedplaatjes remmende 
medicatie) op de afweerreactie, en de cellulaire mechanismen die hieraan ten grondslag 
liggen, staan centraal in de hier beschreven studies. 
Introductie
Sepsis (‘bloedvergiftiging’) is gedefinieerd als een ontregelde afweerreactie op een infectie 
met weefsel-, en orgaanschade tot gevolg, en kan uiteindelijk leiden tot het overlijden van de 
patiënt. Een patiënt met sepsis kan zowel een overmatige als een verminderde afweerreactie 
hebben, en afhankelijk hiervan zou een potentiële behandeling gericht moeten zijn op 
het onderdrukken of het versterken van de afweerreactie. Helaas is het niet gemakkelijk 
om te bepalen of de complexe afweerrespons overmatig is of juist tekort schiet. Omdat 
de groep met sepsispatiënten zo divers is, hebben behandelingen voornamelijk gericht 
op het onderdrukken van het afweersysteem tot nu toe dan ook geen positieve effecten 
laten zien. Voor zowel het zuurstofgehalte als trombocytenaggregatieremmers geldt dat 
er in experi menteel onderzoek (in het laboratorium) is aangetoond dat ze de afweerreactie 
beïnvloeden én dat in associatieonderzoeken is aangetoond dat ze een samenhangen met 
de over leving van kritisch zieke patiënten. Zuurstof en trombocytenaggregatieremmers 
zijn laag drempelig beschikbaar en ze kennen beide weinig (en tevens bekende) risico’s. 
Daarom is het van nut om te weten in welke mate deze twee interventies de afweerreactie 
beïn vloeden en kan het gebruik mogelijk worden toegepast als behandeling in patiënten 
met een ontregeld afweersysteem. Er is echter nog geen wetenschappelijk bewijs bij de 
mens dat laat zien dat veranderingen in zuurstofgehalte of het gebruik van trombo cyten-
aggregatie remmers effect heeft op de afweerreactie. Experimentele endotoxinemie bij 
de mens is een onderzoeksmethode om de effecten van behandelingen gericht op de 
beïnvloeding van het afweersysteem te onderzoeken. Bij deze methode wordt endo toxine, 
wat een dood onderdeel is van de celwand van de E coli bacterie, geïnjecteerd bij gezonde 
proefpersonen. Hierdoor ontstaat een kortstondige afweerreactie, die bestaat uit griep-
achtige symptomen, koorts, een toename van witte bloedcellen in het bloed. Daarnaast 
zijn in het bloed ontstekingseiwitten, ook wel cytokines genaamd, meetbaar. Door 
voorafgaand of gelijktijdig aan de injectie van endotoxine een behandeling toe te passen, 
kan worden bepaald of en in welke mate deze behandeling de afweerreactie beïnvloed. 
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Deel 1 Het effect van zuurstof en zuurstofafhankelijke 
mechanismen op de afweerreactie
In hoofdstuk 2 wordt een overzicht gegeven van de tot nog toe bekende effecten van 
een laag zuurstofgehalte (hypoxie) op de afweerreactie. Vervolgens worden deze effecten 
besproken in de context van een ontregelde afweerreactie bij patiënten op de intensive 
care. Er wordt een overzicht gegeven van de interacties tussen hypoxie en de afweerreactie 
vanuit moleculair, cellulair en klinisch perspectief. Hypoxie heeft directe effecten op de 
transcriptiefactor Hypoxia Inducible Factor (HIF)-1α en de adenosine signaleringscascade. 
HIF-1α en adenosine signalering kunnen de afweerreactie zowel versterken als verzwakken, 
afhankelijk van het cel-, en weefseltype. Tot slot wordt de mogelijkheid om bij kritisch zieke 
patiënten met zuurstoftherapie de afweerreactie bij te sturen beschreven. Een alternatief 
voor het toedienen van zuurstof is het toepassen van farmacologische middelen die 
ingrijpen op zuurstofafhankelijke processen. 
In hoofdstuk 3 worden de effecten van hypoxie op de afweerreactie in muizen en 
mensen beschreven. Muizen werden blootgesteld aan hypoxie of normale hoeveel heden 
zuur stof (normoxie) terwijl een afweerreactie werd uitgelokt door het toedienen van 
endo toxine. Hypoxische muizen hadden een hogere concentratie van het ontstekings-
remmende cytokine Interleukine-10, en een lagere concentratie van verschillende 
onstekingsbevorderende cytokines in het bloed in vergelijking met normoxische muizen. 
Bij muizen werd tevens vastgesteld dat het afweerremmende effect van hypoxie zich 
binnen zeer korte tijd manifesteert, en dat de regulatie plaatsvindt nadat het coderende 
DNA voor de cytokines al is overgeschreven. Onder meer gebruik makende van genetisch 
gemodificeerde muizen bleek dat hypoxie leidt tot een snel verhoogde productie van 
adenosine, en deze hogere concentraties adenosine zorgden via stimulatie van de 
adenosine-2B-receptor tot een verhoging van Interleukine-10. Hierdoor werd vervolgens 
de aanmaak van ontstekingsbevorderende cytokines geremd. Identieke effecten van 
hypoxie werden gevonden bij de mens gedurende experimentele endotoxinemie . Voor het 
eerst werd aangetoond dat blootstelling aan hypoxie leidde ook bij mensen tot een sterk 
verhoogde aanmaak van Interleukine-10 en een verlaging van ontstekingsbevorderende 
cytokines. Studies op bloedcellen van gezonde vrijwilligers lieten zien dat deze effecten ook 
bij mensen wordt veroorzaakt door een adenosine-2B-receptorafhankelijk mechanisme. 
Het ontstekeningsremmend effect van hypoxie zou een beschermingsmechanisme 
van het lichaam kunnen zijn tegen schade die wordt veroorzaakt door een overmatige 
immuunrespons bij een infectie. 
In hoofdstuk 4 worden de effecten van hypoxie en de afweerreactie op de ijzer huis houding 
bij de mens uiteengezet, gebruikmakende van hetzelfde experiment als be schreven 
in hoofdstuk 3. De ijzerhuishouding is strikt gereguleerd door het hormoon hepcidine, wat 
de opname van ijzer uit de darmen remt en opname in immuuncellen stimuleert. Tijdens 
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een afweerreactie wordt er meer hepcidine aangemaakt, terwijl hypoxie de aanmaak van 
hepcidine juist remt. Uit het onderzoek bleek dat de afweerreactie die werd veroorzaakt 
door het toedienen van endotoxine bij proefpersonen inderdaad leidt tot een stijging 
van hepcidine in het bloed. Echter, deze stijging was minder uitgesproken wanneer 
proefpersonen gelijktijdig werden blootgesteld aan hypoxie. Het verlagende effect 
van de afweerreactie op andere ijzerparameters was tevens minder sterk in hypoxische 
proefpersonen. Deze resultaten laten zien dat de stijging in hepcidine uitgelokt door een 
afweerreactie en tevens de gevolgen daarvan kunnen worden geremd door hypoxie. Dit 
is relevant, omdat bij ernstig zieke patiënten de combinatie van een ontstekingsreactie en 
hypoxie geregeld wordt gezien. 
Een geactiveerd afweersysteem zorgt ook voor sterkere neiging tot bloedstolling. En 
hoe wel het wetenschappelijk bewijs hiervoor beperkt is, zijn er aanwijzigen dat hypoxie 
ook de bloedstolling bevordert. In hoofdstuk 5 is onderzocht hoe hypoxie en de afweer-
reactie de bloedplaatjesfunctie en stolling beïnvloeden, wederom gebruik makende van 
dezelfde experimenten die beschreven staan in hoofdstuk 3. De resultaten laten zien 
dat de door endotoxinetoediening uitgelokte afweerreactie leidt tot een toename in 
verbin dingen tussen bloedplaatjes en specifieke witte bloedcellen (trombocyt-monocyt 
complexen (TMC)) en een verhoogde bloedplaatjesreactiviteit. Hypoxie verminderde de 
toename in TMCs en remde tevens de bloedplaatjesreactiviteit. Hypoxie had echter geen 
effect op de veranderingen in plasmatische stolling en endotheelactivatie. Deze resultaten 
ondersteunen dus niet de hypothese dat hypoxie de stolling bevordert bij de mens. 
De aanpassing aan hypoxie is voor een groot deel gereguleerd via een eerder genoemde 
groep van transcriptie factoren: HIFs. Deze HIFs zijn betrokken bij de vorming van nieuwe 
bloedvaten, het glucosemetabolisme en de afweerreactie. De afbraak van HIFs is zuurstof-
afhankelijk, en een van de eiwitten betrokken bij deze afbraak is het Von Hippel-Lindau 
eiwit (pVHL). Patiënten met het Von Hippel-Lindau syndroom hebben een zeldzame 
aangeboren genetische afwijking in het gen dat codeert voor pVHL. Hierdoor is hun HIF 
eiwit overactief, wat leidt tot een groot risico op het ontwikkelen van tumoren. Ook de 
afweerreactie zou door het overactieve HIF versterkt kunnen zijn en dit zou in theorie 
kunnen bijdragen aan het stimuleren van de ontwikkeling van tumoren. In hoofdstuk 6 is 
onderzocht hoe de afweerreactie witte bloedcellen van deze patiënten functioneert, door 
zowel cellen van deze patiënten als van gezonde controlepersonen in het laboratorium 
bloot te stellen aan endotoxine en vervolgens de hoeveelheid geproduceerde cytokines te 
bepalen. De cytokineproductie was niet versterkt in de patiënten, sterker nog, de productie 
van interleukine-6 was lager in patiënten dan in gezonde controles. Deze resultaten laten 
zien dat de genetische afwijkingen in de leukocyten van deze patiënten waarschijnlijk niet 
bijdraagt aan een tumorstimulerende omgeving. 
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Uit voorgaand laboratorium- en associatieonderzoek is gebleken dat naast hypoxie, ook 
hyperoxie (een hoog zuurstofgehalte) effecten kan hebben op de afweerreactie en op de 
prognose van intensive care patiënten. In hoofdstuk 7 staan de effecten van hyperoxie 
(inademing van 100% zuurstof ) op de afweerreactie uitgelokt door endotoxinetoediening 
in muizen en mensen beschreven. Hyperoxie had geen effect op de afweerreactie in 
muizen en mensen. Bovendien werd er geen effect op de fagocytosefunctie van, en de 
productie van radicale zuurstofmoleculen door neutrofielen gevonden, beide belangrijke 
afweermechanismen van dit celtype. Uit deze resultaten valt af te leiden dat hyperoxie 
waarschijnlijk ongeschikt is om het afweersysteem te beïnvloeden bij patiënten op de 
intensive care. 
Deel 2 De effecten van trombocytenaggregatieremmers  
op de afweerreactie
Bloedverdunnende medicijnen die de functie van bloedplaatjes remmen zijn een belangrijk 
onderdeel van de behandeling van hart-en vaatziekten. Deze behandeling bestaat in het 
eerste jaar na een hartinfarct meestal uit een lage dagelijkse dosis acetylsalicylzuur (ASZ, 
ook bekend onder de merknaam Aspirine) en een tweede trombocytenaggregatieremmer. 
Het gebruik van ASZ is in verband gebracht met betere overleving van patiënten met 
sepsis, en de trombocytenaggregatieremmers uit de P2Y12-remmers groep werden ook 
verondersteld afweerbeïnvloedende effecten hebben. In hoofdstuk 8 zijn de effecten van 
veel voorkomende combinaties van trombocytenaggregatieremmers op de afweerreactie 
uitgelokt door endotoxinetoediening onderzocht bij gezonde vrijwilligers. Op de zevende 
dag van een behandeling met een placebo, of ASZ en een placebo, of ASZ en ticagrelor 
(een P2Y12-remmer), of ASZ en clopidogrel (een andere P2Y12-remmer) werd een 
afweerreactie uitgelokt door endotoxine continue via een infuus toe te dienen gedurende 
3 uur. Vergeleken met een placebobehandelde groep leidde behandeling met ASZ tot 
een toename van afweerbevorderende cytokines. Het toevoegen van een van de P2Y12-
remmers had geen relevant effect op deze toename in afweerstimulatie. Deze resultaten 
ondersteunen de observatie dat er het gebruik van ASZ voordelig kan zijn voor patiënten 
met sepsis, omdat de afweerstimulerende effecten van ASZ patiënten beter in staat 
zouden kunnen stellen om infecties te weren. In hoofdstuk 9 wordt een mechanisme 
wat mogelijk ten grondslag ligt aan de afweerstimulerende effecten van ASZ beschreven. 
ASZ remt de prostaglandineproductie, wat de negatieve terugkoppeling op de productie 
van ontstekingsbevorderende cytokines voorkomt. Hierdoor stijgt de cytokineproductie, 
wat kan bijdragen aan een versterkte afweerreactie met een betere bescherming tegen 
binnendringende bacteriën en andere ziekteverwekkers. Deze effecten van ASZ zouden 
wellicht gebruikt kunnen worden om patiënten met sepsis en een onderdrukte afweer-
reactie te behandelen of zelfs als preventie om de onderdrukking van het afweersysteem 
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te voorkomen bij deze groep patiënten. Deze hypothese werd onderzocht in een 
experimentele setting in hoofdstuk 10. In dit onderzoek werden de effecten van ASZ 
op endotoxinetolerantie, wat een model is voor het onderdrukte afweersysteem bij 
patiënten met sepsis, onderzocht. In dit onderzoek werden afweerreacties uitgelokt 
door het tweemaal toedienen van endotoxine, met een interval van zeven dagen. De 
eerste toediening leidt tot endotoxinetolerantie, waardoor er tijdens de tweede toe-
diening van endotoxine een sterk verminderde afweerreactie is. Om te onderzoeken of 
ASZ endotoxinetolerantie kan voorkomen werd een groep voorafgaand aan de eerste 
toediening van endotoxine zeven dagen behandeld met ASZ (zogenaamde profylactische 
behandeling) en na de eerste endotoxinetoediening werden deze proefpersonen ook 
nog zeven dagen met ASZ behandeld. Endotoxinetolerantie werd door ASZ profylaxe 
niet voorkomen, vergeleken met een controlegroep. Om te onderzoeken of ASZ reeds 
ontwikkelde endotoxinetolerantie kan verminderen werden gezonde vrijwilligers alleen in 
de zeven dagen na de eerste toediening van endotoxine behandeld met ASZ. Hierbij werd 
gezien dat een behandeling van ASZ inderdaad endotoxinetolerantie tijdens de tweede 
toediening verminderd vergeleken met een controlegroep. 
Deel 3 Vergelijking van humane endotoxinemie modellen
In hoofdstuk 11 wordt de afweerreactie van gezonde proefpersonen beschreven na 
toediening van verschillende doses endotoxine als bolus, alsmede na de eerdergenoemde 
continue infusie van endotoxine voor 3 uur. De continue infusiemethode leidde tot een 
meer uitgesproken stijging in plasma cytokines en langer aanhoudende symptomen en 
koorts vergeleken met de bolustoediening. Dit model geeft de situatie in patiënten, die vaak 
langdurige activatie van het afweersysteem hebben, wellicht beter weer en biedt tevens 
een langere periode waarin de effecten van afweersysteembeïnvloedende behandelingen 
onderzocht kunnen worden. In hoofdstuk 12 wordt beschreven wat het effect is op de 
afweerreactie van verschillende productiebatches van endotoxine die via een bolus of 
een continue infusie methode gegeven werden aan gezonde vrijwilligers. Verder wordt de 
variatie over de jaren met betrekking tot de werkzaamheid van endotoxine onderzocht. De 
resultaten laten zien dat, hoewel het endotoxine model reproduceerbaar is, er wel variatie 
over de tijd en tussen productiebatches zijn. Daarom zijn verschillende endotoxinestudies 
niet direct vergelijkbaar. 
Discussie en toekomstperspectieven
Sepsisonderzoek
Een belangrijk probleem in sepsisonderzoek is dat sepsis geen homogene, strak gede-
fi nieerde en makkelijk te diagnosticeren ziekte is. De in 2016 herziene definitie is 
“een ontregelde afweerreactie van de gastheer op een ziekteverwekker leidend tot 
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orgaan dysfunctie”. Dat beschrijft dus wel wat sepsis ‘is’, maar niet wie sepsis ‘heeft’. Er is 
bijvoorbeeld geen eenduidige maat om vast te stellen wat een ‘ontregelde gastheer-
reactie’ is. In theorie bestaat de afweerreactie uit een ontstekingsstimulerende component 
en een compenserende ontstekingsremmende component. Als deze reacties niet in 
balans zijn kan dit tot schade leiden door enerzijds te veel ontstekingsactiviteit en 
anderzijds opportunistische infecties. Daarom is het bij sommige patiënten beter om het 
immuunsysteem te remmen, maar bij anderen moet het juist worden gestimuleerd. Het is 
tot op heden nog niet gelukt om indicatoren te vinden die goed vast kunnen stellen wat 
de status van het afweersysteem van een individuele patiënt is. Recent onderzoek heeft 
laten zien dat het wellicht mogelijk is om meer hierover te zeggen door te meten welke 
genen zijn geactiveerd en welke zijn onderdrukt in witte bloedcellen van sepsispatiënten 
(het transcriptoom). Wellicht is het in de toekomst mogelijk met deze, en andere nieuwe 
technieken beter vast te stellen welke patiënten baat hebben bij afweerremmende en 
welke bij afweerstimulerende behandelingen. 
Afweerregulering via zuurstof en adenosine
In dit proefschrift wordt uiteengezet hoe kortdurende hypoxie de aangeboren afweer-
reactie uitgelokt door toediening van endotoxine remt. Hiermee hebben we aangetoond 
dat het toepassen van korte periodes van hypoxie een manier zou kunnen zijn om een te 
sterke afweerreactie te remmen. Voordat dit toepasbaar is moet eerst worden uitgezocht 
of hypoxie ook een afweerremmend effect heeft tijdens een langdurig afweerreactie, zoals 
bij sepsis patiënten of bij patiënten die een ernstig ongeluk hebben gehad of een operatie 
hebben ondergaan. Dit kan bijvoorbeeld worden onderzocht door het in dit proefschrift 
beschreven continue endotoxine model te gebruiken. Zoals beschreven is endotoxine 
‘dood’ materiaal, een onderdeel van de celwand van een bacterie. Daarom zal onderzocht 
moeten worden of er ook goede resultaten worden behaald bij infecties met een levende 
ziekteverwekker, bijvoorbeeld door onderzoek te doen bij proefdieren. Zoals bij iedere 
interventie die een effect heeft, moet in deze toekomstige onderzoeken ook worden 
bepaald wat de optimale dosis, duur, starttijd en frequentie van hypoxie is. Als deze vragen 
kunnen worden beantwoord, en patiënten met een te sterke afweerreactie nauwkeurig 
kunnen worden geïdentificeerd, liggen klinische studies bij patiënten in het verschiet. Een 
andere manier om de afweerremmende effecten van hypoxie toe te passen is door in te 
grijpen op het adenosinemechanisme dat in dit proefschrift is beschreven. Kortdurende 
hypoxie leidt tot hogere adenosinespiegels, wat via de adenosine-2B-receptor leidt tot 
een remming van de afweerreactie. Daarom zou er medicatie kunnen worden ontwikkeld 
die de adenosine 2B receptor gevoeliger maakt voor adenosine, waardoor bij een minder 
uitgesproken toename van adenosine een ontstekingsremmend effect kan optreden. 
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Toepassing van zuurstoftherapie in de klinische praktijk
De resultaten uit dit proefschrift dragen bij aan een beter begrip van resultaten van 
zuurstofgebruik verkregen uit klinische studies en uit observaties in de klinische praktijk. 
De huidige richtlijnen over optimale zuurstofbehandeling zijn niet eenduidig en zijn 
gebaseerd op wetenschappelijk bewijs van lage kwaliteit of de meningen van experts. Wel 
is uit verschillende associatieonderzoeken gebleken dat er een relatie is tussen een laag 
zuurstofniveau in het bloed bij opname op de intensive care en hogere sterfte. Daarnaast 
zijn er ook aanwijzingen dat een te hoog zuurstofgehalte (hyperoxie) schadelijk is en diverse 
eerste onderzoeken hebben laten zien dat een conservatief zuurstofbeleid (streven naar 
een zuurstofsaturatie van 88-92%) toepasbaar en veilig is. Er is tevens gebleken dat een 
streven naar wat lagere zuurstofniveaus leid tot een betere overleving dan streven naar 
hogere niveaus. Op basis van de resultaten in dit proefschrift kan worden gespeculeerd dat 
hyperoxie kan voorkomen dat een hypoxie-gedreven afweerremmend mechanisme wordt 
geactiveerd en dat dit uiteindelijk bijdraagt aan toegenomen orgaanschade en hogere 
kans op overlijden. 
Afweerregulatie door trombocytenaggregatieremming
De resultaten in dit proefschrift laten zien dat ASZ de afweerreactie bevordert en de 
respons van een verzwakt afweersysteem kan versterken. Uit diverse associatiestudies 
is gebleken dat gebruik van ASZ samenhangt met betere overleving van patiënten met 
sepsis. Mogelijk komt dit doordat patiënten die ASZ gebruiken daardoor een betere afweer 
hebben tegen ziekteverwekkers, of omdat ze relatief beschermt zijn tegen verzwakking 
van het afweersysteem. Er zijn op dit moment diverse onderzoeken gaande naar het 
gebruik van ASZ en het voorkómen van sepsis, en het effect van ASZ op de overleving van 
intensive care patiënten. 
Endotoxinemodellen om sepsis te bestuderen
Het bestuderen van de afweerreactie in patiënten met sepsis is complex vanwege de grote 
verschillen tussen patiënten, ziekteverwekkers, tijdsbeloop en andere aanwezige ziektes. 
Mogelijk als een gevolg hiervan hadden behandelingen gericht op het beïnvloeden van 
het afweersysteem welke gunstig leken in proefdieren uiteindelijk toch geen gunstige 
effecten bij patiënten. Het lijkt er op dat de stap van proefdieronderzoek naar klinische 
patiëntenstudies te groot is. Door gebruik te maken van experimentele endotoxinemie 
bij mensen kunnen behandelingen die het afweersysteem beïnvloeden bij dieren op een 
gestandaardiseerde, gecontroleerde en reproduceerbare manier worden onderzocht bij 
de mens in vivo. Dit model wordt sinds 2003 in het Radboudumc gebruikt en is veilig, 
goed verdraagbaar en reproduceerbaar. Om onderlinge verschillen tussen proefpersonen 
zoveel mogelijk te beperken worden in ons centrum alleen jonge mannen onderzocht. 
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Het uitsluiten van vrouwelijke proefpersonen is echter in strijd met de toenemende aan-
dacht voor de verschillen tussen man en vrouw in het voorkomen, beloop en uitkomsten 
van diverse ziekten. Het uitsluiten van vrouwen in experimentele endotoxinemie onder-
zoeken kan dus leiden tot een over- of onderschatting van de werking van de onder zochte 
behandeling bij vrouwen. Echter, omdat de onderzoeken worden verricht om een alge-
meen geldend biologisch principe te onderzoeken, lijkt het vooralsnog te recht vaardigen 
dit met een zo klein mogelijke groep proefpersonen te doen. Om de studies uitvoer-
baar te houden worden proefpersonen gekozen die zoveel mogelijk op elkaar lijken, 
zodat eventuele verschillen veroorzaakt door de onderzochte behandeling zo duidelijk 
mogelijk zijn. Vervolgstudies in patiënten moeten zeker wel zowel mannen als vrouwen 
meenemen. Bovendien blijft voorzichtigheid geboden bij de interpretatie van resul taten 
van onderzoeken die gebruik maken van experimentele endotoxinemie, omdat deze 
modellen slechts een deel van de factoren die een rol spelen bij sepsis nabootsen. 
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Dankwoord
Dit proefschrift is het resultaat van samenwerking met velen. Ik ben dankbaar dat ik met 
zoveel getalenteerde en inspirerende mensen heb kunnen samenwerken. Ik ben geïn-
spireerd, geholpen, gestimuleerd en aangemoedigd en ik ben daarvoor ieder dankbaar. 
Daarnaast ook veel dank aan de vrijwilligers die mij hun gezondheid hebben toevertrouwd, 
zonder hen was dit proefschrift niet mogelijk geweest.
Professor Pickkers, beste Peter, ik bewonder je optimisme, creativiteit, directheid, eerlijk-
heid, enthousiasme en oog voor kansen. Voor elk publiek kan je op onnavolgbare wijze een 
verhaal voor het voetlicht brengen. Bedankt voor het luisterend oor en goede raad. Ik ben 
trots om op de beste IC onderzoeksafdeling te werken. Hoe jij aan het roer staat resul teert 
in werksfeer waarin we elkaar vooruit helpen, betrokken en kritisch zijn en uitdagingen 
niet uit de weg gaan.
Professor Scheffer, beste Gert-Jan, bedankt voor uw vertrouwen in mij om dit project uit 
te voeren. Hoewel op de achtergrond aanwezig, zonder uw steun was deze operatie niet 
mogelijk geweest. Bedankt voor het kritisch meelezen en de goede adviezen. 
Doctor Kox, beste Matthijs. Bedankt voor je onvermoeibare inzet. Als ik terugblik op de 
afgelopen jaren zie ik hoe jij je begeleiding elke keer aanpaste aan mijn niveau. Ik ken 
geen andere copromotoren die zó betrokken zijn als jij. Je bent altijd beschikbaar en je 
stuurt niemand met een kluitje in het riet als het lastig wordt. Ik ben bijzonder trots op 
ons zuurstofproject, het voelt echt als een “joint venture”. Ik kijk met plezier terug op onze 
gesprekken over wetenschap én over al het andere wat je tegenkomt in het leven. Ik heb 
veel van je geleerd over interpretatie van data en logische vervolgstappen en je bent een 
voorbeeld waar het gaat over het presenteren van resultaten in woord en beeld. 
Professor Van der Hoeven, beste Hans. Dank voor de kritische input. Het bleek bij elk artikel 
hoe waardevol het is om een kritische meelezer te hebben met iets meer afstand tot 
het onderwerp. Ik bewonder hoe onder jouw leiding de Intensive Care een inspirerende 
omgeving is waar talenten worden ontplooid en waar boven alles de ambitie is om de 
beste zorg voor de patiënt te leveren met een solide wetenschappelijke basis. 
Jelle Gerretsen, dank, dank, dank! Zonder al jouw uren in het lab was er geen letter van dit 
proefschrift op papier gekomen. Ben Wielockx, je bent van onschatbare waarde voor het 
hypoxieproject. Ik wil je bedanken voor het meedenken, het uitvoeren van veel expe ri-
menten en je vertrouwen tijdens deze samenwerking. Professor Riksen, Niels, bedankt voor 
de soepele samenwerking tijdens de tica-studie en je betrokkenheid bij de hypoxiestudie. 
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Wouter van der Heijden, met je nauwkeurigheid en kritische blik was je een grote toege-
voegde waarde bij de aspirinestudies. Ilona van den Brink en Francien van de Pol, hartelijk 
dank voor al jullie inzet en meedenken bij het uitvoeren van de muis experimenten. Cor 
Jacobs, gastheer van het lab, bedankt voor je hulp met flowcytometrie. 
Professor Wetzels, bedankt voor de investering in mijn eerste wetenschappelijke stapjes 
als derdejaars geneeskundestudent. Quirijn de Mast, goed idee om plaatjes te meten! 
Professor Netea, Professor Joosten en Frank van de Veerdonk, bedankt voor de gelegenheid 
om aan te sluiten bij de cytokinemeetings. Het is van grote waarde om je data aan zulke 
goede onderzoekers te kunnen voorleggen.
Rebecca, Jenneke, Esther, Quirine, Nienke, Linda, Roel, Roger, Guus, Christopher, Lisanne, Lucas, 
Mirrin, Bart, Kim, Jonne, Mark, Paul, Annelies, Lex, Eline, Marieke en Pleun, samen onderzoek 
doen in zo’n groep schept een bijzondere band. Hoewel iedereen aan zijn eigen project 
werkt, heb ik toch altijd het gevoel gehad dat we het samen doen. Van iedereen heb ik wel 
iets geleerd. Ik heb me aan jullie kunnen optrekken en kon me bij jullie opladen of juist even 
ontspannen. Het is een groot plezier om in zo’n team van getalenteerde onderzoekers te 
werken. Uiteraard ook veel dank aan Anne-Miek Broods, door je ondersteuning, snelle en dui-
delijke antwoorden en meedenken heb je het mogelijk gemaakt dit onderzoek uit te voeren. 
Dank aan professor van Crevel, professor van Geuns en professor Juffermans voor het be-
oordelen voor het manuscript en alle opponenten die met mij van gedachten willen wisselen 
tijdens de verdediging.
Research verpleegkundigen Marieke van der A, Chantal Luijten, Hellen van Wezel, Noortje 
Rovers, Tijn Bouw en Hetty van der Eng, bedankt voor het mogelijk maken van al het onder-
zoek op de afdeling. Yvonne Kaspers, er is een praktische oplossing voor elk pro bleem, 
maar je bent vooral het cement dat de afdeling bij elkaar houdt. 
Daarnaast wil ik ook graag de onderzoekers van de afdeling experimentele interne 
geneeskunde, in het bijzonder Rob, Mark, Ajeng, Arjan, Sanne, Martin en Marije, bedanken 
voor de bereidheid om mee te denken en praktische hulp te bieden.
Alle verpleegkundigen van de Medium Care en vooral Jeanette Doornink, bedankt voor 
de gastvrijheid op de afdeling en de hulp bij de endotoxine-experimenten met gezonde 
vrijwilligers.
Aaron, Emmy en Lisa, bedankt voor jullie onvermoeibare inzet tijdens de experimenten. 
Zonder jullie hulp was geen van de endotoxine-experimenten geslaagd. 
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Vera, Louis, Arianne en de andere internisten uit het Rijnstate ziekenhuis, Jacqueline, Jan 
en Gerald, bedankt voor de flexibiliteit en de ruimte om de opleiding interne geneeskunde 
te onderbreken om onderzoek te doen. 
Dit onderzoek was niet mogelijk geweest zonder de financiële steun van het Radboud 
Center for Infectious Diseases (RCI) en van de Nederlandse Vereniging voor Anesthesiologie.
Sinds 2005 ken ik een steeds groter wordende groepsterke, lieve, gedreven, en slimme 
vrouwen die het beste in elkaar naar boven halen en daarvoor wil ik alle Damesch van 
Damesch dispuut Hard Roeien en Meer bedanken. Bij het wedstrijdroeien zag ik voor het 
eerst hoe het is om met een kleine, toegewijde groep heel hard te werken aan één doel. 
Ik ben trots dat ik onderdeel ben van deze club en ben dankbaar voor de vriendschap van 
jullie allemaal. 
Jelle Zwaag, wat een topcollega ben jij. Je zit in het zelfde schuitje en het is zó goed om 
ervaringen uit te wisselen van herkenbare situaties. Je combineert de taken van rela-
tiverings goeroe, psycholoog en conferencier moeiteloos. Of het nu in de auto, in de kroeg, 
in witte jas of achter een bureau is, binnen no time heb je met jou een prettig gesprek.
Noortje, ik zie je als mijn beste vriendin en je bent mijn alternatief voor een grote zus. Alles 
wat ik nog moest doen deed jij net een paar jaar eerder. Ik ben trots op en dankbaar voor 
onze vriendschap. 
Opa en Oma, ik ben trots op hoe jullie in het leven staan, ik realiseer me steeds meer wat 
jullie levensverhaal is en wat ik daaruit kan halen. Timon, al sinds we klein zijn kan ik met 
je sparren, je daagde me uit mijn argumenten scherp te hebben en dat heeft geholpen 
om een kritische wetenschapper te worden. Steven, bedankt voor onze gesprekken over 
hoe de wereld wel óf niet in elkaar steekt. Ik vind het fijn dat deze gesprekken steeds vaker 
plaatsvinden en ben trots op wie je bent. Lieve Janneke. Dankjewel dat je zo nu en dan 
een dagje met mij op stap wil. Dat we dan vooral gewoon leuke dingen doen. En met een 
knuffel van jou… kan ik weer weken vooruit. Mama. Ik heb heel erg veel bewondering 
voor je ambitie en passie, veerkracht en aanpassingsvermogen. En dat is allemaal gedreven 
door de liefde voor ons. Pap. Weet je nog dat je me ging helpen met mijn werkstuk over 
varkens in groep 6? Maar eerst een ijsje eten. Ik heb die middag veel meer geleerd dan 
tekstbewerking. Exemplarisch voor hoe je me al 32 jaar vooruit helpt. 
Lieve Laurens, ik hou van jou. 
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Dorien Kiers werd geboren op 30 maart 1986. In 2004 slaagde ze cum laude op het VWO aan 
het Etty Hillesum College in Den Helder. In 2005 behaalde ze de propedeuse Pedagogische 
Wetenschappen en Onderwijskunde aan de Radboud Universiteit in Nijmegen, waarna ze 
overstapte naar Geneeskunde. Tijdens het tweede en derde jaar deed ze haar eerste onder-
zoekservaring op bij prof. dr. J. Wetzels in de nefrologie. In 2008 volbracht ze haar weten-
schappelijke onderzoeksstage op de Intensive Care van het Vancouver General Hospital in 
Vancouver, Canada, in Nederland begeleid door prof. dr. P. Pickkers. Ze behaalde in 2011 
cum laude het artsexamen, waarna ze begon met de opleiding Interne Genees kunde in het 
Rijnstate ziekenhuis te Arnhem (opleiders mw. dr. V. Mattijssen, dr. L. Reichert en prof. dr. J. 
de Graaf ). 
Mede door de financiële steun van het Radboud Center for Infectious Diseases (RCI) en de 
Nederlandse Vereniging voor Anesthesiologie kon zij in 2013 beginnen aan het promotie-
onderzoek dat leidde tot dit proefschrift, onder begeleiding van prof. dr. P. Pickkers, prof. dr. 
G.J. Scheffer en dr. M. Kox. Met haar onderzoek won ze onder andere de abstractprijs van 
de Nederlandse Internisten Vereniging in 2014 en van het Aegaen International Conference 
on Innate Immunity in 2016. Zij wisselde periodes van promotieonderzoek en het volgen 
van de opleiding tot internist af, waarbij ze vanaf 1 september 2018 de differentiatie tot 
internist-intensivist volgt. 
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